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ABSTRACT 
Stroke related death ranks as the fourth most common cause of mortality in the 
United States. However, even with those who survive the initial ischemic insult, profound 
neurological disability may remain. Current therapeutic options following stroke are 
limited and therefore the development of a treatment that can improve functional 
outcome after the acute phase of the stroke has passed would have a great impact on the 
level of disability and quality of life of stroke sufferers. One potential therapy involves 
the use of anti-Nogo-A immunotherapy post-stroke. Our laboratory has shown that the 
administration of this novel treatment results in sensorimotor recovery in adult and aged 
rats. This therapy has been shown to be efficacious when applied immediately, 24 hours, 
and 1 week post-stroke in rats with mild to moderate sensorimotor deficits. In addition, 
recent results suggest that administration of anti-Nogo-A immunotherapy up to 9 weeks 
after stroke still induces functional recovery and neuroanatomical plasticity in adult rats 
with mild to moderate sensorimotor deficits. However, whether and how long anti-Nogo-
A immunotherapy is efficacious when administered in the chronic stroke phase in rats 
with moderate to very severe sensorimotor deficits is unknown. In the present project we 
sought to investigate the effectiveness of anti-Nogo-A immunotherapy as a therapeutic 
intervention to improve sensorimotor recovery when applied to chronic stroke-impaired 
adult rats with moderate to very severe sensorimotor deficits. Prior to testing the efficacy 
of anti-Nogo-A immunotherapy we set out to evaluate the spontaneous motor recovery 
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profiles in adult rats after stroke. We found that animals displayed different recovery 
profiles based on initial deficit severity after stroke and overall, all spontaneous recovery 
occurred within the first 4 weeks post-stroke. Therefore, the neurological deficit in the 
stroke animals had plateaued by the time anti-Nogo-A immunotherapy was given at 9 and 
25 weeks post-stroke.  We found that animals with moderate to very severe deficits 
treated with anti-Nogo-A immunotherapy at 9 or 25 weeks post-stroke showed improved 
sensorimotor recovery at both time points. However, the improved sensorimotor function 
was not associated with dendritic changes in either the perilesional or contralesional 
cortex. Our finding of improved sensorimotor recovery even when treatment was started 
25 weeks post-stroke demonstrates the promising therapeutic potential for anti-Nogo-A 
immunotherapy to treat stroke sufferers long after the initial ischemic damage has taken 
place. Further neuroanatomical correlates of the improved sensorimotor function are 
being investigated.
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CHAPTER ONE 
OVERVIEW AND HYPOTHESIS 
Stroke is a leading cause of long-term disability worldwide and it is estimated 
nearly 795,000 people experience a new or recurrent stroke every year (AHA, 2013). The 
only clinical treatment for acute stroke is thrombolytic therapy and it must be given in the 
first hours after stroke onset, thereby limiting its usefulness. Therefore, it is important to 
study possible therapeutic interventions that can help repair the brain after the initial 
damage has already occurred. One potential therapy involves the use of anti-Nogo-A 
immunotherapy following stroke. Our laboratory has shown that the administration of 
this novel treatment results in sensorimotor recovery after stroke in adult and aged rats 
and is mediated by dendritic and axonal plasticity (Markus et al., 2005; Papadopoulos et 
al., 2006). Administration of anti-Nogo-A immunotherapy has been shown to be 
efficacious when applied immediately, 24 hours, and 1 week after ischemic stroke in the 
rat (Papadopoulos et al., 2002; Wiessner et al., 2003; Seymour et al., 2005; Markus et al., 
2005;Tsai et al., 2007). However, given the vast number of people living with chronic 
stroke deficits, the question of whether anti-Nogo-A immunotherapy can be efficacious 
when administered long after the ischemic damage has occurred is of extreme 
importance. Recent data from our laboratory suggests that administration of anti-Nogo-A 
immunotherapy up to 9 weeks following ischemic stroke in adult rats that have mild to 
moderate sensorimotor deficits induces functional recovery and neuroanatomical 
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plasticity (Tsai et al., 2010). We aimed to extend these exciting results in this dissertation 
by investigating the important preclinical question of whether there exists a critical 
treatment window for the application of anti-Nogo-A immunotherapy in the chronic stage 
following ischemic injury in adult rats with moderate to very severe sensorimotor 
deficits.  
 
HYPOTHESIS: 
Inhibiting the Nogo-A protein using anti-Nogo-A antibodies at 9 or 25 weeks post-
stroke in adult rats with moderate to very severe sensorimotor deficits will result in 
improved functional recovery and enhanced dendritic plasticity.  
 
Specific Aim 1: Determine the magnitude and time course of spontaneous 
sensorimotor recovery in adult rats during the first 8 and 24 weeks post-stroke. 
Male adult rats will be tested using the skilled forelimb-reaching task post-stroke for up 
to 8 or 24 weeks post-stroke to determine sensorimotor recovery.   
 
Specific Aim 2: Evaluate the critical treatment window for administration of anti-
Nogo-A immunotherapy to induce sensorimotor recovery in the chronic stage after 
ischemic stroke in the adult rat. The same animals in Aim 1 will be used in Aims 2 and 
3. At either 9 or 25 weeks post-stroke, adult rats with severe sensorimotor deficits will be 
treated with intracerebroventircular infusion of anti-Nogo-A immunotherapy, a control 
antibody, or will receive no treatment. Sensorimotor recovery will be tested using the 
3 
 
 
 
skilled reaching task, the skilled horizontal ladder walking task, and the bilateral adhesive 
removal task over the course of 12 additional weeks.  
 
Specific Aim 3: Determine whether treatment with anti-Nogo-A immunotherapy in 
the chronic phase after stroke in adult rats will result in enhanced dendritic 
plasticity in the perilesional and contralesional cortex. The brains from Aim 2 will be 
processed for Golgi-Cox staining and neurons in the perilesional and contralesional 
caudal forelimb motor cortex will be evaluated for dendritic complexity. Specifically, 
layer V pyramidal neurons will be evaluated in the perilesional cortex and layer II/III and 
V pyramidal neurons will be evaluated in the contralesional cortex. 
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CHAPTER TWO 
LITERATURE REVIEW 
CHAPTER OVERVIEW 
 This chapter outlines the relevant concepts and literature background that is 
pertinent to the experiments in this dissertation. Firstly, a general discussion of neuronal 
plasticity and the capacity for neuronal regeneration after injury is presented in the 
context of the developing, adult, and aged central nervous systems. Additionally, 
previous work on factors found within the central nervous system that restrict neuronal 
plasticity, especially the protein Nogo-A, is presented. Finally, the therapeutic potential 
of blocking Nogo-A after various central nervous system injuries is discussed. 
Specifically, the potential of blocking Nogo-A in chronic ischemic stroke, which forms 
the basis of this dissertation, is addressed in detail. 
 
NEURONAL PLASTICITY IN THE MAMMALIAN CENTRAL NERVOUS SYSTEM 
AFTER INJURY 
Definition of Neuronal Plasticity 
Neuronal plasticity, as used in this dissertation, refers to any change in the structure 
or function of neurons in the central nervous system (CNS) in response to a 
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specific internal or external stimulus. Such stimuli can include day-to-day environmental 
experiences of an animal, pharmacological interventions, or even brain injury. Previously, 
the medical and neuroscience community regarded the mature brain as immutable and 
unable to undergo such repair or neural circuit reorganization. It is now known that varying 
degrees of neuronal plasticity take place not only in the developing and young CNS but 
also, given the appropriate circumstances, in the adult and aged CNS as well.  
One important type of neural plasticity seen in response to brain and spinal cord 
injury takes the form of neuronal structural reorganization. This reorganization is 
characterized by the growth of new axons and dendrites and is ultimately thought to lead 
to the recovery of function after injury. There are two main types of axonal structural 
rearrangements that take place after injury, namely regeneration and compensatory 
plasticity (Kartje et al., 2006). During regeneration, a severed axon is able to reconnect 
with its deafferented targets by re-growing from its damaged end. In the case of 
compensatory plasticity, deafferented targets are reinnervated by new axonal growth from 
undamaged spared neurons that can be located quite far from the original injury site. 
Additionally, changes in dendritic complexity may also serve to enhance the functioning 
of damaged circuits.  It is thought that these mechanisms play a large role in the 
spontaneous albeit limited improvements seen after brain and spinal cord injury. However, 
the magnitude of neuronal plasticity that can take place in response to injury is dependent 
on the age of the animal as well as whether the injury took place in the CNS or the 
peripheral nervous system (PNS). By studying the differences in reorganizational potential 
between the developing, adult, and aged CNS as well as in the PNS, important factors 
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governing neuronal plasticity have been discovered and are the basis of new therapeutic 
investigation.  
 
Reorganizational Potential of the Mammalian Developing CNS  
Seminal studies on the recovery of motor function in primates after early brain 
injury were performed by Margaret Kennard in the 1900s and led to the general premise 
that functional recovery after brain injury is faster and more complete in young animals 
than adolescent or adult animals (Kennard et al., 1936, 1938, 1942). This concept became 
known as the “Kennard Principle” and postulates that there is a negative linear 
correlation between recovery potential and age at brain or spinal cord injury, although 
exceptions have been reported (Schneider, 1979). The neuroanatomical corollary of 
improved motor function in young animals after brain injury was evaluated in numerous 
studies and evidence accumulated indicating that the young central nervous system 
remodels after injury by compensatory plasticity. The undamaged cortex opposite to the 
injury extends newly formed axons across the midline toward the injured side and 
reinnervates denervated targets. Specifically, the opposite undamaged cortex sends 
projections to the denervated striatum (Kolb et al., 1992), thalamus (Yu et al., 1995), red 
nucleus (Nah & Leong et al., 1976; Naus et al., 1985), basilar pontine nuclei (Castro and 
Mihailoff, 1983; Kartje-Tillotson et al., 1986), and spinal cord (Castro, 1975; Kartje- 
Tillotson et al., 1985; Rouiller et al., 1991). Since it is thought that neuroanatomical 
plasticity is the underlying mechanism of functional recovery after CNS injury in young 
animals, strategies that could induce the adult and aged CNS to display similar levels of 
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plasticity as seen in the young CNS could make a large difference in the rehabilitation of 
humans after brain and spinal cord injury. 
 
Reorganizational Potential of the Mammalian Adult CNS 
 The reorganizational potential of the mammalian adult CNS is much more limited 
than during development or in the PNS. Classic experiments performed by Aguayo et al. 
investigated whether cut adult CNS axons were capable of long distance regenerative 
growth when exposed to a peripheral sciatic nerve graft (David et al., 1981). An 
autologous 35 mm sciatic nerve segment was grafted into the lower portion of the 
medulla oblongata and lower cervical or upper thoracic spinal cord of adult rats. After 
22-30 weeks post grafting, it was found that axons from spinal and medullary neurons 
had elongated more than 30 mm into the sciatic nerve graft. Another experiment by 
Aguayo et al. showed that when optic nerves were implanted into sciatic nerves, the 
regenerating peripheral axons almost completely avoid the optic nerves (Aguayo et al., 
1978; Weinberg and Spencer, 1979). Results from these experiments suggest that 
although CNS neurons are not capable of long distance regeneration within the 
environment of the CNS, the neurons were capable of long distance growth within the 
environment of the peripheral nerve segment. Seemingly, it was the CNS environment 
exerting a non-permissive effect that rendered the CNS neurons incapable of meaningful 
re-growth.  
Since the molecular basis of the differences within the CNS and PNS environment 
were unknown at that time, Schwab and colleagues decided to investigate whether the CNS 
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environment lacked a potential trophic factor or whether the CNS environment contained 
a non-permissive substrate for neurite growth in the CNS. Neonatal rat sympathetic or 
sensory ganglia were grown in the presence of nerve growth factor (NGF) in a chamber 
culture system where the neurons could grow into explants of either sciatic nerves or optic 
nerves. Schwab et al. found that the neurons very frequently grew into the sciatic nerve 
explants, but never into the optic nerve explants (Schwab et al., 1985). Additionally, the 
same findings were found with previously frozen optic and sciatic nerves that did not 
contain living glial cells.  This experiment suggested the existence of a non-permissive 
substrate in the optic nerves that could not be overcome by the strong fiber outgrowth 
promoting effects of NGF.  
The Schwab laboratory continued to investigate the possible source of the non-
permissive substrate in the CNS and therefore studied the interaction of CNS neurons and 
CNS glia. Rat sympathetic, sensory ganglion, or fetal retinal cells were plated onto 
cultures with dissociated optic nerve glial cells of young rats. They found that while 
immature oligodendrocytes and astrocytes were often touched by neurons and neurites, 
mature oligodendrocytes acted as a non-permissive substance for neuronal adhesion, 
neurite growth, and fibroblast spreading (Schwab et al., 1988). They also showed that 
adult rat spinal cord myelin acted to inhibit cell attachment, neurite outgrowth, and 
fibroblast spreading (Schwab et al., 1988). Rat CNS myelin was analyzed and size 
fractionation of myelin protein by SDS-Page resulted in the identification of two 
membrane bound proteins (a 35 and 250-kD fragment) that were highly non-permissive 
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for neurite growth and fibroblast spreading (Caroni & Schwab, 1988). To generate a 
function-blocking antibody, the Schwab laboratory immunized mice with the rat CNS 
myelin 35-kD and 250-kD protein fractions, raised hybridoma cells, and screened all the 
supernatants for anti-myelin antibodies. The antibody that had the strongest myelin 
neutralizing properties was designated as IN-1 and led to neurite growth and fibroblast 
spreading in vitro (Caroni et al., 1988). A myelin protein homologue of NI-250 was then 
purified from bovine spinal cord myelin (bNI-220) and was also shown to exert a potent 
neurite outgrowth inhibitory effect, including the collapse of growth cones and the 
inhibition of fibroblast spreading (Spillman et al., 1988). The monoclonal antibody IN-1 
was found to neutralize the inhibitory effects of bNI-220. The purification of the bNI-220 
protein led to the identification of six peptide sequences that were used to isolate the gene 
encoding NI-220/250, and this gene was named Nogo (Chen et al., 2000; GrandPre et al., 
2000; Prinjha et al., 2000).  
 
The Nogo Gene and its Protein Products  
Alternative splicing and alternate promotor usage produces three protein isoforms 
from the Nogo gene, Nogo-A, -B, and –C, see Figure 1.1 (Chen et al., 2000; GrandPre et 
al., 2000; Prinjha et al., 2000). All three Nogo isoforms are assigned to the Reticulon 
protein family due to the presence of a shared COOH-terminus containing a reticulon 
homology domain (RHD). Therefore, the Nogo gene has also been named as Reticulon-4 
(RTN4/nogo). This shared COOH-terminus is made up of two long hydrophobic domains 
that are separated by a hydrophilic short loop of 66 amino acids called Nogo-66. All three 
10 
 
 
 
isoforms of Nogo contain the Nogo-66 domain. The Nogo-66 domain in Nogo-A has 
been found to induce growth cone collapse in vitro (Oertle et al., 2003).  Among reticulon 
proteins, there is no homology at the NH2 –terminal, suggesting biologically diverse 
functions for this protein family. Specifically, Nogo-A and Nogo-B isoforms share a 
common NH2-terminus, which has been found to inhibit fibroblast spreading (Oertle et 
al., 2003). Finally, the Nogo-A isoform contains a unique specific region within the NH2-
terminus called the Amino-Nogo domain, which inhibits neurite outgrowth, induces 
growth cone collapse, and inhibits fibroblast spreading (Oertle et al., 2003). The three 
active sites found in Nogo-A are exposed to the extracellular space when Nogo-A is in 
the cell membrane (GrandPre et al., 2000; Dodd et al., 2005).  
11 
 
 
 
Nogo Protein Isoforms 
 
 
 
 
 
 
 
 
 
Figure 2.1. Nogo protein isoforms. Modified with permission from Kempf et al., 2013. 
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Nogo-A Signaling Cascade 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Nogo-A signaling cascade. Modified with permission from Kempf et al., 
2013.  
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Localization of the Nogo Proteins  
 The protein Nogo-A is highly enriched in the endoplasmic reticulum due to its 
endoplasmic reticulum retention signal, however, it is also highly expressed in 
mammalian oligodendrocytes, localized in the outer and innermost adaxonal myelin 
sheath (Huber et al., 2002). Nogo-A is also highly expressed in subpopulations of 
neurons during development, with a relative decrease in expression in adulthood 
(Josephson et al., 2001; Huber et al., 2002; Hunt et al., 2003; Meier et al., 2003). 
Additionally, beyond the CNS, Nogo-A is expressed in developing skin, skeletal muscle 
during differentiation, macrophages, testicular tissue, and in heart tissue (Huber et al., 
2002; O’Neill et al., 2004; Fry et al., 2007; David et al., 2008; Pool et al., 2009; Bullard 
et al., 2008).  
 The protein Nogo-B is expressed in the central and peripheral nervous system as 
well as in peripheral tissues (Huber et al., 2002; Bullard et al., 2008). In the CNS, Nogo-
B has been found to be involved in regulating vascular homeostasis and remodeling 
(Acevedo et al., 2004). Additionally, Nogo-B may play a role in hepatocyte proliferation, 
liver fibrosis, immune function, as well as cervical cancer metastasis (Tashiro et al., 
2013; Gao et al., 2013; Di Lorenzo et al., 2011; Xiao et al., 2013).  
Nogo-C is expressed in skeletal muscle and to lower levels in the brain and heart 
(Huber et al., 2002). The function of Nogo-C remains to be determined. Unlike Nogo-A, 
evidence supports little to no role of Nogo-B and Nogo-C taking part in neurite 
outgrowth inhibition (GrandPre et al., 2000).  
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Nogo-A Receptors and Intracellular Signaling Cascade 
The Nogo-66 domain of all three Nogo isoforms signals through two receptors: 
the Nogo-66 receptor (NgR1) and the paired immunoglobulin-like receptor B (PirB), see 
Figure 1.2 (Fournier et al., 2001; He et al., 2003). NgR is a GPI-linked cell surface 
receptor protein that lacks an intracellular domain and therefore signals through co-
receptors including p75 (Wang et al., 2002; Wong et al., 2002) or TROY/Taj (Park et al., 
2005), and Lingo-1 (Mi et al., 2004). Given the growth arresting effect of Nogo-A 
signaling, including growth cone collapse and neurite outgrowth inhibition, it was 
hypothesized that the signaling cascade most likely acted on cytoskeletal dynamics 
(Gozenbach & Schwab, 2008). The signaling cascade of the Nogo-66 domain and the 
amino-Nogo domain has been found to involve multiple signaling mechanisms. The 
major pathway of signaling involves activation of the small GTPase RhoA and 
concomitant suppression of Rac1, which leads to growth inhibition via a ROCK pathway 
(Fournier et al., 2003; Niederost et al., 2002; Lehmann et al., 1999). Activation of RhoA 
is accomplished by its release from the inhibitory regulator Rho-guanine dissociation 
inhibitor (Yamashita et al., 2003). Next RhoA activates Rho Kinase (ROCK), with its 
ability to activate multiple effectors including Lin-11, Isl-1, and Mec 3 Kinase 1 
(LIMK1) (Hsieh et al., 2006). Once activated, LIMK1 inactivates cofilin through 
phosphorylation, leading to F-actin polymerization, and causing growth cone 
stabalization and the inhibition of neurite outgrowth (Hsieh et al., 2006). The activation 
of the RhoA/ROCK pathway also leads to growth inhibition through microtubule 
disassembly mediated by CRMP2 and actomyosin contraction mediated by MLCII. 
15 
 
 
 
Additionally, the Nogo-66 domain has been found to signal via the paired 
immunoglobulin-like receptor B (PirB) which also signals through p75 (Atwal et al., 
2008).  Although much more is known about Nogo-66 signaling, the amino portion of 
Nogo-A is considered more important for neurite outgrowth inhibition and the putative 
Amino-Nogo receptor has yet to be discovered. Amino-Nogo is thought to also signal by 
activating the RhoA/ROCK pathway as well as activation of CREB and down-regulating 
the neuronal growth program.  
 Additionally, Nogo-A signaling has been found to increase intracellular levels of 
calcium (Bandtlow et al., 1993; Wong et al., 2002; Hasegawa et al., 2004), activate 
Protein Kinase C (PKC, Hasegawa et al., 2004; Sivasankaran et al., 2004), and activate 
Epidermal Growth Factor Receptor (EGFR, Koprivica et al., 2005). Interestingly, many 
downstream effectors activated by Nogo-A signaling are also activated by other myelin 
associated neurite growth inhibitors as well as chondroitin sulfate proteoglycans.  
 Additionally, various changes in gene and protein expression have been found 
after Nogo-A neutralization. Neutralization of Nogo-A by anti-Nogo-A antibodies (11C7 
and 7B12) in rat hippocampal slice cultures led to changes in RNA transcripts in genes 
related to growth, extracellular matrix, cell adhesion, neurogenesis, GTPase signal 
transduction, and growth factors (Craveiro et al., 2008). Furthermore, unlesioned spinal 
cord samples from genetically modified mice lacking Nogo-A, exhibited changes in 
protein expression in proteins related to cytoskeleton, signaling, neuroprotection, 
metabolism, and transport (Montani et al., 2009). These gene and protein changes after 
Nogo-A neutralization provide insight into additional signaling cascades that may be 
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involved in Nogo-A signaling.  
 In summary, the protein Nogo-A has emerged as an important inhibitory molecule 
located in the CNS environment that acts to restrict the regenerative potential of neurons 
and stabilize existing neuronal circuits. With the discovery of Nogo-A, additional factors 
have been found that also restrict neuronal reorganization in the CNS and are detailed in 
the following section.  
 
Additional Molecules Contributing to the CNS Inhibitory Environment 
Although the protein Nogo-A is considered to be one of the most potent neurite 
outgrowth inhibitors, there are various molecules that inhibit neurite outgrowth after 
injury in the CNS. Additional inhibitory proteins found in myelin that contribute to the 
growth restrictive environment seen after injury are myelin associated glycoprotein 
(MAG, McKerracher et al., 1994; Mukhopadhyay et al., 1994), oligodendrocyte and 
myelin glycoprotein (OMgp, Wang et al., 2002), and the repulsive axon guidance 
molecules Ephrin B3 (Benson et al., 2005), and Semaphorin 4D (Moreau-Fauvarque et 
al., 2003). Interestingly, MAG and OMgp also interact with NgR1 as well as PirB and it 
is thought  that myelin inhibitors may signal through multiunit receptor systems and the 
contribution of receptor subunits may depend on the type of neuron (Giger et al., 2008). 
In addition to myelin proteins, chondroitin sulfate proteoglycans, extracellular matrix 
molecules, also contribute to the growth inhibitory environment of the adult CNS 
(Niederost et al., 1999; Schmalfeldt et al., 2000). With the discovery of CNS inhibitory 
molecules, the possibility of developing strategies to inhibit these molecules and improve 
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functional recovery in the human after brain and spinal cord injury is at last a possibility. 
If these strategies prove successful in clinical trials, the field of rehabilitative medicine 
will be revolutionized and brain and spinal cord injured patients will for the first time 
have hope for significant recovery.  
 
Reorganizational Potential of the Aged CNS 
 As previously described, the adult CNS is much more limited in its capacity to 
repair itself after brain or spinal cord injury than the developing CNS or the adult PNS. 
However, some limited reorganization can occur and is the basis of some spontaneous 
recovery seen in patients. However, with age, the adult CNS becomes even less able to 
repair itself. For example, after brain damage due to stroke, functional recovery is 
diminished in the aged (Nakayama et al., 1994; Johnston et al., 2000) and it is possible that 
aging may reduce the ability of the lesioned brain to reorganize after brain and spinal cord 
injury. Animal studies have shown that after focal ischemic stroke in adult and aged rats, 
neurons in the peri-infarct cortex in the aged brain showed a greater degree of oxidative 
DNA and protein damage as well as a reduced induction of the heat shock protein (HSP) 
70, a cell stress protective protein, as compared to the adult brain (Li et al., 2005). 
Additionally, another study showed that aged rats versus adult rats after focal ischemic 
stroke displayed an abnormal profile of growth promoting and inhibiting proteins. For 
example, protein levels of MAG and Ephrin A5 were increased at post-stroke weeks 1 and 
2 in aged rats as compared to young adult rats (Li et al., 2006). These results indicate that 
the aged CNS may be more limited in its ability to repair itself than the adult CNS and 
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therefore therapeutic strategies may need to involve combinatorial therapies that can 
simultaneously stimulate a neuronal growth state and block multiple axonal growth 
inhibitors to induce functional recovery. 
 
NOGO-A BLOCKADE AFTER CNS INJURY 
Following the discovery of Nogo-A’s role in restricting neuronal plasticity in the 
adult and aged CNS, a flurry of investigation has been conducted over the last two 
decades to determine the therapeutic potential of inhibiting the protein Nogo-A in order 
to induce neuronal plasticity and thereby functional recovery after CNS injury. A variety 
of approaches have been used to block the function of Nogo-A including specific 
monoclonal antibodies directed against Nogo-A, Nogo-66 receptor blockers, and 
downstream signaling molecule inhibitors. The following three sections will outline the 
effectiveness of Nogo-A blockade to improve function in various CNS injury paradigms 
with a focus on using monoclonal antibodies to inhibit Nogo-A in a rat model of focal 
ischemic stroke. 
 
Functional Recovery and Neuroanatomical Plasticity after Nogo-A Neutralization after 
Spinal Cord Injury 
Following the discovery of Nogo-A as a myelin associated inhibitor, experiments 
were undertaken to determine whether blockade of Nogo-A function in vivo after spinal 
cord injury would lead to axonal regeneration and functional recovery. In the 1990s Schnell 
and Schwab used the monoclonal antibody IN-1 and delivered it to spinal cord-injured rats. 
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The antibody was delivered to the spinal cord-injured rats by implanting hybridoma cells 
that secreted IN-1 or a non-specific antibody into the brain. Rats treated with IN-1 
displayed functional recovery and correlated with regeneration considerably past the lesion 
site. These exciting results have now been replicated in rats and primates by using local 
intrathecal pump infusions of recombinant IN-1 Fab fragments or highly purified Nogo-A 
specific monoclonal antibodies that recognize various domains in the Amino-Nogo 
segment of the Nogo-A protein. 
 Furthermore, these antibody treatment results have been extended by using other 
approaches to block the function of the protein Nogo-A in spinal cord injury, such as 
blocking the Nogo receptor (NgR). A competitive antagonist for the NgR receptor called 
NEP1-40 has been used to treat spinal cord-injured rats and resulted in axonal regeneration 
and improved recovery (GrandPre et al., 2002). Another NgR antagonist, called 
NgR(310)ecto-Fc, also produced improved axonal growth and recovery of function when 
administered to spinal cord-injured rats. Given the promising results shown after Nogo-A 
inhibition after spinal cord injury in rat and primate studies (Freund et al., 2006; Freund et 
al., 2009), a phase I clinical trial was recently completed evaluating the feasibility and 
safety of administering anti-Nogo-A antibodies intrathecally to acutely spinal cord injured 
patients. The trial reported no safety concerns and a phase II clinical trial is currently in 
preparation (Abel et al., 2011).   
 
Functional Recovery and Neuroanatomical Plasticity after Nogo-A Neutralization after 
Traumatic Brain Injury 
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 Based on the in vivo success of treating rats with spinal cord injury with various 
approaches that block the function of Nogo-A, the effectiveness of blocking Nogo-A after 
traumatic brain injury (TBI) was investigated. Using a lateral fluid percussion brain injury 
model, rats were treated with anti-Nogo-A immunotherapy or a control antibody 24 hours 
after injury.  Using a test of motor function called the composite neuroscore, it was shown 
that there was no difference between the anti-Nogo-A antibody treated rats and the control 
antibody treated rats when tested 4 weeks post-treatment (Lenzlinger et al., 2005; 
Marklund et al., 2007). However, in these same experiments, rats that were treated with 
anti-Nogo-A antibody performed better than the control antibody treated rats on the Morris 
wate maze task for spatial memory (Lenzlinger et al., 2005; Marklund et al., 2007). 
Additionally, rats that were treated with anti-Nogo-A antibody following TBI had a higher 
growth-associated protein-43 expression, an axonal growth marker, in the CA1 of the 
hippocampus than control antibody treated rats (Marklund et al., 2007). More studies are 
needed to address the effectiveness of anti-Nogo-A immunotherapy after TBI for 
improving sensorimotor deficits.  
 
Functional Recovery and Neuroanatomical Plasticity after Nogo-A Neutralization after 
Ischemic Stroke 
Many studies have also been performed evaluating the therapeutic potential of 
blocking Nogo-A in rodent models of ischemic stroke. The rodent model of middle 
cerebral artery occlusion (MCAO) typically damages the ipsilateral sensorimotor cortical 
area and rats are rendered incapable of accurately performing a skilled motor task that 
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involves reaching for, grasping, and bringing a pellet to their mouth with the impaired 
forelimb (Castro et al., 1972; Whishaw et al., 2000). These types of movements have 
been found to be dependent on intact cortico-spinal and cortico-rubral-spinal pathways 
(Castro et al., 1972; Whishaw et al., 2000). Using this model, the motor deficits seen after 
rodent ischemic stroke, like in humans, are generally permanent and limited spontaneous 
recovery occurs over time (Papadopoulos et al., 2002; Weissner et al., 2003; Seymour et 
al., 2005; Markus et al., 2005; Tsai et al., 2007; Tsai et al., 2011).  
Studies mainly from our laboratory have evaluated the therapeutic potential of 
blocking the protein Nogo-A using function blocking antibodies (anti-Nogo-A 
immunotherapy) after ischemic injury in the rat. Adult rats underwent a middle cerebral 
artery occlusion and were immediately treated with the monoclonal antibody IN-1 that 
recognizes the Amino-Nogo domain. These rats were then tested on a skilled reaching 
task and it was shown that treatment with IN-1 led to recovery of 80% of pre-stroke 
skilled reaching ability while control antibody and stroke only rats recovered only 40% of 
their pre-stroke reaching ability (Papadopoulos et al., 2002). Evaluation of the stroke 
lesion in these animals showed that the lesions were confined to the cortical tissue with 
no subcortical involvement and the average hemispheric stroke size was between 8% and 
12%, with no significant difference between groups. Therefore, no neuroprotective effect 
was seen with anti-Nogo-A immunotherapy. This study also displayed for the first time 
the successful application of anti-Nogo-A immunotherapy in rats with small to medium 
sized strokes. This profound functional recovery was also found to be associated with 
new axonal growth from the undamaged hemisphere. The unlesioned hemisphere was 
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found to form new cortico-efferent projections to the contralateral red nucleus 
(Papadopoulos et al., 2002).  
Since immediate treatment following stroke is often not possible in the hospital, 
subsequent studies went on to evaluate the treatment time window that exists for the 
successful administration of anti-Nogo-A immunotherapy after ischemic stroke in adult 
rats. The efficacy of anti-Nogo-A immunotherapy administered 24 hours, 1 week, and 9 
weeks post-stroke was evaluated in three different studies, using three different anti-
Nogo-A antibodies: 7B12, IN-1, and 11C7 respectively (Weisser et al., 2003; Seymour et 
al., 2005; Tsai et al., 2011). All three antibodies recognize the Amino-Nogo domain, 
however 7B12 and 11C7 are more specific and recognize short amino acid sequences 
within the Amino-Nogo domain. Adult rats treated with these function blocking Nogo-A 
antibodies at each of the three time points recovered up to 70 to 78% of their pre-stroke 
skilled reaching ability while control antibody and stroke only animals recovered only 30 
to 50% of their pre-stroke skilled reaching ability (Weisser et al., 2003; Seymour et al., 
2005; Tsai et al., 2011). Functional recovery in these studies was also associated with 
neuroanatomical plasticity, and increases in cortico-efferent projections from the 
undamaged hemisphere were found crossing the midline to reinnervate the contralateral 
deafferented red nucleus (Seymour et al., 2005) and the contralateral cervical spinal cord 
(Weisser et al., 2003). Additionally, increased dendritic complexity was found in layer V 
pyramidal neurons within the undamaged homotopic sensorimotor cortex in adult rats 
treated with IN-1 at the time of stroke (Papadopoulos et al., 2006). Together, these 
studies support the use of anti-Nogo-A immunotherapy in adult rats with small to 
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medium sized strokes in the acute (immediate to 24 hours post-stroke), subacute (1 week 
post-stroke), and early chronic (9 weeks post-stroke) phases after ischemic stroke.  
Given that stroke is more prevalent in human aged populations (Lloyd-Jones et 
al., 2009), it is important to test preclinical therapies in aged rodents. Therefore, anti-
Nogo-A antibodies (7B12) were administered to aged rats 1 week post-stroke. Anti-
Nogo-A immunotherapy improved functional recovery on the skilled reaching task in 
aged rats to the same magnitude as seen in previous studies, although the rate of recovery 
was slower and a longer time period for recovery was necessary as compared to adult rats 
(Markus et al., 2005). Anti-Nogo-A immunotherapy administered 1 week post-stroke has 
also been shown to improve cognitive impairment in aged rats as measured by the Morris 
Water Maze spatial memory task (Gillani et al., 2011). Anti-Nogo-A immunotherapy 
administered 1 week post-stroke has also been found to improve cognitive recovery from 
neglect after cortical aspiration lesion in adult rats (Brenneman et al., 2008). 
Other experimental methods have been used to interfere in the Nogo-A-NgR 
signaling pathway after stroke in rodents. Various mechanisms can be used to inhibit the 
Nogo-66 receptor (NgR) including the NEP1-40 antagonist peptide, the NgR(310)Ecto-
Fc IgG fusion protein that binds to Nogo-A, genetic knockout of the NgR gene, and 
RNAi mediated NgR knockdown. NEP1-40 is a Nogo-66 receptor antagonist peptide that 
competes for the NgR receptor with the Nogo-66 domain (GrandPre et al., 2002). 
Treatment with the NEP1-40 antagonist peptide improved skilled reaching after cortical 
stroke in rodents (Fang et al., 2010; Zai et al., 2011). Another mechanism for blocking 
NgR signaling is the use of a truncated soluble Nogo receptor fragment that binds the 
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Nogo-66 domain (Fournier et al., 2002). Rats treated with this IgG fusion protein after 
stroke displayed improved motor recovery in skilled reaching (Lee et al., 2004). Other 
ways of inhibiting the signaling mediated by NgR include adenovirus-mediated RNA 
interference knockdown of NgR and NgR genetic knockout mice. Knockdown of the 
NgR receptor by RNAi in rats after stroke at 24 hours or two weeks post-stroke lead to 
motor recovery on the Montoya’s Staircase skilled reaching task (Wang et al., 2010).  
NgR -/- mice also showed improved motor recovery after ischemic focal stroke as 
compared to NgR +/+ mice (Lee et al., 2004).  
Although methods of interfering with NgR signaling have been shown to be 
effective in improving recovery after stroke in rodents, antibody based approaches for 
inhibiting the protein Nogo-A directly are thought to be more effective in inducing 
neuronal plasticity. This is due to several reasons. Firstly, the Nogo-A protein is thought 
to signal through three different receptors at minimum, which include NgR, PirB, and the 
proposed Amino-Nogo receptor. Antibody binding to Nogo-A may lead to direct and 
indirect inability (steric inhibition) of the protein to bind all three receptors at once. 
Secondly, antibody binding of Nogo-A leads to endocytosis and a decreased level of 
Nogo-A levels at the cell membrane (Joset et al., 2010). Finally, signaling through the 
Amino-Nogo domain and the unknown Amino-Nogo receptor is thought to lead to gene 
changes in the neuron that render it more responsive to growth promoting signals (Joset 
et al., 2010).  
The following section will describe the pathophysiology, epidemiology, and 
recovery potential of human ischemic stroke. Afterwards, the unanswered questions 
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regarding the use of anti-Nogo-A immunotherapy to improve recovery of function in 
chronic large sized strokes will be discussed.   
 
STROKE 
Introduction 
 Cerebrovascular disease encompasses conditions that arise as a result of 
pathology affecting cerebral blood vessels. Stroke is defined as the sudden focal loss of 
brain function due to an interruption of cerebral blood flow. Following decreased blood 
flow, neurons begin to dysfunction due to the lack of oxygen and nutrients. Neurological 
functioning is compromised and the brain will become permanently damaged if blood 
flow is not reestablished as soon as possible. Strokes are either ischemic or hemorrhagic, 
depending on whether the compromised cerebral blood flow is caused by a blockage in a 
cerebral blood vessel or by rupture of a cerebral blood vessel respectively. Ischemic 
strokes caused by an occluded blood vessel are the most common type of stroke seen 
(87%), while the remainder of strokes are hemorrhagic (AHA, 2013). Most commonly, 
ischemic strokes occur due to thrombosis or emboli from a large vessel or the heart while 
hemorrhagic strokes often occur due to rupture of blood vessels due to hypertension or 
rupture of intracranial aneurysms (Biller, 2012).   
Prevalence and Incidence 
Over 6 million American adults living in the United States have suffered a stroke 
and it is estimated that an additional 795,000 people will experience a new or recurrent 
stroke each year (AHA, 2013). Globally, it is estimated that upwards of 60 million people 
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have suffered a stroke and yearly more than 16 million new stroke events will occur 
(Truelsen & Bontina, 2009). While the overall incidence of stroke is declining in many 
developed countries, the overall burden of stroke is increasing due to the aging 
population globally (WHO, Global Burden of Stroke, 2013).  
 
Constellation of Symptoms Seen Post-Stroke 
 Symptoms of a stroke start suddenly and are dependent on the area of brain tissue 
that is affected. Commonly, stroke causes deficits across many modalities including 
motor, sensory, language, and cognitive domains, with the severity related to how 
extensive the stroke damage was (Kelly-Hayes et al., 2003). Due to the extensive deficits 
caused by stroke, it is considered to be the leading cause of serious long-term disability in 
the United States (Survey of Income and Program Participation, a survey of the US 
Bureau of the Census). Among ischemic stroke survivors over the age of 65, a large 
proportion still suffers from significant disabilities after 6 months post-stroke (Kelly-
Hayes, 2003). Specifically, up to 80% experience motor dysfunction, including 50% who 
are suffering from hemiparesis and 30% who are unable to walk without assistance 
(Kelly-Hayes, 2003). Almost half of stroke survivors suffer from cognitive symptoms 
and 35% had depressive symptoms (Kelly-Hayes, 2003).  Language troubles also plague 
stroke sufferers, with approximately 19% having aphasia (Kelly-Hayes, 2003).  The most 
severely affected stroke survivors are dependent in activities of daily living (~26%) and 
are institutionalized in nursing homes (~26%) (Kelly-Hayes, 2003).  
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Treatment Strategies 
 Currently, the only approved treatment strategy for acute ischemic stroke is the 
use of recombinant tissue plasminogen activator (tPA) within the first 4.5 hours after 
stroke onset (Hacke et al., 2008). Unfortunately, multiple barriers exist for the 
widespread utilization of tPA in most stroke cases. Firstly, a large percent of stroke 
patients do not recognize the symptoms of stroke and therefore delay seeking treatment. 
According to one study, only 23.5% of stroke patients arrive at the emergency room 
within 3 hours of symptom onset, and only 4.3% end up receiving thrombolytic therapy 
(CASPR Investigators, 2005). Additionally, it is estimated that only 21% of U.S. counties 
have a hospital and this may also lead to delays in seeking treatment (CDC, 2008). Other 
factors limiting the use of tPA include delays in diagnosis, misdiagnoses, and adverse 
side effects. Once the short time window for tPA administration has passed, rehabilitative 
strategies are the only viable approaches in the subacute and chronic stages after stroke. 
Such therapy may include physical therapy, speech therapy, occupational therapy, and 
neuropsychological and cognitive therapy. Although real improvements in function are 
seen after rehabilitation, the magnitude of recovery is limited (Duncan et al., 2000). 
Additionally, neuroprotective therapies once held great promise in preclinical trials, 
however this class of drugs mainly failed in clinical trials (Cheng et al., 2004; Savitz et 
al., 2007; Ginsberg et al., 2007; Faden et al., 2007; Young et al., 2007). Therefore, it is 
important to investigate treatment strategies that can be used successfully after a stroke 
has already taken place to enhance recovery. The population of chronic stroke sufferers is 
large and optimism exists among neuroscientists for the development of neurorestorative 
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therapies, such as anti-Nogo-A immunotherapy, that can improve functional recovery 
after stroke by enhancing brain plasticity even in the chronic phases after stroke.  
 
Prognosis for Functional Recovery in Stroke  
 For most patients, the majority of significant recovery occurs during the first 3-6 
months after stroke (Skilbeck et al., 1983). Although limited in magnitude, further 
improvements may occur beyond 6 months and for many years if the stroke patient 
engages in stimulating and rehabilitative activities. Many factors play a role in the time 
course and magnitude of functional recovery after stroke. In general, the strongest 
prognostic factor for the magnitude of stroke recovery is the severity of the initial deficit. 
In addition, stroke severity affects the time course of recovery as well. Data from the 
Copenhagen Study of stroke survivors showed that 95% of mild stroke survivors reached 
their best recovery within 6 weeks post-stroke while moderate, severe, and very severe 
stroke patients reached their best recovery at 10, 15, and 13 weeks post-stroke 
respectively (Jorgensen et al., 1995a, 1995b).  
 
Enhanced Potential for Neuronal Plasticity Early After Stroke Injury 
 Immediately after stroke, it is recognized that a critical time window opens that 
reinstates a molecular environment in the adult CNS that is more conducive to neuronal 
plasticity. The peri-infarct tissue that lies beyond the glial scar turns into a growth 
permissive zone where levels of growth inhibitory molecules are reduced and growth-
promoting molecules are increased during the first month after stroke in adult rats 
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(Carmichael, 2006; Carmichael et al., 2005; Carmichael et al., 2001). Additionally, a 
transient increase in neurotrophic factors such as basic fibroblast growth factor (bFGF) 
and nerve growth factor (NGF) are seen after focal ischemia in ipsilateral non-ischemic 
areas (Speliotes et al., 1996). Furthermore, hyperexcitability exists in the tissues 
ipsilateral and contralateral to the infarct, though dissipating over several weeks 
(Buckkremer-Ratzmann et al., 1996). Finally, recovery after brain injury can be delayed 
by pharmacological prevention of hyperexcitability during the first 3 weeks after 
ischemia, but not during later time points (Schaller et al., 1986). Therefore, treatments 
that enhance neuronal plasticity such as rehabilitation and restorative therapies may be 
more efficacious when applied early after stroke (within the first four weeks in adult rats) 
than when applied later. Research in rats exposed to rehabilitation support this 
hypothesis. Biernaske et al. exposed adult rats after stroke to enriched environments and 
rehabilitative reach training starting at 5 days, 14 days, or 30 days after focal ischemia. 
The effect of enriched rehabilitation was found to be time dependent. Animals that were 
exposed to enriched rehabilitation beginning at 5 days post-stroke showed a statistically 
greater improvement in skilled reaching than rats that began the enriched rehabilitation at 
14 days post-stroke. Furthermore, rats that began the rehabilitation scheme at 30 days 
post-stroke did not display any improved motor performance as compared to control 
animals. Changes in dendritic complexity in the homotopic contralesional sensorimotor 
cortex were also time dependent and only animals that underwent the enriched 
rehabilitation paradigm at 5 days post-stroke displayed increases in dendritic complexity 
in layer V pyramidal neurons (Biernaske et al., 2004). These results support the view that 
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the remaining ipsilesional and contralesional cortical tissues are more responsive to 
rehabilitation early after stroke. Therefore, in humans and rodents, it is likely that 
spontaneous neuronal plasticity will be most likely to occur in the early weeks after 
stroke.  
 
Mechanisms of Stroke Recovery 
Early spontaneous recovery after stroke in humans (within hours to days) is 
attributed to the resolution of edema and the reperfusion of the ischemic penumbra 
(Dombovy et al., 1991). Recovery seen over the course of weeks, months, and years after 
stroke is considered to be the result of spontaneous neural circuit reorganization 
(Carmichael et al., 2006; Murphey et al., 2009), with neurogenesis and angiogenesis 
(Thored et al., 2007; Hermann et al., 2009) potentially playing a role as well. Through 
rehabilitation, the stroke-injured brain is able to relearn tasks, and other undamaged areas 
of the brain are thought to take over the lost functions. With the advent of functional 
neuro-imaging techniques such as functional Magnetic Resonance Imaging (fMRI), 
Positron Emission Tomography (PET), Electroencephalography (EEG), and 
Magnetoencephalography (MEG), extensive investigations of the neural correlates of 
motor recovery after stroke have been evaluated at the systems level. Various motor areas 
in both the damaged (ipsilesional) hemisphere and the undamaged (contralesional) 
hemisphere have been implicated (Chollet et al., 1991; Grefkes et al., 2008; Weiller et al., 
1992).  
In the damaged hemisphere, increased task related neural activity has been found 
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using fMRI in the spared adjacent tissue around the infarct and the primary sensorimotor 
cortex, as well as in secondary motor areas such as the premotor cortex and the 
supplementary cortex (Chollet et al., 1991; Cramer et al., 2003; Johansen-Berg, et al., 
2002). Increased activation has also been found in the ipsilateral cerebellum (Chollet et 
al., 1991).  
Cortical reorganization has also been seen in the undamaged hemisphere. 
Increased neural activation related to movement of the affected hand has been seen in the 
contralesional sensorimotor cortex as well as in secondary motor areas such as the 
premotor cortex and the supplementary motor cortex, and the ipsilateral cerebellum 
(Chollet et al., 1991; Rehme et al., 2010).  
The factors leading to increased activation of ipsilesional versus contralesional 
motor areas and which pattern of activation leads to better recovery is controversial. 
Feydey et al. showed that the nature of the lesion affects cortical reorganization and may 
dictate which hemisphere is recruited in recovery mechanisms. They found that in strokes 
that affected most of the primary motor cortex, it was more likely for the contralesional 
hemisphere to show increased activation (Feydey et al., 2002). Conversely, strokes that 
mostly spared the primary motor cortex were more likely to show increased activation in 
the ipsilesional hemisphere (Feydey et al., 2002). Additionally, studies have shown that 
activity in bilateral premotor areas and in contralesional primary motor cortex correlate 
with more severe motor impairment (Loubinoux et al., 2007; Marshal et al., 2009; Ward 
et al., 2003; Ward et al., 2004). A recent meta-analysis evaluated the current literature on 
motor related neural activity after stroke and found that better motor performance was 
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associated with greater activation in the ipsilesional primary motor cortex (Rehme et al., 
2012). Acutely after stroke, neural activity is enhanced in both hemispheres and is 
correlated with stroke recovery, while over the course of 12 months post-stroke, good 
recovery is correlated with the return of ipsilesional activation patterns (Ward et al., 
2003; Tombari et al., 2004; Rehme et al., 2010).  
 
Summary 
 Currently, the only FDA approved treatment for stoke is thrombolysis. However, 
most stroke patients do not receive this therapy and are left with permanent and profound 
deficits. A treatment that could restore function long after the acute phases after stroke 
have passed would greatly decrease disability among stroke survivors. Anti-Nogo-A 
immunotherapy has been shown to be successful in restoring lost functions after small 
and medium sized strokes in adult and aged rats when applied immediately or up to 9 
weeks post-stroke. However, it is not known whether anti-Nogo-a immunotherapy is 
effective in adult rats with large strokes. Additionally, it is not known how long the 
treatment window exists for the administration of anti-Nogo-A immunotherapy in chronic 
stroke-impaired rats. Therefore, this dissertation proposes to examine the treatment time 
window and efficacy of anti-Nogo-A immunotherapy in the early and late chronic phases 
after ischemia in adult rats with large sized strokes. 
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CHAPTER THREE 
METHODOLOGY AND EXPERIMENTAL DESIGN 
INTRODUCTION 
The experiments outlined in this dissertation involve testing the hypothesis of 
whether blocking the function of Nogo-A after chronic moderate to very severe stroke in 
a rodent model of focal ischemic infarction will induce functional sensorimotor recovery. 
In the clinic, there is a tendency towards pessimism regarding the expected success of 
interventions, whether pharmacological or rehabilitative, to be successful in chronic 
stroke. A similar pessimistic outlook exists for the success of interventions for severe 
stroke, with many questioning the appropriate use of resources to try to rehabilitate this 
low likelihood recovery population. We decided to assess whether treatment with anti-
Nogo-A immunotherapy in the chronic phases after stroke can lead to functional recovery 
in adult rats with moderate to very severe chronic sensorimotor deficits. This chapter will 
outline the experimental design, rationale, and methods used for this dissertation 
 
Methodological Considerations in Preclinical Stroke Studies 
Over the past decade many therapeutic agents and strategies were tested in 
preclinical studies and found to be efficacious in small animal models of ischemia. 
Billions of dollars later, none of these treatments except tPA, were found to be effective 
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in human trials (Turner et al., 2013). In general, it is thought that various experimental 
design issues in preclinical studies may have contributed to the translation failure of 
neuroprotective strategies. In 1999, Dr. Marc Fisher and Dr. Gary Houser of 
Massachusetts University conceived of assembling a select group of the world’s leading 
scientists to meet and discuss issues that were critical for the development of drugs and 
devices for stroke treatment. The recommendations of this group are known as the Stroke 
Therapy Academic Roundtable Preclinical Recommendations (STAIR) and updates to 
their statements are issued on a periodic basis (Fisher et al., 1999; Fisher et al., 2009). 
Furthermore, recent meta-analyses have shown that when quality scores are calculated for 
preclinical studies using the STAIR criteria, there is a troubling negative association 
between studies with low methodological quality and large estimates of treatment 
efficacy (Horn et al., 2001). Clearly, problems with preclinical study design are 
contributing factors in the failure of “bench to bedside translation”. Therefore, the most 
recent recommendations of the STAIR committee as well as recommendations from key 
reviews on the topic of preclinical design quality will be discussed as applicable 
throughout this methodology chapter (Fisher et al., 1999; Dirnagl et al., 2006; Fisher et 
al., 2009; Kahle & Bix, 2012). For an overview of specific recommendations for the 
design of preclinical studies and how the experiments in this dissertation adhere to those 
recommendations, refer to Table 3.1.  
Additional factors that complicate the evaluation of treatment effects in both 
preclinical and human clinical trials include the suboptimal reporting of a priori 
35 
 
 
 
inclusion/exclusion criteria as well as post-randomization exclusions. The gold standard 
for avoiding these types of problems is to design studies with strict a priori 
inclusion/exclusion criteria as well as to use an intention-to-treat (ITT) paradigm for the 
analysis of the data. Intention-to-treat paradigms involve analyzing all the data from 
subjects as they were randomized, regardless of study protocol or treatment delivery 
deviations. This approach is considered to provide the highest level of evidence regarding 
the treatment efficacy since investigator bias under the disguise of well intentioned post-
randomization exclusions is not allowed to influence the data (Fisher et al., 1999). The 
use of this type of analysis is highly recommended in human randomized clinical trials 
(FDA Guidelines, 1988). Additionally, this type of analysis may give a better estimate of 
what the treatment efficacy would be in actual clinical use as deviations from treatment 
paradigms are frequent. As of yet however, not many preclinical studies adhere to this 
type of analysis. Therefore, in order to adhere to similar levels of stringency seen in 
human clinical trials, the data in this dissertation were first analyzed using an intention-
to-treat paradigm. Given that the intention-to-treat analysis may provide very 
conservative estimates of treatment efficacy, a second analysis was done that excluded 
animal subjects that majorly deviated from the experimental protocol. This analysis is 
known as a per-protocol analysis (PP), and is often conducted with human clinical trial 
data as well. PP paradigms may lead to treatment estimates that are inflated and may be 
more reflective of optimal conditions and not typical efficacy. In human clinical trial 
literature, the results from these types of analyses are considered to have a higher chance 
of specified and unspecified bias due to the loss of pure randomization procedures. 
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Therefore, if a study conducts post-randomization exclusions, the potential of this 
treatment to improve recovery must be evaluated in light of both an ITT and a PP 
analysis. The results from this project will be expressed from both of these types of 
analyses to provide an accurate picture of treatment efficacy. Finally, reporting of 
dissertation study parameters and results was based on specific guidelines described in 
the Consolidated Standards of Reporting Trials (CONSORT) and the Animal Research: 
Reporting In Vivo Experiments (ARRIVE) checklists (Schultz, et al., 2010; Kilkenny et 
al., 2010). These checklists were used to improve the reporting in this dissertation.  
Experimental Design and Timeline 
See Figure 3.1 for a description of experimental design and timeline. As described 
in CHAPTER ONE, the experimental overview and hypothesis chapter, Specific Aim 1 
evaluated the spontaneous sensorimotor recovery profile of all the animal subjects that 
underwent a focal ischemic stroke. This aim was designed like a prospective 
observational cohort study to determine the relationship between sensorimotor recovery 
across three different behavioral tasks during the acute and chronic phases after stroke 
induction. Furthermore, retrospective analysis of sensorimotor recovery and its 
correlation to stroke size was performed using histological sections. Post-stroke data was 
collected from all animal subjects for a total of 8 weeks post-stroke (2 months). A subset 
of animals from the original set was examined for a total of 24 weeks post-stroke (6 
months), see Figure 3.1.   
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Specific Aim 2 evaluated anti-Nogo-A immunotherapy as a treatment to improve 
sensorimotor function in adult rats suffering from chronic stroke with moderate to very 
severe deficits. This aim was designed as a randomized, single blind, preclinical trial 
evaluating treatment efficacy at two different chronic administration time points, 
approximately 2 and 6 months post-stroke. This was done to evaluate the treatment 
window for anti-Nogo-A immunotherapy in the chronic stage following ischemia in 
moderate to very severely impaired rats. All data was evaluated using an intention-to-
treat paradigm as well as a per-protocol paradigm. The animals used in the ITT and PP 
analyses are shown in Table 3.2.  The animals excluded from the PP analysis are shown 
in Table 3.3 and a description of these exclusions is listed in Table 3.4.   
Aim 3 involved post-mortem evaluation of neuroanatomical plasticity following 
anti-Nogo-A immunotherapy in the brains of treated rats, specifically evaluating dendritic 
complexity of layer V pyramidal neurons located in the perilesional and contralesional 
caudal forelimb motor cortex.  
All animals (n = 75) underwent focal ischemic stroke. Post-stroke data was 
collected for n = 66 animals. After a period of 8 weeks, n = 35 animals (according to 
inclusion/exclusion criteria) were randomized into three balanced groups, taking into 
account the severity of their stroke deficit. The three experimental groups treated at 9 
weeks post-stroke consisted of: (1) middle cerebral artery occlusion (MCAO)/anti-Nogo-
A immunotherapy (n = 14), MCAO/control antibody (n = 12), and MCAO only (n = 9). 
A subset of the original n = 66 animals, namely n = 7 animals were used to collect post-
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stroke data for a total of 24 weeks. These animals were then randomized into three 
groups. The three experimental groups treated at 25 weeks (6 months) post-stroke 
consisted of: (1) middle cerebral artery occlusion (MCAO)/anti-Nogo-A immunotherapy 
(n = 4), MCAO/control antibody (n = 2), and MCAO only (n = 2). 
Animal Subjects 
Animal Subjects Background. The selection of species, strain, and even vendor is an 
extremely important parameter in the design of preclinical studies and in the potential 
success of translating preclinical treatment results to clinical trials in humans. Studies 
have shown that different rat strains and even the same strains from different vendors 
display remarkable differences in regards to behavioral performance, evolution of injury 
after lesion models, and recovery responses to treatment interventions (O’Bryent et al., 
2011; Oliff et al., 1995; Oliff et al., 1996). Therefore when evaluating a treatment 
intervention during the preclinical phase it is important to maintain the same parameters 
as closely as possible to previous work in order to properly compare across studies. In 
keeping with this premise, the previous work in the Kartje laboratory using anti-Nogo-A 
immunotherapy after stroke has mostly focused on using male adult (2-3 month old) 
Long Evans black-hooded rats to evaluate recovery potential (Seymour et al, 2005; 
Papadopoulos et al., 2006; Tsai et al., 2007; Gillani et al, 2010; Tsai et al., 2011). 
Consequently, the experiments in this dissertation were conducted using the Long Evans 
black-hooded rat strain (2-3 months of age) to maintain experimental homogeneity. This 
outbred strain was initially selected for our laboratory experiments due to the rats’ 
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temperament being very amenable for behavioral training. Additionally, Long Evans 
black-hooded rats have been shown to display superior skilled reaching ability, larger 
forelimb movement representations in the motor cortex, and lower cortical stimulation 
intensities needed to initiate forelimb movements as compared to other rat strains 
(Vandenberg et al., 2002). All these factors have lead to the continued use of this rat 
strain in our laboratory as a model species for the evaluation of sensorimotor function 
after cerebral injury. Although the use of this strain to evaluate the efficacy of anti-Nogo-
A immunotherapy in chronic severe stroke in this dissertation is considered prudent in 
regards to facilitating comparison across similar studies, it is also important to note that 
once a particular hypothesis has been tested in this setting of homogenous methodology, 
the next step in evaluating a treatment for bench to bedside translation is evaluating its 
efficacy across various heterogenic parameters such as rat strain, age, sex, health status, 
ischemic lesion model, and ultimately different species such as larger mammals and 
nonhuman primates. With this approach, preclinical to clinical trial translation failure can 
be minimized and the robustness of a particular treatment strategy can be evaluated.  
Animal Subjects Description. All experiments described in this dissertation were 
approved by the Institutional Animal Care and Use Committee of Hines Veterans Affairs 
Hospital under IACUC protocol # H10-028. IACUC documentation is provided in 
Appendix A of this dissertation. A total of 75 adult male Long Evans black-hooded rats 
(2 months of age at the start of the study) were used. All animals, strain ID HsdBLU:LE, 
were ordered from the Harlan Laboratories animal facility, Barrier 217, in Indianapolis. 
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This was done in order to maintain the same genetic background in the animals, as 
animals were ordered in overlapping cohorts. Animals were housed in standard cages (2 
rats per cage) with a 12-hour light/dark cycle in a fully accredited animal care facility at 
Hines Veteran Affairs Hospital. Due to aggressive fighting, some rats had to be separated 
and housed individually (n = 10). Rats had access to fresh water ad libitim and were fed 
standard laboratory chow (Harlan 2018 Rodent Diet). Rats were food restricted to 95% of 
their predicted weight by age at the start of the experiments. Rats were fed approximately 
12 grams of standard rat chow each at the beginning of the study (2 month old rats 
weighing 250-300 grams each) and increased over time to approximately 16-20 grams 
per rat (7-16 month old rats weighing 400-500 grams). All animals were number coded 
and investigators conducting behavioral testing and neuroanatomical analyses were 
blinded to the treatment condition throughout the experiment.  
Behavioral Training and Testing 
Skilled Forelimb Reaching Task  
Reaching Task Background. Skilled forelimb movements involve the ability to reach for 
an object and manipulate it using the digits. These movements are thought to originate 
from general food-handling behavior (Ivanco et al., 1996) and are displayed by various 
mammals including rats, primates, and humans. The level of homology across skilled 
forelimb movements such as reaching for food is quite striking when comparing rodents 
and humans as shown in Figure 3.2 (Iwaniuk et al., 2000; Whishaw et al, 1992;Sacrey et 
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al., 2009;Klein et al., 2012). These similarities can be explained by the morphological 
homology across mammalian species that includes similarities in skeletal and muscular 
structure, as well as comparable neural control of motor movement (Iwaniuk et al., 2000). 
Due to this fact, this natural behavior has become the focus of a select number of 
behavioral tests meant to measure movement deficits after various insults to the central 
nervous system in preclinical studies. One such test is the skilled forelimb-reaching task. 
This task is a sensitive skilled motor task designed to test voluntary skilled forelimb 
function in normal as well as brain damaged rats. It has been shown that the execution 
and coordination of skilled forelimb movements in this task are dependent on the 
synergism of multiple descending cortico-efferent pathways that primarily include the 
corticospinal tract originating from both the rostral and caudal forelimb motor cortex, the 
rubrospinal tract, the tectospinal tract, as well as the reticulospinal tract (Kennedy, 1990; 
Neafsey et al., 1986; Naus et al., 1985; Akintude and Buxton, 1992). Damage to any of 
these tracts will lead to impairment of skilled forelimb reaching performance. 
Additionally, damage to the dorsolateral striatum impairs forelimb reaching as well 
(Whishaw et al., 2007). Expectantly, various forms of neurological injury, including focal 
ischemic stroke in the rat, have produced acute and chronic deficits in skilled forelimb 
reaching due to damage to the various motor systems involved in skilled motor control 
(Markus et al., 2005; Papadopoulos et al., 2009). Therefore, this task is considered to be a 
good model of skilled movement in the rat that can be used to evaluate therapies aimed at 
improving manual dexterity in humans.  
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Reaching Task Description. Although reach to eat behavior in rats is a natural and 
spontaneous behavior, rats must be trained to perform the skilled reaching task. Training 
begins with food restricting the rats as stated previously. This is done to motivate the rats 
to reach for a food object, a round sucrose pellet (45 mg; Bilaney Consultants, 
Frenchtown, NJ). Rats were trained within approximately 2-4 weeks. Rats were placed in 
the reaching apparatus in pairs during the first 1-3 days of training to decrease anxiety 
during the habituation period. The reaching apparatus is a Plexiglas chamber (30 x 36 x 
30 cm) with an oval opening on one wall (1.5 x 3 cm). Underneath the oval opening there 
is a shelf where sugar pellets are placed on a grid (see Figure 3.3). Rat pairs were given 
two 10-minute trials per day (morning/afternoon). The trials consisted of placing 10-15 
pellets near the oval opening in order to entice the rats to reach. Once both rats began 
reaching through the oval opening for sugar pellets, they were separated and singly 
trained. Training continued daily (Monday through Friday), for two 10-minute trials per 
day. At this time sugar pellets were placed near the opening, one at a time, to train rats to 
grasp the pellets with precision. Once rats began showing a limb preference and started 
grasping the pellets successfully, the pellet was moved slightly farther from the opening 
and lateral, since Long Evan black-hooded rats are documented to be able to reach out at 
a considerable distance and tend to reach to the side, instead of straight out. Placing the 
pellet laterally also dissuades the rat from using their non-preferred forelimb. The rats 
were slowly challenged to reach for a pellet that was located at a final distance of 1 cm 
away from the opening (see Figure 3.3). Rats were trained daily, until a success score of 
15 out of 20 pellets was obtained for three consecutive days. Once the rat successfully 
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completed this criterion, it was deemed to be “at baseline”.  
Reaching Task Analysis. A successful pellet was defined as a pellet that was grasped by 
the rat with the preferred forelimb off the shelf, pulled back inside the reaching apparatus, 
and placed in the mouth without being dropped. Rats naturally grasp food with both 
forelimbs while eating, however some use only their preferred forelimb during eating. 
Therefore, the contribution of the non-preferred forelimb during eating was not 
quantified, as long as the pellet was eaten from the preferred forelimb and was not 
dropped. Additionally, rats typically eat while sitting on their hindlimbs, with their 
forelimbs lifted against gravity. However, some rats at baseline eat with their forelimbs 
resting on the ground and move their head down to their paws. Therefore, a successful 
reach was defined as grasping a pellet and bringing it to the mouth with the forelimbs 
either held up against gravity or with forelimbs resting on the floor. As a caveat, rats did 
display increased prevalence of non-preferred forelimb assisted eating, as well as 
decreased ability to hold forelimbs against gravity post-stroke. However, due to the 
complexity of testing these behaviors, these changes were not quantified, only noted. The 
types of errors that led to non-successful pellets were also noted.   
 During evaluation post-stroke (specific aim 1) and post-treatment (specific aim 2), 
rats were tested once a day (20 pellet trial), 1-5 days a week. The exact number of testing 
sessions per week during the different parts of the experiment are summarized in Table 
3.5.   
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Inclusion/Exclusion Criteria:  
*Inclusion/exclusion criteria were based on performance in the skilled reaching task 
only.  
 A Prior Inclusion Criteria. Rats that were trained on the skilled reaching task to a 
criterion of 15/20 successful pellets, 3 days in a row, were included in the study and 
proceeded to undergo ischemic stroke surgery. All animals were trained to this criterion.  
A Priori Exclusion Criteria. Following stroke surgery, rats were tested on the skilled 
forelimb-reaching task weekly. At either 8 or 24 weeks post-stroke, rats were assessed for 
a new post-stroke baseline, through three days of skilled reaching testing. Any rats that 
scored more than 10/20 successful pellets were excluded from Aim 2 and Aim 3 
experiments, namely treatment with anti-Nogo-A immunotherapy.  
Post-Randomization Exclusion Criteria. Additional exclusion criteria were deemed 
necessary for the PP analysis. For an in depth description of these exclusions, refer to 
Table 3.4. Briefly, animals were excluded from the PP analysis due to antibody pump 
technical problems, behavioral abnormalities that interfered with assessment of skilled 
forelimb reaching score, animals displaying no functional spontaneous recovery post-
stroke prior to treatment initiation (success score = 0/20), and severe (> 80%) subcortical 
striatal damage.  
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Ladder Rung Walking Task  
Walking Task Background. The ladder rung-walking task is a test used to assess skilled 
walking, limb placement, and limb co-coordination (Metz et al., 2009; Metz and 
Whishaw, 2002). This task has been found to be sensitive to acute and chronic deficits 
seen after various motor system lesions, including different models of rat stroke including 
MCAO (Rieck-Burchardt et al., 2004; Farr et al., 2006; Papadopoulos et al., 2009; 
Gemerasca Mestriner et al., 2013). Through the use of qualitative and quantitative 
measures, this task is able to determine subtle losses of movement capacity as well as 
assess performance during post-lesion recovery periods.   
Walking Task Description. The horizontal ladder apparatus consists of two, 1-meter 
Plexiglas panels connected with irregularly placed metal rungs (minimum inter rung 
distance of one cm, rung diameter of 3 mm, Fig. 3.4). Animal cages were placed 
underneath each side of the horizontal ladder, one clean cage at the start and a home cage 
at the end. Each rat was placed individually in the clean cage and allowed to climb up 
onto the ladder and to cross the ladder. The rat was motivated to cross the ladder in order 
to reach their home cage. Rats were habituated to this task over the course of three 
consecutive days, with one daily 10 minute session or until each rat crossed the ladder 
three times. Once the rats were habituated to the apparatus, they were videotaped while 
crossing the horizontal ladder for three trials. The animals were tested using the skilled 
horizontal ladder walking task across three time-points during the experiments outlined in 
this dissertation: at baseline (prior to stroke), 8 or 24 weeks post-stroke (prior to 
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treatment), and at 20 or 32 weeks post-stroke (final testing week post-treatment).  
Walking Task Analysis. Qualitative and quantitative performance on the ladder rung 
walking task was assessed using the videotaped trials. Although both forelimb and 
hindlimb function can be analyzed using this task, only the preferred forelimb 
(determined by the skilled reaching task) was evaluated. Qualitative analysis of forelimb 
placement involves analysis of videos frame-by-frame and scoring the foot placements 
according to a 7-category foot fault scale developed by Metz and Whishaw (2003).  The 
foot fault scoring scale is described in Table 3.6. Briefly, a foot placement is assigned a 
score of 0 when the limb completely misses the rung and a fall occurs (total miss), a score 
of 1 when the limb slips off the rung and causes a fall (deep slip), a score of 2 when the 
limb slips off the rung but the animal is able to maintain balance and keeps stepping 
(slight slip), a score of 3 when the limb was placed on a rung but moved to another rung 
before weight bearing (replacement), a score of 4 when the limb was either aimed for one 
rung and placed on another or when a limb was repositioned on the same rung 
(correction), a score of 5 when the limb was placed on a rung using either the wrist or 
digits of the forelimb (partial placement), and a score of 6 when the mid portion of the 
palm of the limb was placed on the rung with full weight bearing support (correct 
placement). When more than one error occurred, the lowest score was used. The final 
score was expressed as the mean foot fault score per step.  Quantitative analysis of the 
skilled horizontal ladder-walking task involved counting the number of foot fault errors 
that occurred while crossing the ladder. The errors were based off the foot fault scoring 
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scale and were defined as foot faults with scores 0, 1, and 2, effectively anytime the 
forelimb slipped off the rung or missed it completely. Foot faults were expressed as the # 
of foot faults per 10 steps (based on three crossings).   
Bilateral Tactile Adhesive Removal Task  
Adhesive Removal Background. Contralateral tactile sensory neglect commonly occurs 
after cortical or striatal injury in humans and over time the complete sensory neglect can 
dissipate, leaving a patient with residual tactile extinction deficits (Benton et al., 1952; 
Benton et al., 1972). A patient with tactile extinction will be able to perceive unilateral 
tactile stimulation however simultaneous bilateral tactile stimulation will mask the ability 
of the patient to perceive stimulation on the affected side. However, with time, this tactile 
extinction deficit can also improve and patients are often left with “obscuration deficits”, 
where the perception of the contralateral stimulus is reduced. This evolution from 
complete contralateral tactile sensory neglect to obscuration has also been demonstrated 
in rats (Schallert et al., 1984). The bilateral tactile adhesive removal task is a sensitive 
test for discriminating these types of sensorimotor dysfunctions in rodents, and was 
originally described by Schallert et al. (1982; 1983). This task, as described by Dr. 
Schallert was originally based on the human clinical sensory exam used to test sensory 
neglect, which is called the Double Simultaneous Stimulation Test (DSS). In the tactile 
DSS exam, patients are presented with tactile sensory stimulation unilaterally and then 
bilaterally to the same location on each side of the body. This test allows the physician to 
determine if sensory loss is located in the primary somatosensory cortex as evidenced by 
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the patient denying unilateral sensation or if there is damage in the higher level sensory 
association cortex as evidenced by the patient losing the ability to discriminate sensation 
during bilateral stimulation. The rodent version of this test is a good translational 
functional outcome assessment as it is directly comparable to the human version of the 
same test.  
Adhesive Removal Description. Sticky paper sheets with adhesive backing (Staples, 
product # 490429) were used to manually cut out small 0.5 inch by 0.5 inch square 
adhesive stickers (161 mm2). Rats were well handled before attempting this task. Each rat 
was taken out of its home cage and was held by one investigator while another 
investigator placed two adhesive stickers on the forelimbs, one on the palmar surface of 
each forepaw, covering the whole palm and most of the digits, see Figure 3.5. The order 
of placement (right versus left) was randomized for every trial. Additionally after sticker 
placement, both forelimbs with the stickers were simultaneously pressed firmly before 
the trial started. Quickly, before the rat could attempt to remove the stickers, the rat was 
placed inside the skilled reaching apparatus for the duration of the trial. Before data 
acquisition started, rats were given one training day consisting of four trials to habituate 
the rats to the testing procedure. Then the animals were tested using the bilateral tactile 
adhesive removal task across three time-points during the experiments outlined in this 
dissertation: at baseline (prior to stroke), at 8 or 24 weeks post-stroke (prior to treatment), 
and at 20 or 32 weeks post-stroke (final testing week post-treatment). 
Adhesive Removal Analysis. Each trial consisted of a maximum of 240 seconds (4 
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minutes). Rats typically contact the stickers with their mouths and removed them using 
their teeth. During the trial, it was noted which forelimb sticker was touched with the 
mouth first and which was removed first. The time it took for each forelimb sticker to be 
contacted (contact latency) and removed (removal latency) was also recorded for each 
forelimb using four separate stopwatches. Four trials were given per session until a >75% 
forelimb bias was found, defined as which forelimb sticker was contacted using the 
mouth first. If a greater than 75% bias for either forelimb was not found, an additional 
trial was given. The inter-trial rest period lasted 2-3 minutes.  
Magnitude of Sensory Asymmetry Testing  
Asymmetry Testing Description. Once a forelimb bias has been found in the bilateral 
tactile adhesive removal task, the magnitude of sensory asymmetry between the forelimbs 
can be quantified. The test is conducted by progressively increasing the size of the sticker 
on the impaired forelimb and decreasing the size of the sticker on the non-impaired 
forelimb by an equal amount (20.2 mm 2) until the rat reverses its bias from the non-
impaired forelimb to the impaired forelimb. There are seven levels of magnitude ratios 
(Schallert et al., 2000; Schallert and Whishaw, 1984). The reversal of this original bias 
represents the magnitude of sensory asymmetry score and a higher score indicates a 
greater degree of somatosensory impairment. This testing has been shown to be very 
sensitive to the extent of brain damage in various lesion models (Schallert et al., 1982; 
Schallert et al., 1983; Schallert et al., 1984; Schallert et al., 1986; Barth et al., 1990).  
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Asymmetry Testing Analysis.  As described above, there are 7 levels of magnitude 
differences that each rat is tested with. Testing begins at level 3, and depending on 
whether the rat takes off the sticker on the impaired or non-impaired forelimb, testing 
will continue with levels higher or lower. For example, at level 3 if the rat has not 
reversed its bias for the non-impaired forelimb, the rat will be tested with the level 4 
sticker sizes. At this point, if the rat contacts the impaired forelimb first, it will receive a 
score of 3.5, signifying that the rat switches bias from the non-impaired forelimb to the 
impaired forelimb somewhere between level 3 and level 4. In addition to the seven levels, 
if the original bias is towards the impaired forelimb (i.e. at baseline) the scores are given 
a positive sign, if however the bias is towards the non-impaired forelimb (i.e. post-stroke) 
the scores are given a negative sign.  
 
Stroke Surgery 
Stroke Procedure Background. Human clinical stroke is a heterogeneous disorder with 
various etiologies, presentations, and recovery profiles. However, 80% of human strokes 
are ischemic in nature and typically affect the middle cerebral artery territory (AHA, 
2013). Therefore, a majority of preclinical studies model human stroke by occluding the 
middle cerebral artery in the rat. The rat, although not perfect, is a good model for human 
focal ischemic stroke due to similarities in cerebral vasculature (Macrae et al., 1992), 
genomics (Ginsberg et al., 1996), and post-stroke deficits (Whishaw et al., 1992). 
However, when evaluating recovery data post-intervention in the rat it is important to 
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note that the rodent brain, among other differences, is lissencephalic and has a higher 
grey matter to white matter ratio than does the human brain.   
Stroke Procedure Description. A focal ischemic stroke was induced by using the middle 
cerebral artery occlusion (MCAO) method as described in Chen et al. (Chen et al., 1986), 
and as in our previous work (Papadopoulos et al., 2002; Markus et al., 2005, Seymour et 
al., 2005; Papadopoulos et al., 2006; Tsai et al., 2007; Gillani et al., 2009; Tsai et al., 
2011). See Figure 3.6 for a surgical view of the MCAO procedure. Rats were 
anesthetized with isoflurane inhalant anesthesia (3% in oxygen) and body temperature 
was maintained during the entire procedure. Temperature was maintained using a rectal 
probe and automatic heating pad during the MCAO procedure and during the transient 
CCA occlusion temperature was maintained manually with a heating pad and was 
manually checked using a rectal thermometer. Animals’ core body temperature were 
maintained at normal physiological ranges, between 99 to 101 degrees F. The bilateral 
common carotid arteries (CCA) were isolated from an anterior cervical incision and the 
common carotid artery ipsilateral to the intended ischemic stroke hemisphere was 
permanently ligated using a 5-0 chromic gut suture. Rats were then placed in a 
stereotaxic frame and a 2 cm vertical incision was made between the eye and ear and the 
temporalis muscle was retracted. A burr hole was made to expose the middle cerebral 
artery (MCA) and it was permanently occluded by cauterization and then transected with 
microscissors. Lastly, the contralateral CCA was temporarily occluded for 45 minutes 
using an aneurysm clip. After the aneurysm clip was removed, the surgical wound was 
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closed and animals were warmed using a heating pad until awake. Animals were 
monitored during the post-op period until fully awake, and able to eat and drink. If 
animals showed signs of severe lethargy post-stroke, a 1 cc saline injection was given to 
protect against dehydration and animals were given standard rat chow dissolved in water 
to facilitate feeding. Animals were tested for either 8 or 24 weeks to determine 
sensorimotor deficits prior to antibody infusion as described below.  
Antibody Intracerebroventricular Infusion 
Antibody Infusion Background. An intracerebroventricular antibody infusion approach 
was used in these experiments. This approach is considered to be a clinically viable 
approach as such delivery systems are already used in humans to administer anti-spastic 
agents such as baclofen for dystonia and opiates to treat intractable cancer pain 
(Fleischhack et al., 2005). Previous work from our laboratory has shown that intrathecal 
injection of anti-Nogo-A antibodies also induces sensorimotor recovery after ischemic 
stroke in rodents. Therefore, application of anti-Nogo-A antibody is clinically feasible, 
either through intracerebroventricular infusion or intrathecal delivery. In fact, a phase I 
clinical trial, testing the safety of intrathecal delivery of anti-Nogo-A immunotherapy in 
spinal cord injury patients recently was completed and there have been minimal side 
effects to this treatment.  
Antibody Infusion Description. After the post-stroke testing period, either 8 or 24 weeks 
post-stroke, rats were randomized to either stroke only, anti-Nogo-A antibody, or control 
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antibody treatment groups (see experimental timeline Figure 3.1) with careful attention to 
balance pre-stroke deficit from post-stroke week 8 on the skilled reaching task. Antibody 
infusion was initiated at the beginning of either 9 weeks or 25 weeks post-stroke. Rats 
were placed in a stereotaxic frame and a midline incision was made in the scalp. A burr 
hole on the same side as the stroke lesion exposed the cortex. A cannula was placed into 
the lateral cerebral ventricle at coordinates 1.3 mm lateral, 0.8 mm posterior, and 3.8 mm 
ventral (relative to bregma) and secured to the skull with cyanoacrylate gel. Through a 
mid-scapular incision an Alzet osmotic mini-pump (model 2ML2; Duract Corporation, 
Cupertino, CA, USA) was implanted subcutaneously posterior to the scapulae and 
connected to the cannula with polyethylene tubing. Either purified mouse monoclonal 
anti-Nogo-A antibody (11C7; IgG1) or control antibody (anti-BRDU, IgG1) was infused 
at a rate of 15-micrograms/ hour (2.5 mg/ml) for two weeks, after which the animals are 
again anesthetized and the pumps removed.  
Perfusion and Golgi-Cox Staining 
Golgi-Cox Method Background. In 1873 the Italian physician and scientist, Camillo 
Golgi, discovered what was then called the “black reaction” to stain whole neurons and 
effectively ushered in a new era of neuroscience discovery. The black reaction became 
known as the Golgi stain and was improved and used by Ramon y Cajal to study the 
morphology of neurons and to the eventual birth of the neuron doctrine. Since then, this 
method has been adapted and used by countless investigators studying neuronal 
morphology as well as changes to neuronal morphology following various insults.   
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Golgi-Cox Method Description. At either 21 or 33 weeks post-stroke (one week after the 
end of sensorimotor testing), rats were overdosed with pentobarbital (100mg/kg, i.p.) and 
transcardially perfused with 0.9% saline and10,000 U heparin/liter. The brains were 
removed and immersed whole in Golgi-Cox solution (Glaser et al., 1981) for two weeks. 
The brains were then coronally sectioned at 200 microns on a vibratome, mounted on 2% 
gelatinized slides and reacted as described by Gibb and Kolb (Gibb et al., 1998). Slides 
were coded to blind the experimenters to antibody treatment group. Refer to Figure 3.7 
for Gogi-Cox method overview.  
Stroke Lesion Analysis 
Method Description. Golgi-Cox stained coronal brain sections were quantitatively 
analyzed (+4.7 to -5.2 mm from bregma according to Paxinos and Watson, 1998) using a 
computer-interfaced imaging system (NIH Image) by the method described in Kawamata 
et al., 1999) (total area of the intact contralateral hemisphere – total area of the intact 
ipsilateral hemisphere, and multiplied by the total distance between sections). Stroke size 
was expressed as a percentage of the intact contralateral hemispheric volume, see Figure 
3.8.  
Neuroanatomical Analysis 
Description of Tracing Neurons. Layer V pyramidal neurons were located within the 
caudal forelimb area (CFA) region of the unlesioned motor cortex and the perilesional 
area of the lesioned motor cortex with the aid of an atlas, see Figure 3.9 (Paxinos & 
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Watson, 2005) and according to previous electrophysiological studies (Neafsey et al., 
1986). Criteria for inclusion in the analyses were that the neuron had to be well 
impregnated, unobstructed by other dendrites, blood vessels or glia cells, and that the 
dendritic aborization were intact and visible in the plane of the section.  
Neuronal Morphology Analysis. An average of 6 apical and basilar dendritic trees of 
layer V pyramidal neurons were traced using Neurolucida software and Leica DM 4000B 
with a 40x objective. Dendritic trees were analyzed for dendritic length and number of 
branch segments using the branched structure analysis tool of Neurolucida. Branches 
emanating from the apical shaft were considered first order as well as branches 
originating from the cell body (basilar) were considered first order, see Figure 3.10.  
Statistical Analysis for Behavioral Data 
Skilled Forelimb Reaching Task. An alpha value of  < 0.05 was considered statistically 
significant for all behavioral data. Skilled reaching data, including post-stroke 
spontaneous recovery data and anti-Nogo-A immunotherapy data from both ITT and PP 
datasets, was analyzed initially using a repeated measures analysis of variance (RM 
ANOVA), as has been done in previous work and most recently in Tsai et al, 2010. 
However, there are many disadvantages to using the RM ANOVA in the analysis of 
longitudinal data, most important of which are its inability to analyze data sets with 
missing data points across time, its assumption that measured values across time points 
are independent with no correlation, its rigid variance-covariance structure, and its focus 
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on estimation of group mean trends without information about how specific individuals 
change across time. A more robust way to analyze longitudinal data is to use non-linear 
mixed effects modeling to gather information about recovery curves including initial 
severity, rate of recovery, and final magnitude of recovery reached at the plateau. The 
biological response to a treatment is often nonlinear and therefore the most accurate way 
to analyze this type of data is to use a bespoke mathematical equation that will match the 
data. Therefore, the statistical software SAS was used to run the “nlmixed proc” 
procedure to generate a non-linear model of the reaching data. The equation that was 
used for modeling of the reaching data was an exponential function expressed by pi = 
theta1 + (theta2 – theta1) * exp (-theta3 * (time-8)), where pi signifies probability of 
success (# of successful pellets out of 20), theta 1 signifies the upper asymptote (final 
magnitude of success score reached at plateau), theta 2 signifies the y-intercept (initial 
pre-treatment stroke severity), and theta 3 signifies the rate (rate of recovery). For a 
graphical display of the nlmixed proc equation, refer to Figure 3.11.  
Skilled horizontal ladder walking task. Slips per ten steps were analyzed using a RM 
ANOVA.  
Bilateral adhesive removal task/Magnitude of sensory asymmetry testing. Sensory contact 
and removal latencies were analyzed using a RM ANOVA.  
Neuroanatomical Data. . An alpha value of  < 0.05 was considered statistically 
significant for all neuroanatomical data. All statistical analyses were performed with 
57 
 
 
 
SPSS 17.0 (SPSS, Chicago, IL). Total stroke lesion size was evaluated using a one way 
ANOVA. Dendritic plasticity measurements were analyzed using a one way ANOVA. 
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Experimental Design and Timeline 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 3.1. Experimental Design and Timeline   
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Comparison of dissertation experimental design and preclinical design 
recommendations. 
Table 3.1. Recommendations for improved preclinical trial quality. 
Recommendations are summarized from various recommendation statements and reviews 
regarding preclinical study quality (Fisher et al., 1991; van der Worp et al., 2005; 
Dirnagl, 2006; Kahle & Bix, 2012; Fisher et al., 2009).  
Recommendation Dissertation Experiments  Previous Work 
Randomization Yes; Randomization based on stroke 
deficit severity pre-treatment.  
- 
Blinded Surgery Procedure Yes; Animals were randomized post 
surgery.  
- 
A priori inclusion/exclusion criteria/  
report excluded animals 
Yes - 
Analyze as randomized (ITT) Yes; ITT and PP analysis performed. - 
Monitor physiological parameters Yes; Temperature controlled during 
MCAO  
- 
A priori power analysis Yes - 
Use CIs, do not use SEMs Yes; Both were used  - 
Professional advice on statistics Yes - 
Replicate key findings Yes - 
Report mortalities Yes - 
Report exact details on animal (sub)strains Yes - 
Report sponsorship, conflict of interest Yes; Anti-Nogo-A antibody was 
received from Novartis as a gift.  
- 
Define SOPs (including quality checks) Yes; As defined in ACORP Details. - 
Drug (clinically relevant treatment 
window  
and delivery route) 
Yes; Chronic treatment time point (9 
weeks or 25 weeks post-stroke in 
moderate to severe stroke deficit. 
ICV delivery.  
Intrathecal delivery (Tsai et al., 2007); 
Established treatment window 24 hours to 9 
weeks post-stroke in mild-moderate stroke 
deficit (Weissner et al. 2003; Seymour et 
al., 2005; Tsai et al., 2010) 
Blinded drug administration No - 
Blinded outcome evaluation Yes - 
Use of aged, diabetic, or hypertensive 
 animals 
No  Aged rats + stroke, treated at 1 week post-
stroke (Markus et al., 2005); Adult 
Spontaneously Hypertensive Rats (SHR) 
treated 24 hours post-stroke (Weissner et 
al., 2003) 
Assessment of both infarct and functional 
outcome 
Yes - 
Outcome assessment in the chronic phase 
 (7-30 days) 
Yes - 
Dose-response curve performed No 5 mg versus 1.65 mg (total received) anti-
Nogo-A antibody more effective after 
MCAO in SHR (Weissner et al., 2003) 
Initial rodent studies, then consider  
gyrencephalic species 
Rat study only Evidence of functional recovery and 
sprouting shown in primates treated with 
anti-Nogo-A antibodies after spinal cord 
injury + cortical lesions using ibotenic acid 
(Fouad et al., 2004; Freund et al., 2006, 
2007, 2009); Primates + stroke yet to be 
tested  
Permanent MCAO then transient MCAO Permanent MCAO model used only Transient MCAO not evaluated yet; Other 
stroke models not evaluated yet 
Using ARRIVE guidelines for reporting in 
 vivo experiments  
Yes - 
Using CONSORT guidelines for reporting 
RCTs 
Yes - 
60 
 
 
 
 
List of Animal Numbers used in ITT and PP Analysis 
 
 
 
 
Table 3.2. List of animals used in the two different analyses used for evaluation of 
anti-Nogo-A immunotherapy in chronic stroke. An ITT and PP data analysis paradigm 
was used for evaluating anti-Nogo-A immunotherapy treatment effects in animals treated 
at 9 or at 25 weeks post-stroke. 
 
 
 
 
  
Analysis 11C7 Control Antibody Stroke Only 
ITT  
(treatment at 9 
weeks post-stroke) 
 
 
09, 14, 32, 34, 47, 
48, 51, 56, 64, 67, 
72, 76, 84, 89 
 (n = 14) 
27, 31, 41, 45, 49, 
52, 53, 59, 74, 77, 
78, 82 
( n = 12) 
11, 16, 32, 55, 60, 
61, 68, 80, 88 
 
(n = 9) 
PP 
(treatment at 9 
weeks post-stroke) 
 
 
09, 14, 34, 47, 51, 
56, 76 
(n = 7) 
31, 41, 45, 49, 52, 
59, 74, 77, 78, 82 
(n = 10) 
11, 16, 32, 55, 61, 
68, 80, 88 
(n = 8) 
ITT  
(treatment at 25 
weeks post-stroke) 
 
 
06, 18, 19, 20 
(n = 4) 
12, 13 
(n = 2) 
17, 24 
(n = 2) 
PP 
(treatment at 25 
weeks post-stroke) 
 
 
06, 18, 19 
(n = 3) 
12, 13 
(n = 2) 
17, 24 
(n = 2) 
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PP Analysis Exclusions 
 
 
Rat 
ID 
Treatment 
Timepoint 
Treatment 
Group 
Pump 
Disconnect 
Absolute 
Deficit 
Severe FL 
Switching 
Severe 
Striatal 
Damage 
KP32 9 weeks 11C7 x    
KP48 9 weeks 11C7 x x   
KP64 9 weeks 11C7   x  
KP67 9 weeks 11C7 x    
KP72 9 weeks 11C7   x  
KP84 9 weeks 11C7    x 
KP89 9 weeks 11C7  x   
KP20 25 weeks 11C7  x   
KP27 9 weeks Control Ab  x   
KP53 9 weeks Control Ab  x   
KP54 9 weeks Stroke 
Only 
 x   
KP60 9 weeks Stroke 
Only 
 x   
 
Table 3.3. Exclusion categories for animals excluded in PP analysis. 
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Detailed Descriptions of Post-Randomization Exclusions for  
Per-Protocol Analysis 
 
Exclusion Type Description 
Pump Disconnect Tubing connecting cannula to osmotic pump was disconnected at removal 
from animal. Final volume of antibody delivered intracerebroventricularly 
is unknown. Full treatment regimen not administered.  
Absolute Deficit During the reaching task, the rat was never able to grasp a pellet 
successfully during any post-stroke testing time point (post-stroke + post-
treatment). This type of rat is unable to perform the reaching task and it is 
assumed that no recovery of motor function as tested by the reaching task 
is possible (supported by data).    
Severe FL Switching After stroke, rat changes forelimb preference and this extreme reliance on 
the non-impaired forelimb leads to inaccuracy in testing the impaired 
forelimb (forelimb affected by stroke). Extreme reliance on non-impaired 
forelimb leads to maladaptive changes in strategies used in reaching such 
as: posture, aiming, two-handed reaching, learned non-use, learned bad-
use. Performance score is deemed inaccurate with a large signal to noise 
ratio.  
Severe Striatal 
Damage 
Rats with ischemic necrosis leading to a complete loss of the dorsolateral 
striatum have an inability to initiate forelimb movements and typically 
show little improvement (ref). Rats displaying grasps in the air for pellets 
instead of on the shelf typically have striatal damage (ref) and therefore 
are to be excluded.  
 
 
Table. 3.4. Detailed Descriptions of Post-Randomization Exclusions for 
Per-Protocol Analysis. 
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Comparisons in Rat and Human Reaching 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Comparisons between limb movements made by normal rats and 
humans during a reach for food task. Information in figure modified from Sacrey et 
al., 2009 and Whishaw et al., 1992.  
Movement Component Rat Human 
Orientation towards food Olfaction Vision 
Advance Similar Similar 
Pronation of paw/hand 
over food 
Similar Similar 
Grasp Whole paw grasp Pincer grasp (between 
thumb and index finger) 
Supination of paw/hand 
with retraction, rotation 
at wrist, placement of 
food in mouth 
Similar Similar 
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Diagram of Skilled Reaching Task 
 
 
 
 
 
 
 
Figure 3.3. Diagram of skilled reaching task. Rats are trained to reach for sugar pellets 
placed on a ledge. The number of successful pellet is attained when the rat reaches out 
with its preferred forelimb, grasps the pellet, pulls the forelimb back inside and brings the 
sugar pellet to the mouth without dropping it. 
 
 
 
 
 
 
 
Success Score:  # Successful 
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Number of Skilled Reaching Testing Sessions per Time Point 
 
Experimental Time Point # of Sessions (days per week) 
Baseline 3 
Post-Stroke Weeks 1-7 or 1-23 1 
Pre-Treatment Baseline  
(post-stroke week 8 or 24) 
3 
Treatment Weeks  
(post-stroke weeks 9-20 or 25-32) 
3-5 
 
 
 
Table 3.5. Number of Skilled Reaching Testing Sessions per Time Point 
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Skilled Horizontal Ladder Walking Task 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Diagram of Skilled Horizontal Ladder Walking Task. A normal rat can 
easily traverse the horizontal ladder with little to no errors (1 slip or less). After brain 
injury, the number of slips and errors increases. 
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Foot Fault Scoring Scale 
 
 
Category Points Description 
Total Miss 0 Forelimb completely misses a rung; a fall occurs 
Slight Slip 1 Forelimb slips off rung with weight bearing; a fall occurs 
Deep Slip 2 Forelimb slips off with weight bearing; no fall occurs 
Replacement 3 Forelimb placed on a rung but then replaced on another 
Correction 4 Forelimb aimed for one rung but placed on another or 
repositioned on the same rung 
Partial 
Placement 
5 Forelimb placed on rung with either wrists or digits of 
forelimb 
Correct 
Placement 
6 Mid portion of palm of forelimb is placed on rung with full 
weight bearing 
*Table information modified from Metz et al., 2009 
 
 
Table 3.6. Overview of foot fault scoring system. The table describes the scoring 
system based on assigning points (0 to 6) for each foot fault category. Information in the 
table is modified from Metz et al., 2009. 
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Bilateral Adhesive Removal Task 
 
 
 
 
 
 
 
 
Figure 3.5. Diagram of bilateral adhesive removal task. 
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MCAO Procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. MCAO procedure. Procedure shown involves a Fisher 344 rat, however the 
procedural steps are performed identically in either Fisher 344 or Long Evans black-
hooded rats. Pictures compliments of Daniel Sheperd.  
Dissect Ipsilateral CCA 
Permanent occlusion with  
suture ligation 
 
Craniotomy to expose MCA  
Permanent occlusion of MCA 
using suture ligation 
Dissect contralateral CCA 
Untied suture left as marker 
Transient 45-minute occlusion 
of contralateral CCA 
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Golgi-Cox Method for Staining Neuronal Morphology 
 
 
 
 
 
Figure 3.7. Golgi-Cox staining procedure. 
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Analysis of Stroke Volume and Lesion Location 
 
 
 
Figure 3.8. Analysis of Stroke Volume and Lesion Location 
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Selection of Neurons 
 
 
 
 
 
 
 
Figure 3.9. Location of selected neurons. 
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Analyzing Dendritic Morphology 
 
 
 
 
Figure 3.10. Dendritic Analysis. (A) Representative neuron morphology. (B) Example 
of branching pattern and numbering scheme 
   
A 
B 
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Non-Linear Mixed Effects Modeling of Skilled Reaching 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Graphical display of equation used for non-linear mixed effects 
modeling of skilled reaching data.
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CHAPTER FOUR 
TIME COURSE OF SPONTANEOUS SKILLED REACHING RECOVERY 
POST-STROKE 
ABSTRACT 
Following human clinical stroke, spontaneous recovery of function is limited but 
does occur. The majority of spontaneous recovery of motor function occurs within 3 
month post-stroke, with small improvements in function seen up to 6 months post-stroke 
and beyond. Severity at initial stroke onset is considered to be the best prognostic factor 
in determining recovery after stroke in humans. Patients with mild to moderate stroke 
deficits immediately after stroke improve faster and better than patients with severe 
stroke deficits. New therapeutic strategies are commonly tested in rat models of ischemic 
stroke, including the middle cerebral artery occlusion model. In order to increase the 
successful translation of preclinical findings to human trials it is important to model 
human stroke appropriately in the rodent models used in preclinical studies. Therefore, 
prior to testing the efficacy of anti-Nogo-A immunotherapy in the chronic phase after 
stroke in adult male rats, we set out to evaluate and compare the spontaneous motor 
recovery profiles in adult rats after stroke to that of humans after stroke. Adult male rats 
underwent a middle cerebral artery occlusion and were evaluated for motor recovery in 
skilled reaching performance for 8 weeks and 24 weeks post-stroke. On average, rats 
showed a profound impairment on the skilled reaching task at post-stroke week 1. Similar 
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to humans, animals displayed different recovery profiles based on initial deficit severity 
immediately after stroke. Overall, spontaneous recovery was seen in the first few weeks 
after stroke, with no improvements seen beyond 4 weeks (one month) post-stroke, even 
in animals evaluated out to 24 weeks post-stroke (6 months). Similar to the recovery 
profile seen in humans, the majority of spontaneous motor recovery occurs early post-
stroke with essentially little to no improvements seen beyond 6 months post-stroke.   
 
 
 
 
 
 
 
 
 
 
  
77 
 
 
 
INTRODUCTION 
Neuronal death and damage following ischemic stroke leads to permanent deficits 
in motor, sensory, language, and cognitive function. The potential burden of disability 
post-stroke is very large and with the world’s population aging, the magnitude of 
disability and loss of function is likely to increase exponentially (WHO, 2011; United 
Nation, 2001).  
 Treatment options post-stroke are fairly limited, and often the patient is faced 
with limited options for improving recovery after stroke. One mechanism of improved 
function after stroke is due to spontaneous recovery. Although limited, spontaneous 
recovery occurs to varying degrees following stroke. Numerous studies have shown that 
initial clinical severity after stroke is the strongest prognostic factor for spontaneous 
clinical recovery after stroke in humans (Jorgensen et al., 1995; Jorgensen et al., 1996; 
Jorgensen et al., 2000). Overall, most spontaneous recovery occurs before 6 months post-
stroke. In the Copenhagen study (Jorgensen et al., 2000), it was estimated that 80% of 
patients reach their best neurological recovery within 4.5 weeks, with varying time 
profiles based on initial severity post-stroke. Therefore, clinical stroke recovery profiles 
vary from patient to patient based on initial clinical severity, potential for spontaneous 
recovery, individual potential for neuroplasticity, and other various factors. Generally, it 
is thought that the majority of spontaneous recovery plateaus by 6 months post-stroke 
leaving a patient with little options for further improved recovery in the chronic phase.  
Hence, there is a need for the development of therapeutics options that can 
improve functional recovery post-stroke in the chronic stable phase after spontaneous 
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recovery has ended. One such promising therapy is anti-Nogo-A immunotherapy (Tsai et 
al., 2010). By inhibiting the protein Nogo-A, the regenerative potential of neurons is 
enhanced, and it is possible to induce reorganization of neural circuits, leading to 
functional recovery. In order to improve the translatability of preclinical findings using 
this therapy to human clinical trials it is important to model human stroke appropriately 
in preclinical studies using this therapy. Therefore, before the application of anti-Nogo-A 
immunotherapy in the chronic phase after stroke, we set out to evaluate the time course of 
spontaneous sensorimotor recovery in the adult rat after stroke up to 24 weeks post-stroke 
(6 months) and to compare it to the recovery patterns seen in human stroke recovery. Rats 
underwent a stroke procedure by permanent occlusion of the middle cerebral artery and 
sensorimotor recovery was assessed weekly for 8 or 24 weeks post-stroke using the 
skilled forelimb reaching task.  
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RESULTS  
Spontaneous recovery of skilled reaching success score over 24 weeks post-stroke 
Rats were trained to reach a baseline criterion of 15 successful pellets out of 20 on the 
skilled forelimb reaching task. Then skilled forelimb reaching recovery was assessed for 
a total of 8 weeks post-stroke in a cohort of 66 rats and was assessed for an additional 24 
weeks post-stroke for a subset of the former cohort, in 7 rats (see Figure 4.1A and 4.1B). 
Analysis of the first 8 weeks post-stroke showed a significant main effect of time during 
the post-stroke recovery phase, Figure 4.1A (p < 0.001, repeated measures ANOVA). 
Initially, all animals exhibited a profound decrease in skilled reaching performance at 1 
week post-stroke (p < 0.001). On average, rats improved until post-stroke week 2 (0.019) 
and then reached a recovery plateau until post-stroke week 7. Reaching success was 
significantly different between post-stroke week 7 and week 8.  
 Analysis of the smaller cohort assessed out to 24 weeks post-stroke (Figure 4.1B) 
showed that there was also a significant main effect of time on skilled reaching 
performance (p <0.033). Following stroke, there was a profound decrease in skilled 
reaching performance at post-stroke week 1 (p < 0.001). There was also a significant 
difference between skilled reaching performance between post-stroke week 1 and post-
stroke week 4 (p = 0.022). Further statistically significant improvements in skilled 
reaching performance were not seen beyond post-stroke week 4.  
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Recovery profiles based on initial skilled reaching severity at post-stroke week 1 
Animals were categorized into four stroke severity deficit groups based on the skilled 
reaching score at post-stroke week 1, Figure 4.2A. Figure 4.2B shows the scoring criteria 
used to categorize animals to mild, moderate, severe, and very severe stroke deficit 
groups.  
Repeated measures ANOVA showed that there was a significant interaction 
between stroke severity category and skilled reaching recovery over time (p = 0.001). On 
average across all deficit categories, post-stroke recovery plateaued by post-stroke week 
4. Bonferroni post-hoc testing showed that recovery profiles between the mild and 
moderate categories was not significantly different across time (p = 0.203). However, the 
recovery profiles of the severe and very severe deficit groups were different from the 
either the mild or moderate recovery group and different from each other (all p values < 
0.01) (see Figure 4.2A).   
Recovery profiles for animals in each stroke severity category were analyzed 
separately to determine the time course of recovery. Since the recovery profiles of mild 
and moderate stroke severity animals was found to be non-significant, these two 
categories were combined to evaluate the time course of recovery. Post-stroke, animals in 
the combined mild and moderate deficit category did not exhibit a significant change 
over time in their skilled reaching performance after stroke (p = 0.085, repeated measures 
ANOVA).    
Animals in the severe stroke category displayed a change in skilled reaching 
recovery over time (p < 0.001, repeated measures ANOVA). Skilled reaching 
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performance improved from post-stroke day 3 over time up to post-stroke week 3 (p < 
0.001). No significant improvements were seen beyond post-stroke week 3 (p > 0.05).   
Animals in the very severe category showed no improvements across time and 
were never able to grasp and bring any pellets to the mouth on any attempt out of 20 
during the skilled reaching task.   
 
Body weight of rats post-stroke 
The body weights of rats post-stroke across the 4 stroke severity deficit categories was 
compared. There was no different between the weight of rats in any stroke deficit severity 
group across time (p = 0.577, Repeated Measures ANOVA), see Figure 4.3.  
 
No correlation between skilled reaching performance and post-stroke body weight 
Rats were food restricted in order to provide motivation for performing the skilled 
reaching task. Therefore it was evaluated whether there was a correlation between weight 
and success score at baseline or post-stroke week 8 across all rats post-stroke. There was 
no significant correlation between either baseline weight (p = 0.091, Pearson’s 
Correlation) or post-stroke weight (p = 0.901, Pearson’s Correlation) with performance 
on skilled reaching.  
 
Positive correlation between initial skilled reaching impairment and final reaching 
recovery 
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The correlation between skilled reaching success score at early time points post-stroke 
was correlated with final reaching recovery at post-stroke week 8 (see Table 4.1). Post-
stroke severity at post-stroke week 1 (p < 0.01, Pearson’s Correlation) and post-stroke 
week 4 (p < 0.01, Pearson’s Correlation) was strongly correlated with post-stroke week 8 
recovery.   
 
No difference in skilled reaching performance at baseline based on skilled reaching 
forelimb preference 
 
Rats were trained to perform the skilled reaching task to a criterion of 15 successful 
pellets out of 20. Most rats were trained to this criterion within 2-4 weeks. Rats exhibit a 
forelimb preference when trained on the skilled reaching task. The majority of rats 
displayed a purely single forelimb preference (right or left) on the skilled reaching task 
(78%) while a minority displayed ambidextrous reaching patterns (22%), Figure 4.4A. 
Based on these categories, 49% of rats had a right forelimb preference, 29% had a left 
forelimb preference and 22% were ambidextrous. A chi squared test of the distribution 
forelimb preferences among the rats indicated that the distribution was significantly 
different (p = 0.019). A larger proportion of rats displayed a single right forelimb 
preference than a left preference or ambidexterity. Ambidextrous rats were not excluded 
from the study since it was possible to elicit a largely single forelimb reach by placing the 
sugar pellet very far lateral. Including ambidextrous rats, a significantly larger proportion 
of the total, 66% of rats displayed primarily a right forelimb preference, while 34% of 
rats displayed a largely left forelimb preference (p = 0.009). Neither primary forelimb 
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preference nor ambidexterity influenced performance on the skilled reaching task at 
baseline, Figure 4.4.B. There were no differences in mean skilled reaching performance 
across animals with different forelimb preferences (p = 0.731, one-way ANOVA). 
 
No difference in skilled reaching performance at post-stroke week 8 based on 
baseline forelimb preference 
 
The final skilled reaching recovery score at post-stroke week 8 was evaluated by original 
forelimb preference (right, left, ambidextrous right, and ambidextrous left) at baseline. 
There was no difference between the scores at post-stroke week 8 on the skilled reaching 
task based on original forelimb preference determined at training, Figure 4.5 (p = 0.510, 
one-way ANOVA).  
 
Increased prevalence of forelimb preference change post-stroke and a correlated 
decrease in skilled reaching performance 
 
Following stroke, there was an increase in the reliance of animals using the unimpaired 
forelimb to reach for pellets in the skilled reaching task, Figure 4.6A. The percent of 
animals with solely a right forelimb preference dropped to 28% after stroke versus a 
baseline value of 49%. Likewise, the percent of animals with solely a left forelimb 
preference decreased to 18% after stroke compared with a baseline value of 29%. The 
percentage of animals displaying ambidextrous reaching patterns increased to 53% after 
stroke compared with a baseline value of 22%.   
Due to the increased prevalence of animals using the unimpaired forelimb after 
stroke, we evaluated whether animals with a change in forelimb preference had an effect 
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on recovery of skilled reaching ability at post-stroke week 8.  First we evaluated whether 
there was a difference between animals with a right or left preference within switching 
categories, i.e. animals that never relied on the unimpaired forelimb, animals that were 
ambidextrous from baseline, and animals that began to rely on the unimpaired forelimb 
after stroke. There was no difference in post stroke week 8 success scores among animals 
with right or left forelimb preferences that never used the unimpaired forelimb (p = 
0.323), were ambidextrous from baseline (p = 0.348), or that developed a stroke 
preference for the unimpaired forelimb (p = 0.473). Since there was no effect of original 
right or left forelimb preference and switching status, it was evaluated whether overall 
there was a difference in skilled reaching success score at post-stroke week 8 across 
animals that never switched (right and left preferences combined), animals that were 
ambidextrous from baseline (right and left preferences combined) or animals that 
developed a new preference for the unimpaired forelimb (right and left preferences 
combined). Switching status had a significant effect on post-stroke week 8 success score 
(p = 0.004). There was no difference between animals that never switched and those that 
were ambidextrous from baseline (p = 0.066). The skilled reaching scores at post-stroke 
week 8 were also not significantly different between the ambidextrous group and the 
group that developed a new forelimb preference (p = 1.0). However, there was a 
significant difference in the skilled reaching success score at post-stroke week 8 between 
animals that never switched and animals that developed a new forelimb preference after 
stroke (p = 0.006), Figure 4.6B.  
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Figure 4.1. Spontaneous recovery of skilled reaching success score over 24 weeks 
post-stroke. (A) shows how skilled reaching performance changed over the course of 8 
weeks post-stroke. Initially, there was a significant decrease in the skilled reaching 
success score at 1 week post-stroke (p < 0.001). The success score improved until post-
stroke week 2 (p = 0.019) with no further improvements until post-stroke week 8 (p = 
0.001). (B) shows how skilled reaching performance changed over the course of 24 
weeks post-stroke in a subset of animals. Similarly to the larger cohort, there was a 
significant decrease in the skilled reaching success score at 1 week post-stroke (p < 
0.001). Furthermore, there was an improvement in success score from week 1 to week 4 
post-stroke (p = 0.022), with no further improvements seen at post-stroke week 8 or 24. 
*p < 0.05, **p < 0.01, ***p < 0.001 comparing the current week to the previous week, 
repeated measures ANOVA. Error bars denote ± standard error of the mean.   
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Figure 4.2. Spontaneous skilled reaching recovery based on initial severity at post-
stroke week 1. Animals were categorized into four stroke severity groups based on the 
skilled reaching score attained at post-stroke week 1. (A) shows the recovery profiles of 
animals based on mild, moderate, severe, and very severe deficit categories. The recovery 
profiles of the mild and moderate stroke groups were statistically insignificant (p = 0.203, 
repeated measures ANOVA). However, recovery profiles for the severe and very severe 
stroke groups were significantly different from that of the mild and moderate stroke 
groups (p < 0.01) and different from each other (p <0.01). Animals within the mild and 
moderate stroke deficit categories displayed no significant improvement of reaching 
success score over time (p = 0.085). Animals with a severe stroke deficit improved until 
post-stroke week 3 (p < 0.001). No improvements were seen in the very severe deficit 
animals. (B) shows the criteria used to categorize animals into mild, moderate, severe, 
and very severe stroke deficit groups. Error bars denote ± standard error of the mean. 
Deficit Category Success Score Criterion at 
Post-Stroke Week 1 
% of total stroke population 
Mild        greater than 10  7. 6 (n= 5) 
Moderate 5 to 10 9.1 (n = 6) 
Severe less than 5/greater than 0 65.2 (n = 43) 
Very Severe     0 18.2 (n = 12) 
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Body Weight of Rats Post-Stroke 
 
Figure 4.3. Body weight of rats post-stroke. Rats that underwent stroke were weighed 
once a week starting at week 0 (pre-stroke) and lasting through week 8 post-stroke. 
Weight was considered as a measure of health and simultaneously as an indirect measure 
of motivation to perform the food restriction based skilled reaching task. There was no 
difference in the body weight of rats across any stroke deficit category (mild, moderate, 
severe, very severe) across time (p = 0.577). Error bars denote ± standard error of the 
mean. 
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Correlation between Weeks Post-Stroke and Success Score 
 
 
 
 
 
 
Time Point PSWk1 PSWk4 PSWk8 
PSWk1 -- 0.649** 0.753** 
PSWk4 0.649** -- 0.798** 
PSWk8 0.753** 0.798** -- 
 
 
* p < 0.05, ** p < 0.01 
 
Table 4.1. Pearson’s correlations between skilled reaching success scores across 
different post-stroke weeks. 
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Figure 4.4. The effect of forelimb preference on skilled reaching success score at 
baseline. At the start of training, all rats use both forelimbs to make largely 
unsuccessful attempts for pellets. With training, most rats begin to show a forelimb 
preference and pellet retrieval improves. (A) Once baseline criteria are attained, the 
majority of rats (78%) show a single forelimb preference on the skilled reaching 
task, with a minority displaying ambidextrous reaching patterns (22%). (B) There 
were no differences in mean skilled reaching performance across animals with 
different forelimb preferences (p = 0.731). Error bars denote ± standard error of the 
mean. FL = forelimb, Ambi = ambidextrous
A 
B 
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Skilled Reaching Performance at Post-Stroke Week 8 based on Baseline Forelimb 
Preference 
 
 
Figure 4.5. Relationship between baseline forelimb preference and post-stroke week 
8 reaching score. Forelimb preference determined at baseline (right, left, ambidextrous 
right, ambidextrous left) had no effect on the final skilled reaching success score at post-
stroke week 8 (p = 0.510). Error bars denote ± standard error of the mean. FL = forelimb, 
Ambi = ambidextrous 
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Figure 4.6. Increased reliance on unimpaired forelimb and correlated decrease in 
skilled reaching performance. (A) Following stroke, the number of animals using 
unimpaired forelimb to reach for sugar pellets during the skilled forelimb reaching task 
increased by 31%. (B) There was a significant difference in the skilled reaching success 
score at post-stroke week 8 in animals that never changed forelimb preference and 
animals that changed forelimb preference after stroke (p = 0.006). Animals that changed 
preference after stroke and used their unimpaired forelimb as well as their original 
reaching forelimb had a lower average skilled reaching score at post-stroke week 8 than 
animals that did not use their unimpaired forelimb during reaching. Note: attempts with 
the unimpaired forelimb were not counted in the success score. Only attempts with the 
training defined ‘preferred limb’ were counted towards the success score. Error bars 
denote ± standard error of the mean. **p < 0.01 
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DISCUSSION 
 
In this study we have demonstrated that spontaneous sensorimotor recovery takes place in 
adult rats post-stroke as measured by the skilled forelimb reaching task. The time course 
and magnitude of recovery is related to initial stroke deficit severity at post-stroke week 
1. Overall, animals displayed spontaneous sensorimotor recovery on the skilled reaching 
task within one month (4 weeks) post-stroke with no further improvements in skilled 
reaching performance out to 6 months (24 weeks) post stroke. Interestingly, the time 
course of recovery of adult animals post-stroke is similar to reports of human post-stroke 
recovery. Therefore, the rat model of ischemic stroke (MCAO) is a valid model that can 
be used to study treatment effects in the acute and chronic phases after stroke.  
 Overall, in rats that were evaluated for 8 weeks post-stroke, the rats displayed a 
large decrease in skilled reaching ability post-stroke at week 1. Spontaneous recovery of 
function was seen up to week 2 post-stroke. Beyond the second week post-stroke, no 
further statistically significant improvements in reaching ability were seen up to post-
stroke week 7. However, a statistically significant increase in skilled reaching 
performance was also seen from post-stroke week 7 to post-stroke week 8. It is likely that 
this improvement in function, after a total of 5 weeks of plateau in skilled reaching 
success score is related to a change in the frequency in testing. Animals were tested once 
a week during post-stroke weeks 1-7 and were tested three times during post-stroke week 
8. Therefore, the increase in the pellet score likely represents a practice effect and not 
true recovery. A similar recovery pattern was found in the smaller subset of animals that 
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were evaluated for a total of 24 weeks. Rats displayed a large decrease in skilled reaching 
performance at post-stroke week 1, with improvement in skilled reaching score occurring 
between post-stroke week 1 and post-stroke week 4. Statistically significant 
improvements were not seen beyond post-stroke week 4 until the end of the assessment 
of spontaneous recovery at post-stroke week 24. Overall, the majority of improvements 
seen post-stroke take place within two weeks post-stroke with an unequivocally stable 
deficit seen at 6 months post-stroke. The time course for spontaneous recovery of skilled 
forelimb reaching in these experiments is supported by previous studies in our lab that 
used a stroke only group as a control group during other anti-Nogo-A immunotherapy 
experiments. On average, spontaneous skilled reaching improvements were seen in stroke 
only animals up to 2-4 weeks post-stroke, mirroring the results in the present experiments 
(Papadopoulos et al., 2002; Seymour et al., 2005; Tsai et al., 2007).   
In humans, the most valid predicting factor for stroke recovery is the magnitude 
of initial stroke severity. Therefore, we evaluated if initial stroke deficit as measured by 
the skilled reaching task affected the recovery profile of adult rats post-stroke. A strong 
correlation between success score at early post-stroke weeks (week 1 and 4) was found 
with the recovery success score at post-stroke week 8. Therefore, it is likely that initial 
stroke deficit is a factor in the prognosis of stroke recovery in rats. To further assess the 
relationship between recovery and initial deficit in rats we categorized the rats into 4 
stroke deficit categories based on post-stroke week 1 (mild, moderate, severe, and very 
severe) and analyzed the corresponding recovery profiles.  
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Animals in the mild deficit category (n = 5) displayed a small statistically 
insignificant improvement from day 3 post-stroke to post-stroke week 1. No further 
improvements over time were seen up to post-stroke week 8. Since the deficits in this 
group were so mild, improvements post-stroke were not detectible possibly due to a 
ceiling effect. This has also been demonstrated in human stroke recovery as well (Duncan 
et al., 1992). Patients with very mild post-stroke deficits display very little to no 
measureable improvements over time, and any improvements that do occur do so within 
the first month post-stroke. Since this population has near normal use of the forelimb (rat) 
or upper extremity (human) post-stroke it is less likely to show significant improvements 
in function. Due to the low level of deficits and no recovery seen in the mild deficit 
category, animals in this deficit category would be unlikely to show improvements in 
recovery due to treatment interventions or rehabilitation.  
The recovery profile of animals in the moderate deficit category was statistically 
indistinguishable from the recovery profile seen in animals with mild initial deficits. 
However, it is possible that due to the low number of animals in this group (n = 6) there 
was not enough statistical power to distinguish between the recovery profiles of mild and 
moderate deficit animals. Animals in the moderate deficit category displayed lower 
reaching success scores at post-stroke week 1 than the mild deficit category, but over 
time, their success scores improved and at post-stroke week 7 and 8 became 
indistinguishable from that of the mild deficit category. Animals in the moderate deficit 
category start from a greater post-stroke deficit and although statistically insignificant, 
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display an increased rate of recovery over the first weeks post-stroke, eventually reaching 
the same overall recovery plateau as the mild deficit animals.  
Animals in the severe deficit category (n = 43) show a slow and steady rate of 
improvement from post-stroke day 3 to post-stroke week 3. From post-stroke week 3 to 
post-stroke week 7 no statistically significant improvements area seen. A statistically 
significant increase in skilled reaching success score is seen from post-stroke week 7 to 
post-stroke week 8. As discussed previously, this is likely due to the change in testing 
frequency from week 7 to week 8. The severe deficit animals were shown to be the most 
sensitive to this increase in testing frequency among the deficit categories. Additionally, 
primarily among the severe and very severe deficit category animals, we observed an 
increase in animals switching their forelimb preference post-stroke and relying on the 
unimpaired forelimb during skilled reaching. Although, attempts with the unimpaired 
forelimb were not counted as an attempt, the use of the unimpaired forelimb may have 
affected the ability of the rat to successfully grasp the pellet with its impaired forelimb. 
Comparison of post-stroke week 8 success scores in animals that had no change in their 
forelimb preference post-stroke to animals that changed their forelimb preference to the 
unimpaired forelimb post-stroke showed that there was a statistically significant decrease 
in the mean success score at post-stroke week 8. There have been reports in the literature 
that large cortical lesions are more likely to cause a change in forelimb preference 
(Castro-Alamancos et al., 1991) and therefore would support our finding of increased 
forelimb preference change among animals in the severe and very severe deficit 
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categories. The decrease in the mean recovery success score in the animals with forelimb 
preference change may have be due to the switching behavior interfering in obtaining 
successful pellets with the impaired forelimb, or it may have been simply a symptom of 
the greater stroke severity in these animals that leads to the lower success score and 
higher prevalence of switching behavior.   
Animals in the very severe deficit category (n = 12) immediately after stroke were 
not able to successfully grasp and place a pellet in the mouth during the skilled reaching 
task. However, the rats did attempt to obtain pellets, and sometimes would drag the pellet 
into the cage and drop it or would knock it away. This group of animals showed 
absolutely no change in reaching performance over the course of 8 weeks. This group 
may be the hardest to rehabilitate and may not show improvements in skilled reaching 
even with rehabilitation or restorative treatments. Patients with very little to no recovery 
post-stroke have also been reported in stroke literature (Prabhakaran et al., 2007; Stinear 
et al., 2012). This absolute deficit population may not show traditional improvements in 
sensorimotor function but may instead show improvements in ancillary measures such as 
spasticity or shoulder pain (Stinear et al., 2012).   
Given that animals in the mild and moderate deficit categories showed recovery 
up to 65% of baseline performance it is likely that treating this group of animals with 
anti-Nogo-A immunotherapy may not show statistically detectible improvements due to a 
ceiling effect. Since the severe stroke category only showed recovery up to 25% of 
baseline performance, it may be more likely that treating these animals with anti-Nogo-A 
immunotherapy would show an effective improvement in function because there would 
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be more room for anti-Nogo-A immunotherapy effects to be seen. Finally, the very 
severe stroke category could be treated with anti-Nogo-A immunotherapy, however this 
group may be too severely damaged to show improvement.     
One of the potential limitations to the interpretation of recovery profiles based on 
initial severity is the unequal distribution of rat numbers within the different deficit 
categories. The mild and moderate deficit categories each had approximately 5 rats while 
the severe category had 43 rats and the very severe category had 12 rats. The low number 
of animals in the mild and moderate deficit categories may have led to the inability to 
detect statistical differences between these two recovery groups. Additionally, since the 
distribution of deficits post-stroke was so heavily localized in the ‘severe’ deficit 
category, it is possible that there are additional clusters of recovery trajectories within this 
category. Further analysis of this data could use initial severity post-stroke as well as 
stroke size and location in order to predict recovery clusters. Additionally, since post-
stroke recovery in rats and humans has been shown to progress non-linearly (Jorgensen et 
al., 1995), the data could be analyzed using a non-linear model with initial severity and 
stroke lesion characteristics as covariates in order to further characterize spontaneous 
recovery post-stroke in adult rats.  
In conclusion, animals undergoing ischemic focal stroke undergo a short 
spontaneous recovery time course, up to 4 weeks depending on severity of initial deficit, 
and do not show further improvements over time up to post-stroke week 24 (6 months) 
on the skilled forelimb reaching task. Therefore, when treatments or rehabilitative 
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strategies are initiated after 1 month post-stroke in adult rats, regardless of initial severity, 
any improvements seen are likely to be due to the therapy and not spontaneous recovery.    
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CHAPTER FIVE 
 
SENSORIMOTOR RECOVERY AND DENDRITIC PLASTICITY AFTER 
CHRONIC TREATMENT DELAY USING ANTI-NOGO-A IMMUNOTHERAPY 
IN THE ADULT RAT WITH MODERATE TO VERY SEVERE STROKE 
DEFICITS. 
 
ABSTRACT 
 
Yearly, more than 700,000 people in the United States suffer from a new or 
recurrent stroke and the majority are left with permanent life changing impairments. 
Therefore, the development of strategies to enhance neural repair following stroke is of 
utmost clinical importance. One promising new approach is to inhibit the Nogo-A 
protein, a myelin associated protein that acts to restrict neuronal plasticity in the adult 
central nervous system. A previous study from our laboratory showed that inhibition of 
protein Nogo-A at 9 weeks post-stroke in rats with mild to moderate deficits resulted in 
sensorimotor recovery and was associated with axonal plasticity (Tsai et al., 2010). The 
current study was designed to further evaluate the treatment time window for the 
administration of anti-Nogo-A immunotherapy in the chronic period following stroke. 
We aimed to examine the extent functional recovery in rats with moderate to very severe 
chronic sensorimotor deficits. Adult rats were trained on the skilled forelimb reaching 
task and subsequently underwent a unilateral permanent middle cerebral artery occlusion. 
Rats received anti-Nogo-A antibody, control antibody, or no treatment at one of two 
delayed treatment time points: 9 weeks post-stroke (subchronic) or 25 weeks post-stroke 
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(chronic), approximately corresponding to 2 and 6 months post-stroke. Sensorimotor 
performance was assessed up to12 weeks following treatment initiation and was 
evaluated using an intention-to-treat and per-protocol analysis. Following testing, rats 
were sacrificed and brain tissue was processed and stained to evaluate dendritic 
morphology using the Golgi-Cox method. Layer V pyramidal neurons in the perilesional 
caudal forelimb motor cortex and layer II/III and layer V pyramidal neurons in the 
contralesional caudal forelimb motor cortex were evaluated for dendritic tree complexity. 
Both intention-to-treat and per-protocol analysis showed that anti-Nogo-A 
immunotherapy administered at either 9 or 25 weeks post-stroke resulted in improved 
sensorimotor recovery on the skilled forelimb reaching task but no significant recovery 
was seen in sensory function or skilled walking. The improved performance on the 
skilled reaching task was not associated with dendritic changes in layer V pyramidal 
neurons in the perilesional caudal forelimb motor cortex or layer II/III or layer V 
pyramidal neurons in the contralesional caudal forelimb motor cortex. Our finding of 
improved sensorimotor recovery even when treatment was started 25 weeks post-stroke 
demonstrates the promising therapeutic potential for anti-Nogo-A immunotherapy to treat 
stroke sufferers long after the initial ischemic damage has taken place.    
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INTRODUCTION 
Stroke is a leading cause of death and the primary cause of serious long-term 
disability in the United States (AHA, 2013; CDC, 2005). Neuronal damage subsequent to 
the interruption of blood supply in the brain leads to the profound sensorimotor, 
linguistic, and cognitive deficits seen following stroke. Stroke is classified into two main 
categories, ischemic or hemorrhagic. The majority of strokes are ischemic in nature 
(87%), while the rest are either intracerebral hemorrhages (10%) or subarachnoid 
hemorrhages (3%) (Woo et al., 1999). It is estimated that there are over 6 million stroke 
survivors living in the United States at the present time and over 700,000 new or 
recurrent strokes take place each year (AHA, 2013). Given these statistics, it is clear that 
the potential burden of disability seen after stroke is profound. In fact, 80% of ischemic 
stroke survivors over the age of 65 have hemiparesis or cannot walk without assistance. 
Additionally troubling is the fact that up to 26% of these ischemic stroke survivors are 
institutionalized in a nursing home and lose all ability for independent living (Kelly-
Hayes et al., 2003).   
 Unfortunately, treatment options following ischemic stroke are limited, and 
therefore exacerbate the magnitude of disability seen after stroke. Acutely after ischemic 
stroke, the only therapeutic option is to use thrombolytic therapy to lyse the blood clot 
causing the ischemia. However, the use of tissue plasminogen activator (tPA) is only 
effective when used within 4.5 hours of stroke onset, and its efficacy at promoting 
improvement of function is greatest when applied early in the 4.5-hour time window 
(Hacke et al., 2008). Given the short treatment time window of tPA therapy, only a small 
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percentage of patients (4.3%) receive the drug (CASPR Investigators, 2005). With the 
majority of ischemic stroke patients not receiving thrombolytic therapy, patients can only 
hope for recovery of function through spontaneous recovery mechanisms and their 
potential augmentation through stroke rehabilitation.  
 Given the fact that spontaneous recovery is the main mechanism available for 
recovery after stroke, it is important to take a pragmatic view of its efficacy. Although 
real gains in function can occur through spontaneous recovery, in general, the recovery 
potential after moderate to very severe strokes is generally limited even with the addition 
of rehabilitative approaches. This is due to the limited ability of the adult mammalian 
central nervous system (CNS) to engage in restorative regeneration and neuroplasticity 
after injury. The lack of widespread regeneration and neuroplasticity in the CNS after 
injury is in part related to the inhibitory environment that surrounds neurons. The main 
components of this growth restrictive environment include inhibitory proteins that are 
associated with myelin. The most potent of these myelin inhibitory proteins is Protein 
Nogo-A (Gozenbach and Schwab, 2008). Protein Nogo-A is expressed on the membrane 
of oligodendrocytes and restricts the outgrowth of neurites after CNS injury (Caroni et 
al., 1988; Caroni Schwab, 1988; Chen et al., 2000; GrandPre et al., 2000; Prinjha et al., 
2000). Therefore, the neutralization of Nogo-A has become a fascinating and active 
avenue for preclinical and clinical investigation as a therapeutic approach to improving 
CNS regeneration and neuroplasticity and thereby functional recovery after CNS injury.  
 Previous studies from our laboratory have shown that inhibition of the protein 
Nogo-A after focal ischemic stroke in the adult rat immediately and one week post-stroke 
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results in significant recovery of skilled reaching ability. This improved recovery was 
associated with axonal and dendritic plasticity in the contralesional sensorimotor cortex 
(Papadopoulos et al, 2002; Seymour et al., 2005; Papadopoulos et al., 2006). In order to 
properly model human stroke, anti-Nogo-A immunotherapy was also tested in aged rats 
one week post-stroke. The skilled reaching recovery results mirrored the effects seen in 
adult rats, albeit with a slower rate of improvement (Markus et al 2005). Most recently, 
our lab began investigating the use of anti-Nogo-A immunotherapy in chronic stroke. A 
small set of animals with mild to moderate stroke deficits were treated with anti-Nogo-A 
immunotherapy 9 weeks post-stroke and evaluated for skilled reaching recovery. Tsai et 
al (2010) showed that adult rats treated at 9 weeks post-stroke had a similar rate and 
magnitude recovery profile as those treated at one week post stroke. The reaching 
recovery seen in these animals was also associated with enhanced corticorubral axonal 
sprouting from the contralesional forelimb motor cortex to the deafferented red nucleus. 
These results opened up the possibility of anti-Nogo-A immunotherapy being a powerful 
treatment even in the chronic phases after ischemic injury and set the stage for further 
investigation of recovery of function after chronic stroke following anti-Nogo-A 
immunotherapy.  
 The following experiments described in this chapter set out to further evaluate the 
effective treatment time window for anti-Nogo-A immunotherapy chronically after stroke 
in adult rats. Additionally, the efficacy of anti-Nogo-A immunotherapy has been 
evaluated in rats with mild to moderate stroke deficits and small to medium stroke sizes 
primarily involving the cortex. Therefore, we also set out to evaluate the efficacy of anti-
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Nogo-A immunotherapy in adult rats with moderate to very severe chronic sensorimotor 
deficits and medium to large stroke sizes that include cortical and subcortical damage.   
Rats were treated with anti-Nogo-A immunotherapy at either 9 weeks (subchronic time 
point) or 25 weeks (chronic time point) post-stroke. Treatment efficacy was evaluated 
using an intention-to-treat and a per-protocol analysis.       
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METHODS 
 General methods common to both aims 1 and 2 are described in chapter 3. 
Methods specific to the experiments outlined in this chapter (Aim 2 experiments) are 
described here.  
 
A priori inclusion criteria  
All rats (n = 75) were trained to successfully reach 15 out of 20 pellets, for three 
consecutive days and then all rats underwent a MCAO procedure. After stroke, all 
surviving rats (n =66) were tested on the skilled reaching task once a week to assess for 
spontaneous recovery for a total of 8 weeks or 24 weeks prior to treatment group 
randomization (see chapter 4 on spontaneous recovery (Aim 1)).  All remaining rats were 
included in the study if they were able to reach with their impaired forelimb through the 
opening aperture in the skilled reaching apparatus, and at least touch the pellets on some 
attempts out of 20 total.    
 
A priori exclusion criteria  
 Rats were excluded if a score of  > 10/20 pellets was attained during any testing 
session post-stroke, weeks 1-8 for the subchronic delay treatment cohort and weeks 1-24 
for the chronic treatment delay cohort. A total of 23 out of 66 rats (35%) rats were 
excluded from the study with a score > 10/20 pellets. 
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Randomization 
Based on the skilled reaching deficit at post-stroke week 8 (subchronic treatment cohort) 
or post-stroke week 24 (chronic treatment cohort), animals were randomized across three 
stroke groups: Stroke/Anti-Nogo-A Ab, Stroke/Control Ab or Stroke Only. Treatment 
was initiated at the beginning of week 9 for the subchronic treatment delay cohort and at 
the beginning of week 25 for the chronic treatment delay cohort.  
 
Description of the intention-to-treat (ITT) dataset for the subchronic treatment 
delay cohort (treatment at 9 weeks post-stroke) 
 
In the intention-to-treat (ITT) dataset, all animals regardless of experimental 
protocol deviation were included in the final skilled reaching analysis as randomized. The 
subchronic treatment cohort was analyzed as both an ITT and a PP dataset. The ITT 
dataset for the subchronic treatment delay cohort is composed of the following treatment 
groups: Stroke/Anti-Nogo-A Ab (n = 14); Stroke/Control Ab (n = 12); Stroke Only (n = 
10).  
 
Description of the Per-Protocol (PP) dataset for the subchronic treatment delay 
cohort (treatment at 9 weeks post-stroke) 
 
The per-protocol (PP) dataset includes all animals from the subchronic treatment 
delay ITT dataset that adhered to the experimental protocol without major deviations. 
Experimental protocol deviations that led to post-randomization exclusions included 
treatment pump disconnection upon removal (2 rats), absolute deficit animals that never 
grasped a pellet and scored a 0 out of 20 throughout the experiments (6 rats), severe 
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behavioral compensation using the unimpaired forelimb to reach for pellets and the 
resultant inability to obtain an accurate score for the impaired forelimb (2 rats), and 
severe striatal damage (1 rat). The PP dataset for the subchronic treatment delay cohort is 
composed of the following treatment groups: Stroke/Anti-Nogo-A Ab (n = 7), 
Stroke/Control Ab (n = 10), Stroke Only (n = 8). 
 
Description of the dataset for the chronic treatment delay cohort (treatment at 25 
weeks post-stroke) 
 
The chronic delay treatment cohort (treatment initiated at 25 weeks post-stroke) 
had a minimal number of animals, thereby making an ITT vs. PP distinction obsolete. 
However, there were no animals with pump disconnections, no absolute deficit animals 
included, no severe behavioral abnormalities, or severe striatal damage in any animals 
that were randomized to this treatment time point (total n = 7). The dataset for the chronic 
treatment delay cohort is composed of the following treatment groups: Stroke/Anti-Nogo-
A Ab (n = 3), Stroke/Control Ab (n = 2), Stroke Only (n = 2). The two control groups, 
animals treated with control antibody and stroke only animals, were combined in order to 
perform statistical calculations given the small number of animals in this dataset.  
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RESULTS 
Body weight of adult rats at baseline, post-stroke, and post-treatment.  
At the beginning of the experiments, rats were approximately 2 months of age and 
weighed approximately 250 grams. There was no difference in overall weight between 
the stroke groups in either the subchronic treatment cohort or the chronic treatment 
cohort at: arrival prior to food restriction, after skilled reaching training/food deprivation 
prior to the stroke procedure, prior to treatment initiation, or at the conclusion of the 
study (p > 0.05).  
 
Morbidity and mortality associated with experimental procedures  
  Following stroke surgery (n = 75), a total of 9 rats (12%) died either during or 
within 24 hours of the stroke procedure.  
Stroke lesion size did not differ across stroke groups in animals treated with anti-
Nogo-A immunotherapy at 9 weeks post-stroke.  
 
Total stroke lesion volume was measured for all animals and expressed as a % of 
the intact contralateral hemisphere. In the cohort of animals treated with anti-Nogo-A 
immunotherapy at 9 weeks post-stroke, there were no significant difference between the 
stroke sizes between stroke groups within the ITT dataset (p = 0.775, one-way ANOVA), 
Figure 5.1A. ITT stroke lesion volumes were found to be 27.7 % ± 1.9 in the Stroke/Anti-
Nogo-A Ab group, 29.6 % ± 1.9 in the Stroke/Control Ab group, and 28.4 % ± 2.3 in the 
Stroke only group, Figure 5.1A. 
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In the PP dataset, there was also no significant difference between the stroke sizes 
between stroke groups (p = 0.809, one-way ANOVA), Figure 5.1B. PP stroke lesion 
volumes were found to be 27.2 % ± 3.0 in the Stroke/Anti-Nogo-A Ab group, 29.2 % ± 
2.2 in the Stroke/Control Ab group, and 27.1 % ± 2.7 in the Stroke only group, Figure 
5.1B.  
The overall stroke size in both the ITT and PP datasets was similar and therefore 
post-randomization exclusions did not affect the average stroke size (p = 0.957, one-way 
ANOVA).  
Topological location of the stroke lesion included major damage to the caudal 
forelimb motor area, varying levels of damage to the rostral forelimb motor area, and 
minimal to moderate damage to the striatum, Figure 5.2. 
 
 
Stroke lesion size did not differ across stroke groups in animals treated with anti-
Nogo-A immunotherapy at 25 weeks post-stroke. 
 
There was no significant difference between the stroke sizes across the anti-Nogo-
A antibody treated or control stroke groups (p = 0.279), Figure 5.3. Stroke lesion 
volumes were found to be 23.7 % ±4.0 in the Stroke/Anti-Nogo-A Ab group and 35.2 % 
± 8.2 in the combined control group (Control Ab + Stroke Only), Figure 5.3. Topological 
location of the stroke lesion included major damage to the caudal forelimb motor area, 
varying levels of damage to the rostral forelimb motor area, and minimal to moderate 
damage to the striatum, Figure 5.2.       
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Improved skilled reaching performance in animals treated with anti-Nogo-A 
immunotherapy at 9 weeks post-stroke (ITT and PP analyses). 
 
ITT Analysis of Skilled Reaching Recovery following treatment with anti-Nogo-A 
antibody at 9 weeks post-stroke with a General Linear Model Repeated Measures 
ANOVA 
 
To test whether treatment with anti-Nogo-A immunotherapy at 9 weeks post-
stroke can improve sensorimotor function in rats with moderate to very severe stroke 
deficits, skilled reaching performance was assessed across 12 weeks post-treatment 
initiation (20 weeks post-stroke). Figure 5.4 shows the individual reaching recovery 
scores of each animal in the ITT dataset across treatment type starting at post-stroke week 
7 (two weeks prior to treatment) and ending with post-stroke week 20 (the final testing 
week following treatment initiation).  
 Skilled reaching was first analyzed using a general linear model repeated 
measures ANOVA. Repeated measures analysis of animals treated at 9 weeks post-stroke 
(ITT) showed no statistically significant effect of treatment group upon reaching score 
across time (p = 0.235), Figure 5.5A. However, inspection of the recovery profiles 
indicated that the anti-Nogo-A Ab group had a trend towards a small improvement in 
final reaching performance. Figure 5.5B shows a linear regression applied to the recovery 
profiles of each treatment group showing that the two control groups, Stroke/Control Ab 
and Stroke Only, have a nearly horizontal recovery slope while the Stroke/Anti-Nogo-A 
Ab group shows a larger recovery slope, though modest. We therefore decided to 
evaluate whether there existed a significantly different mean linear rate of recovery 
across the different treatment groups. The mean linear recovery rate was quantified 
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starting from post-stroke week 7 and ending with post-stroke week 20. We decided to use 
both post-stroke weeks 7 and 8 as the pre-treatment stroke impairment baseline to 
account for skilled reaching practice effects caused by the change in testing frequency 
from post-stroke week 7 to post-stroke week 8 and beyond.1 The mean linear rate of 
recovery (Figure 5.5C) was found to be significantly different between the different 
treatment groups (p = 0.039), one-way ANOVA. Bonferroni post-hoc testing showed that 
the mean linear rate of recovery in the anti-Nogo-A antibody treated group was 
significantly greater than the recovery rate in animals treated with control antibody (p = 
0.045) but not significantly different from stroke only animals that received no treatment 
(p = 0.234).  
 
ITT Analysis of Skilled Reaching Recovery following treatment with anti-Nogo-A 
antibody at 9 weeks post-stroke with a Non-Linear Mixed Effects Logistic Regression 
Model 
 
A non-linear mixed effects logistic regression model was used to fit a 3 parameter 
binomial logistic exponential function to the ITT recovery profiles in each treatment 
group. The exponential function is represented by P(t)	=	Ɵ1	+	(Ɵ2	–	Ɵ1)*e(‐Ɵ3*(t‐7)),	
where	P	=	probability	of	success,	t	=	time,	Ɵ1	=	recovery	asymptote,	Ɵ2		=	initial	
deficit	(y‐intercept),	and	Ɵ3	=	exponential	recovery	rate. This statistical method was 
                                                            
1 Rats were tested once a week during post-stroke weeks 1-7 in order to maintain skilled reaching ability 
without introducing motor rehabilitation. During post-stroke week 8 it was decided to test the rats 3 days in 
a row in order to re-establish an accurate post-stroke impairment baseline. However, this change in testing 
frequency introduced practice effects and we observed a significant improvement in skilled reaching score 
across all groups from post-stroke week 7 to week 8. 
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chosen to further analyze the recovery of animals treated with anti-Nogo-A 
immunotherapy at 9 weeks post-stroke (ITT dataset) due to the increased ability of non-
linear modeling methods to handle longitudinal data with its inherent complexity without 
violating statistical assumptions. For a discussion of linear versus non-linear handling of 
the longitudinal data in this dissertation please refer to chapter 3.  
Figure 5.6A shows the fitted group-level logistic recovery functions for each 
treatment group based on the non-linear model. The initial deficit severity (post-stroke 
week 7), modeled by the parameter 2 (Figure 5.6B), was shown to be the same across all 
three treatment groups (p = 0.317). Fitted functions including all parameter estimates 
were found to be statistically identical for the two control groups, Stroke/Control Ab and 
Stroke Only. Specifically, the exponential recovery rate and final skilled reaching 
recovery asymptote was found to be statistically the same across both control groups. 
Analysis of the exponential recovery rate between the two control groups and the anti-
Nogo-A antibody treated group shows that the control animals improve faster than the 
anti-Nogo-A antibody group. However, the control groups reach their maximal recovery 
by post-stroke week 9 and show very little improvement beyond that time point. In 
contrast, the anti-Nogo-A antibody treated animals improve slowly but continue to 
improve over time and reach their  maximal recovery asymptote at approximately post-
stroke week 20 and beyond (theoretically), as modeled by the function. The anti-Nogo-A 
antibody treated animals reach a statistically greater final recovery magnitude of 33.31% 
success than the final recovery magnitude of approximately 20% success reached by 
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either the control antibody treated animals or the stroke only animals (p < 0.001 and p < 
0.01 respectively). Parameter estimates and associated significance level contrasts are 
shown in Table 5.1 and 5.2 respectively for the non-linear modeling of animals treated 
with anti-Nogo-A immunotherapy at 9 weeks post-stroke (ITT).  
 
PP Analysis of Skilled Reaching Recovery following treatment with anti-Nogo-A antibody 
at 9 weeks post-stroke with a General Linear Model Repeated Measures ANOVA 
 
Post-randomization exclusions were applied to the ITT dataset and the PP dataset 
was created. Figure 5.7 shows the individual reaching recovery scores of each animal in 
the PP dataset across treatment type starting at post-stroke week 7 and ending with post-
stroke week 20.  
 Mirroring the statistical handling of the ITT data, we analyzed the PP skilled 
reaching recovery response to anti-Nogo-A immunotherapy initiated at 9 weeks post-
stroke by using a general linear model repeated measures ANOVA. Repeated measures 
analysis of animals treated 9 weeks post-stroke (PP) showed a statistically significant 
interaction between time and treatment group for reaching success score attained (p = 
0.004), Figure 5.8A. However, Bonferroni post-hoc testing did not show any statistically 
significant pairwise comparisons (p > 0.05). Figure 5.8B shows a linear regression 
applied to the recovery profiles of each treatment group showing that the two control 
groups, Stroke/Control Ab and Stroke Only, have a nearly horizontal recovery slope 
while the Stroke/Anti-Nogo-A Ab group shows a larger recovery slope and final 
magnitude. We therefore decided to evaluate whether there existed a significantly 
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different mean linear rate of recovery across the different treatment groups. The mean 
linear recovery rate was quantified starting from post-stroke week 7 and ending with 
post-stroke week 20. The mean linear rate of recovery (Figure 5.8C) was found to be 
significantly different between the different treatment groups (p < 0.01), one-way 
ANOVA. Bonferroni post-hoc testing showed that the mean linear rate of recovery in the 
anti-Nogo-A antibody treated group was significantly greater than the recovery rate in 
animals treated with control antibody (p < 0.01) and significantly greater from stroke 
only animals that received no treatment (p < 0.01).  
 
PP Analysis of Skilled Reaching Recovery following treatment with anti-Nogo-A antibody 
at 9 weeks post-stroke with a Non-Linear Mixed Effects Logistic Regression Model 
 
The same non-linear mixed effects logistic regression model that was used for the 
ITT dataset was fit to the PP dataset to evaluate the efficacy of anti-Nogo-A 
immunotherapy in animals treated 9 weeks post-stroke. Figure 5.9A shows the fitted 
group-level logistic recovery functions for each treatment group based on the non-linear 
model. The initial deficit severity (post-stroke week 7), modeled by the parameter 2 
(Figure 5.9B), was shown to be the same across all three treatment groups (p = 0.317). 
Fitted functions including all parameter estimates were found to be statistically identical 
for the two control groups, Stroke/Control Ab and Stroke Only. Specifically, the 
exponential recovery rate and final skilled reaching recovery asymptote was found to be 
statistically the same across both control groups. Analysis of the exponential recovery 
rate between the two control groups and the anti-Nogo-A antibody treated group shows 
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that the control animals improve faster than the anti-Nogo-A antibody group. However, 
the control groups reach their maximal recovery by post-stroke week 9 and show very 
little improvement beyond that time point. In contrast, the anti-Nogo-A antibody treated 
animals improve slowly but do not approach their maximal recovery asymptote until 
post-stroke week 20 and beyond (modeled projection). The anti-Nogo-A antibody treated 
animals reach a statistically greater final recovery magnitude of 55.75% than the final 
recovery magnitude of approximately 25% reached by either the control antibody treated 
animals or the stroke only animals (p < 0.001). Parameter estimates and associated 
significance level contrasts are shown in Table 5.3 and 5.4 respectively for the PP non-
linear modeling of animals treated with anti-Nogo-A immunotherapy at 9 weeks post-
stroke.  
 
Correlation of Total Stroke Lesion Volume and Final Skilled Reaching Recovery in 
animals treated with anti-Nogo-A immunotherapy at 9 weeks post-stroke (ITT and 
PP datasets)  
 
Due to the variability in stroke lesion size among animals treated with anti-Nogo-
A immunotherapy we evaluated whether stroke size was correlated with final skilled 
reaching recovery success score (post-stroke week 20). Figure 5.10B shows a scatterplot 
of the correlation between stroke lesion volume % and final success score for both the 
ITT and PP datasets across treatment groups. A negative although insignificant 
correlation was found between total stroke volume and final skilled reaching recovery 
score in both the ITT and PP datasets (p > 0.05). When the same data was expressed as 
the stroke volume lesion % versus the final pellet difference (post-stroke week 20 – post-
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stroke week 8) virtually no association was seen between stroke size and improvement 
across all treatment groups in both the ITT and PP dataset (p > 0.05), Figure 5.10C.  
 
Correlation of % damage based on lesion location and the Final Skilled Reaching 
Recovery in animals treated with anti-Nogo-A immunotherapy at 9 weeks post-
stroke.  
 
Percent damage was measured for the rostral forelimb motor cortex, the caudal 
forelimb motor cortex, and the striatum based on coordinates found in Paxinos and 
Watson (2005) as well as Neafsey et al. (1986). A small subset of the ITT animal dataset 
was used for this preliminary analysis: 4 animals treated with anti-Nogo-A antibody, 3 
animals treated with control antibody, and 3 animals that received no treatment. First we 
evaluated the correlation between the success score at post-stroke week 20 and % damage 
in the three brain areas outlined above. In the animals treated with anti-Nogo-A 
immunotherapy, there was a negative correlation between all three brain areas and final 
reaching recovery score, however only the correlation between damage in the rostral 
forelimb motor cortex was found to be significantly correlated with final reaching score 
at post-stroke week 20 (r = -0.997, n = 4, p = 0.003). In animals treated with either 
control antibody or no treatment (combined control group), there was a negative 
correlation between all three brain areas and final reaching recovery score, however only 
the correlation between damage in the rostral and caudal forelimb motor cortex was 
found to be significantly correlated with final reaching score at post-stroke week 20 ((r = 
-0.873, n = 6, p = 0.023)(r = -0.817, n = 6, p = 0.047) respectively). Next we evaluated 
how the strength of the correlations change between the % damage of the three brain 
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areas and the final pellet difference. In animals treated with anti-Nogo-A immunotherapy, 
the relationship between % damage in the rostral forelimb area and final pellet 
improvement showed an insignificant though negative correlation (r = -0.785, n = 4, p = 
0.215), Figure 5.11B. In animals treated with control antibody or no treatment, there was 
virtually no association seen between damage in the rostral forelimb motor cortex, the 
caudal forelimb motor cortex, or the striatum and the final pellet difference, Figure 
5.11B.  
 
No sensory recovery in animals treated with anti-Nogo-A immunotherapy at 9 weeks 
post-stroke (ITT and PP datasets)  
 
Recovery of somatosensory function was evaluated using the bilateral adhesive 
removal task. The time necessary to contact the sticker on the impaired forelimb and the 
time to remove the sticker from the impaired forelimb was measured. There was no 
difference between treatment groups in the time necessary for animals to contact and 
remove the sticker on the impaired forelimb (p = > 0.05, Figure 5.12).   
 
No skilled walking improvement in animals treated with anti-Nogo-A 
immunotherapy at 9 weeks post-stroke (ITT and PP datasets)  
 
Recovery of skilled walking ability was evaluated using the horizontal ladder 
skilled walking task. There were no significant difference between treatment groups in 
the mean skilled walking movement score (p = >0.05, Figure 5.13A) or in the number of 
slips per ten steps while traversing the horizontal ladder (p =  >0.05, Figure 5.13B).  
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Improved skilled reaching performance in animals treated with anti-Nogo-A 
immunotherapy at 25 weeks post-stroke (“PP”). 
 
Animals were treated at 25 weeks post-stroke with either anti-Nogo-A antibody, 
control antibody, or no treatment. Skilled reaching performance was assessed for this 
dataset for 9 weeks post-treatment initiation (post-stroke weeks 25 through 32).   
A general linear model repeated measures ANOVA was used to analyze the 
skilled reaching recovery response to anti-Nogo-A immunotherapy initiated at 25 weeks 
post-stroke. Repeated measures analysis of animals showed a statistically significant 
interaction between time and treatment group for reaching success score attained (p = 
0.004), Figure 5.14A. However, Bonferroni post-hoc testing did not show any statistically 
signification pairwise comparisons (p > 0.05).  Figure 5.14B shows a linear regression 
applied to the recovery profiles of each treatment group showing that the combined 
control group, Stroke/Control Ab and Stroke Only, has a nearly horizontal recovery slope 
while the Stroke/Anti-Nogo-A Ab group shows a larger recovery slope and final 
magnitude. We therefore decided to evaluate whether there existed a significantly 
different mean linear rate of recovery across the different treatment groups. The mean 
linear recovery rate was quantified starting from post-stroke week 23 and ending with 
post-stroke week 32. The mean linear rate of recovery (Figure 5.14C) was found to be 
significantly different between the different treatment groups (p < 0.01), one-way 
ANOVA. Due to the small number of animals in this dataset, non-linear analysis was not 
applied.  
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No Change in Dendritic Complexity of Layer V Pyramidal Neurons within the 
Perilesional Caudal Forelimb Motor Cortex  
 
Following the completion of sensorimotor testing of animals treated with anti-
Nogo-A immunotherapy at 9 weeks, animals were perfused and processed for analysis of 
neuronal morphology using the Golgi-Cox method. The animals included for the analysis 
of neuroanatomical plasticity were not distinguished based on the behavioral ITT or PP 
datasets. Intact, non-ischemic Layer V pyramidal neurons in the medial perilesional 
cortex within the rostrocaudal coordinates of the caudal forelimb motor cortex were 
chosen for analysis. Neurons were selected within 2 mm of the ischemic border. The 
number of branches in different branch orders and the dendritic length in different branch 
orders was analyzed separately for each layer V neuron’s apical and basilar dendritic tree. 
Inhibition of protein Nogo-A resulted in no discernable effect on the complexity of the 
apical arbors of perilesional layer V neurons as evidenced by no significant differences 
across treatment groups in terms of the number of apical branches across branch order, 
total number of apical branches, dendritic length across branch order, or total dendritic 
length (p > 0.05, Figures 5.15). Inhibition of the protein Nogo-A also resulted in no 
discernable effect on the complexity of the basilar arbors of perilesional layer V neurons 
as evidenced by no significant differences across treatment groups in terms of the number 
of basilar branches across branch order, total number of basilar branches, dendritic length 
across branch order, or total dendritic length (p >0.05, Figures 5.16).    
 
 
No Change in Dendritic Complexity in Layer II/III or Layer V Pyramidal Neurons 
within the Contralesional Caudal Forelimb Motor Cortex  
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The brains of animals treated at 9 weeks post-stroke with anti-Nogo-A antibody, 
control antibody, or no treatment were also analyzed for dendritic complexity changes in 
the contralesional caudal forelimb motor cortex. Pyramidal neurons in layers II/III and V 
were selected for analysis. Inhibition of protein Nogo-A resulted in no discernable effect 
on the complexity of the apical arbors of contralesional layer II/III or layer V pyramidal 
neurons located in the caudal forelimb motor cortex as evidenced by no significant 
differences across treatment groups in terms of the number of apical branches across 
branch order, total number of apical branches, dendritic length across branch order, or 
total dendritic length, Figures 5.17 and 5.19. Inhibition of protein Nogo-A also resulted in 
no discernable effect on the complexity of the basilar arbors of contralesional layer II/III 
or layer V pyramidal neurons located in the caudal forelimb motor cortex as evidenced by 
no significant differences across treatment groups in terms of the number of basilar 
branches across branch order, total number of basilar branches, dendritic length across 
branch order, or total dendritic length, Figures 5.18 and 5.20. 
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Stroke Lesion Size in animals treated with anti-Nogo-A immunotherapy at 
9 Weeks Post-Stroke 
 
 
 
Figure 5.1. Stroke lesion size did not differ across stroke groups in animals treated 
with anti-Nogo-A immunotherapy at 9 weeks post-stroke. Total stroke lesion volume 
was measured for all animals and expressed as a % of the intact contralateral hemisphere. 
(A) No significant difference in the stroke size was found across stroke groups in the ITT 
dataset (p = 0.775, one-way ANOVA). ITT stroke lesion volumes were found to be 27.7 
% ± 1.9 in the Stroke/Anti-Nogo-A Ab group, 29.6 % ± 1.9 in the Stroke/Control Ab 
group, and 28.4 % ± 2.3 in the Stroke only group. (B) No significant difference was 
found in stroke size across stroke groups in the PP dataset (p = 0.809, one-way ANOVA).  
PP stroke lesion volumes (PP) were found to be 27.2 % ± 3.0 in the Stroke/Anti-Nogo-A 
Ab group, 29.2 % ± 2.2 in the Stroke/Control Ab group, and 27.1 % ± 2.7 in the Stroke 
only group. 
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Representative Stroke Lesion Topology 
 
 
 
Figure 5.2. Diagram of stroke lesion topology. Diagram displays the differences in 
lesion territory between a large and small stroke size. The large lesion (approximately 
40% stroke size) damages most the rostral-caudal hemispheric axis including damage to 
the rostral forelimb motor area, caudal forelimb motor area, and the dorso-lateral 
striatum. The small stroke lesion (approximately 15% stroke size) damages a more 
limited portion of the hemisphere including primarily the caudal forelimb motor cortex 
with minimal damage to the rostral forelimb motor cortex and dorso-lateral striatum. 
Topologies of small and large lesions are similar in both the treatment delayed cohort 
(treatment at 9 weeks post-stroke) and the prolonged treatment delay cohort (treatment at 
25 weeks post-stroke). 
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Stroke Lesion Size in animals treated with anti-Nogo-A immunotherapy at  
25 Weeks Post-Stroke Stroke Lesion Size  
 
 
 
Figure 5.3. Stroke lesion size did not differ across stroke groups in animals treated 
with anti-Nogo-A immunotherapy at 25 weeks post-stroke. In the cohort of animals 
treated with anti-Nogo-A immunotherapy at 25 weeks post-stroke (prolonged treatment 
delay), there was no significant difference between the stroke sizes across the two stroke 
groups (p = 0.279, t-test). Stroke lesion volumes were found to be 23.7 % ±4.0 in the 
Stroke/Anti-Nogo-A Ab group and 35.2 % ± 8.2 in the combined control group (Control 
Ab + Stroke Only). 
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Individual Animal Skilled Reaching Recovery following treatment administered at  
9 Weeks Post-Stroke (Intention-To-Treat [ITT] Dataset) 
 
Figure 5.4. shows the reaching recovery scores of each animal in the ITT dataset across 
time based on (A) treatment with anti-Nogo-A antibody (B) treatment with control 
antibody and (C) no treatment. Each plot shows the individual mean recovery score at 
each week as well as the group mean recovery score at each week.  
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Mean Skilled Reaching Recovery following Anti-Nogo-A Immunotherapy, Control 
Antibody, or no treatment Administered at 9 Weeks post-Stroke (ITT Dataset) 
 
 
 
 
 
 
 
 
Figure 5.5. Treatment analysis with anti-Nogo-A immunotherapy, control Ab, or no 
treatment analyzed using a general linear model repeated measures ANOVA. (A) 
Skilled reaching performance was analyzed at baseline, post-stroke, and post-treatment 
using a repeated measures ANOVA. There were no differences in rats across stroke 
groups in pre-stroke success scores. Following stroke surgery, rats across all stroke 
groups develop a large impairment in skilled reaching that persists across time. Following 
treatment initiation, there was no significant effect of treatment between groups on 
skilled reaching performance. (B) shows the linear recovery rate following treatment. The 
linear regression is shown using post-stroke scores at week 7 and 8 as the initial scores 
prior to treatment initiation. The Stroke/Anti-Nogo-A Ab group shows a statistically 
significant linear rate of recovery as compared to the Stroke/Control Ab group (p =0.045) 
but not as compared to the Stroke Only Group (p = 0.234), one-way ANOVA). (*p < 
0.05)     
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Non-linear Modeling of Skilled Reaching Recovery in animals treated with anti-
Nogo-A immunotherapy at 9 weeks post-stroke (ITT Dataset) 
 
 
Figure 5.6. Improved skilled reaching performance (ITT) following anti-Nogo-A 
immunotherapy in adult rats with chronic severe stroke deficits using nonlinear 
modeling. (A) shows the fitted group-level logistic recovery profiles for each treatment 
group based on the non-linear model. Animals in the Stroke/Anti-Nogo-A Ab group 
showed an improved recovery profile as compared to the Stroke/Control Ab and Stroke 
Only groups (B) Initial deficit severity at post-stroke week 7 was the same across all 
groups, as shown by the Ɵ2 parameter (p > 0.05). (C) The Stroke/Anti-Nogo-A Ab group 
showed a greater final recovery than either the Stroke/Control Ab or Stroke Only group, 
as given by the Ɵ1 parameter (p < 0.001 and 0.01 respectively). (D) Analysis of the 
exponential recovery rate shows that the Stroke/Anti-Nogo-A Ab group had a slower rate 
of recovery over a longer timeframe, while the Stroke/Control Ab and Stroke Only 
groups had a faster recovery rate over a shorter timeframe. Error bars denote ± standard 
error of the estimate (** p < 0.01, *** p < 0.001). 
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Parameter Estimates from Non-linear Model of Skilled Reaching Recovery at 9 
weeks  post-stroke (ITT Dataset)  
 
 
Group 1 Estimate Standard 
Error 
Lower 
Confidence 
 Level 
Upper 
Confidence 
Level 
Anti-Nogo-A 
Ab 
0.3331 0.01573 0.3022 0.3640 
Control Ab 0.2064 0.005209 0.1962 0.2166 
Stroke Only 0.2109 0.006904 0.1973 0.2245 
 
 
Group 2 Estimate Standard 
Error 
Lower 
Confidence  
Level 
Upper 
Confidence 
Level 
Anti-Nogo-A 
Ab 
0.1142 0.01402 0.08662 0.1417 
Control Ab 0.1370 0.02242 0.09293 0.1810 
Stroke Only 0.08982 0.02111 0.04836 0.1313 
 
 
Group 3 Estimate Standard 
Error 
Lower 
Confidence  
Level 
Upper 
Confidence 
Level 
Anti-Nogo-A 
Ab 
0.1142 0.01402 0.08662 0.1417 
Control Ab 0.1370 0.02242 0.09293 0.1810 
Stroke Only 0.08982 0.02111 0.04836 0.1313 
 
 
Table 5.1. The estimates, standard error, and  lower/upper confidence level intervals for 
the parameters (1,  2,  3) of the non-linear functions fitted to the Stroke/Anti-Nogo-A 
Ab, Control Ab, and Stroke Only groups are listed above in A, B and C respectively. 
  
A. Parameter estimates for recovery asymptote 
B. Parameter estimates for initial deficit severity 
C. Parameter estimates for recovery rate 
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Parameter Estimate Contrasts (ITT Dataset treated at 9 weeks post-stroke) 
 
1 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.3331 Anti-Nogo-A Ab 
 
-- 0.000001* 0.005517* 
 
0.2064 Control Ab 
 
0.000001* -- 0.637628 
0.2109 Stroke Only 
 
0.005517* 
 
0.637628 -- 
 
 
2 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.1142 Anti-Nogo-A Ab
    
-- 0.316637 0.316637 
0.1370 Control Ab 
   
0.316637 -- 0.316637 
0.08982 Stroke Only 
   
0.316637 0.316637 -- 
 
 
3 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.2116 Anti-Nogo-A Ab
 
-- 0.000335* 0.008230* 
0.7627 Control Ab 
 
0.000335* -- 0.192050 
0.5699 Stroke Only 
 
0.008230* 0.192050 -- 
 
 
Table 5. 2. Significance levels for parameter estimate contrasts between treatment 
groups. Hypothesis testing was performed by comparing the full non-linear model with 
all 9 parameters to reduced versions of the original model with certain parameters held 
constant. The skilled reaching outcome variable is binomial (success or no success) and 
therefore the dataset is modeled by a χ2 distribution. Fitted models are contrasted by 
using χ2 likelihood based ratio tests.  
  
A. Contrast comparisons for recovery asymptote 
B. Contrast comparisons for initial deficit severity 
C. Contrast comparisons for recovery rate 
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Individual Animal Skilled Reaching Recovery following Anti-Nogo-A Ab, Control 
Ab, or no treatment Administered at 9 Weeks Post- Stroke (PP Dataset)    
 
Figure 5.7. shows the reaching recovery scores of each animal in the PP dataset across 
time based on (A) treatment with anti-Nogo-A antibody (B) treatment with control 
antibody and (C) no treatment. Each plot shows the individual mean recovery score at 
each week as well as the group mean recovery score at each week. 
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Improved Skilled Reaching Performance following Anti-Nogo-A Immunotherapy 
Administered at 9 Weeks Post-Stroke (PP Dataset) 
 
Figure 5.8. Analysis of improved skilled reaching recovery (PP) following treatment 
with anti-Nogo-A immunotherapy using a general linear model repeated measures 
ANOVA. (A) Following treatment initiation, a significant time x treatment group 
interaction (weeks post-stroke) was found for skilled reaching recovery (p = 0.004), 
however Bonferroni post hoc testing revealed no statistically significant pairwise 
comparisons. Repeated measures ANOVA analysis of percent change from post-stroke 
week 24 (B) also showed a significant time x treatment interaction, with statistically 
significant improved recovery for animals treated with anti-Nogo-A immunotherapy 
starting at post-stroke week 26 and lasting until the end of treatment (error bars omitted 
for clarity). The Stroke/Anti-Nogo-A Ab group showed a significantly larger mean linear 
rate of recovery (C) as compared to the Stroke/Control Ab and Stroke Only Groups (p < 
0.001) (F(2,24) = 24.789, p < 0.001, one-way ANOVA).    
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Non-linear Modeling of Skilled Reaching Recovery in animals treated with anti-
Nogo-A immunotherapy at 9 weeks post-stroke (PP Dataset) 
 
Figure 5.9. Improved recovery in skilled reaching performance (PP) following anti-
Nogo-A immunotherapy. (A) shows the fitted group-level logistic recovery profiles for 
each treatment group based on the non-linear model. Animals in the Stroke/Anti-Nogo-A 
Ab group showed an improved recovery profile as compared to the Stroke/Control Ab 
and Stroke Only groups. Initial deficit severity at post-stroke week 7 (B) was the same for 
all groups (p > 0.05). The Stroke/Anti-Nogo-A Ab group showed a greater recovery 
asymptote (C) than either the Stroke/Control Ab or Stroke Only group (p < 0.001). 
Analysis of the exponential recovery rate (D) revealed that the Stroke/Anti-Nogo-A Ab 
group had a slower rate of recovery over a longer timeframe, ultimately resulting in a 
higher recovery asymptote, while the Stroke/Control Ab and Stroke Only groups had a 
faster recovery rate over a shorter timeframe, but ultimately a lower recovery asymptote. 
Error bars denote ± standard error of the estimate. *** p < 0.001, comparison of 
Stroke/Anti-Nogo-A Ab group against both Stroke/Control Ab and Stroke Only groups.   
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Parameter Estimates from Non-linear Model of Skilled Reaching Recovery (PP 
Dataset treated at 9 weeks post-stroke) 
 
 
Group 1 Estimate Standard 
Error 
Lower 
Confidence 
 Level 
Upper 
Confidence 
Level 
Anti-Nogo-A 
Ab 
0.5575 0.03445 0.4898 0.6253 
Control Ab 0.2445 0.005621 0.2334 0.2555 
Stroke Only 0.2610 0.008147 0.2449 0.2770 
 
 
Group 2 Estimate Standard 
Error 
Lower 
Confidence  
Level 
Upper 
Confidence 
Level 
Anti-Nogo-A 
Ab 
0.08720 0.02028 0.04731 0.1271 
Control Ab 0.1594 0.02482 0.1105 0.2082 
Stroke Only 0.1135 0.02599 0.06234 0.1646 
 
 
Group 3 
Estimate 
Standard 
Error 
Lower 
Confidence  
Level 
Upper Confidence 
Level 
Anti-Nogo-A 
Ab 
0.1753 0.03309 0.1103 0.2404 
Control Ab 0.8423 0.4159 0.02434 1.6602 
Stroke Only 0.5754 0.2152 0.1520 0.9987 
 
 
Table 5.3. The estimates, standard error, and  lower/upper confidence level intervals for 
the parameters (1,  2,  3) of the non-linear functions fitted to the Stroke/Anti-Nogo-A 
Ab, Control Ab, and Stroke Only groups are listed above in A, B and C respectively (PP 
Analysis). 
  
A. Parameter estimates for recovery asymptote 
B. Parameter estimates for initial deficit severity 
C. Parameter estimates for recovery rate 
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Parameter Estimate Contrasts (PP treated at 9 weeks post-stroke)  
 
1 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.3331 Anti-Nogo-A Ab
 
-- < 0.000001* 0.000004* 
 
0.2064 Control Ab 
 
< 0.000001* -- 0.157234 
0.2109 Stroke Only 
 
0.000004* 
 
0.157234 -- 
 
 
2 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.1142 Anti-Nogo-A Ab
    
-- 0.070651 0.070651 
0.1370 Control Ab 
   
0.070651 -- 0.070651 
0.08982 Stroke Only 
   
0.070651 0.070651 -- 
 
 
3 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.2116 Anti-Nogo-A Ab
 
-- < 0.000001* < 0.000001*
0.7627 Control Ab 
 
< 0.000001* -- 0.116484 
0.5699 Stroke Only 
 
< 0.000001* 0.116484 -- 
 
 
Table 5. 4. Significance levels for parameter estimate contrasts between treatment 
groups (PP Dataset). Hypothesis testing was performed by comparing the full non-linear 
model with all 9 parameters to reduced versions of the original model with certain 
parameters held constant. The skilled reaching outcome variable is binomial (success or 
no success) and therefore the dataset is modeled by a χ2 distribution. Fitted models are 
contrasted by using χ2 likelihood based ratio tests.  
  
A. Contrast comparisons for recovery asymptote 
B. Contrast comparisons for initial deficit severity 
C. Contrast comparisons for recovery rate 
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Figure 5.10. Correlation between total stroke volume and reaching recovery in the 
ITT and PP datasets. (A) shows the total stroke lesion volume. (B) shows a negative 
correlation although insignificant between the final reaching score and the total stroke 
lesion volume in both ITT and PP datasets. (C) shows the lack of an association between 
reaching recovery and stroke lesion volume when the final reaching score is expressed as 
the percent improvement from pre-treatment (post-stroke week 8).   
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Correlation of Lesion Location and Final Reaching Recovery 
 
Figure 5.11. Correlation between lesion location and final reaching recovery. (A) 
shows the negative correlation between final reaching success score post-treatment (post-
stroke week 20) and damage in the caudal forelimb motor cortex, rostral forelimb motor 
cortex, and the striatum in both the Stroke/Anti-Nogo-A Ab group and the control group. 
When controlling for initial pre-treatment severity by using percent change from pre-
treatment, only the correlation between rostral forelimb motor cortex and final 
improvement percent was found to be correlated in animals treated with anti-Nogo-A 
immunotherapy. 
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Somatosensory Recovery following treatment with anti-Nogo-A immunotherapy at  
9 weeks post-stroke.  
 
 
Figure 5.12. No somatosensory recovery following treatment with anti-Nogo-A 
immunotherapy at 9 weeks post-stroke (ITT + PP Dataset). (A and A’) There was no 
difference across groups for the time it took the rats to contact the sticker on the impaired 
forelimb in either the ITT or PP dataset respectively (p > 0.05). (B and B’) There was no 
difference across groups for the time it took the rats to remove the sticker on the impaired 
forelimb in either the ITT or PP dataset respectively (p > 0.05).  
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Recovery of Skilled Walking in animals treated with anti-Nogo-A immunotherapy 
at 9 weeks post-stroke 
 
 
 
Figure 5.13. No skilled walking recovery following treatment with anti-Nogo-A 
immunotherapy at 9 weeks post-stroke (ITT + PP Dataset). (A and A’) There was no 
difference across groups for the movement score across time in either the ITT or PP 
dataset respectively (p > 0.05). (B and B’) There was no difference across groups in the 
number of foot slips across time in either the ITT or PP dataset respectively (p > 0.05). 
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Mean Skilled Reaching Recovery following treatment Administered at 25 Weeks 
Post-Stroke (“PP” Dataset)  
 
 
Figure 5.14. Analysis of improved skilled reaching recovery (“PP”) following 
treatment using Generalized Linear Model statistics. (A) Following treatment 
initiation, there was a significant interaction between time x treatment across groups on 
skilled reaching performance but individual time point analysis did not show significantly 
different means. Percent change from post-stroke week 24 (B) also showed a significant 
time x treatment interaction with improved recovery for animals treated with anti-Nogo-
A immunotherapy starting at post-stroke week 26 and lasting until the end of treatment 
(error bars omitted for clarity). The Stroke/Anti-Nogo-A Ab group shows a statistically 
significant linear rate of recovery (C) as compared to the Stroke/Control Ab group (p 
=0.016), one-way ANOVA).*p< 0.05, **p < 0.001  
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Apical Dendritic Complexity of Layer V Pyramidal Neurons Located in the 
Perilesional Caudal Forelimb Motor Cortex 
 
 
 
Figure 5.15. Apical dendritic tree morphology. Apical tree morphology was quantified 
for number of branch points by branch order and branch length by branch order. (A) 
Treatment with anti-Nogo-A immunotherapy had no effect on the number of dendritic 
branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment with 
anti-Nogo-A immunotherapy had no effect on the total number of branches in the apical 
dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A 
immunotherapy had no effect on the apical branch length across branch orders (p > 0.05, 
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on 
the total apical dendritic length (p > 0.05, one-way ANOVA). 
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Basilar Dendritic Complexity of Layer V Pyramidal Neurons Located in the 
Perilesional Caudal Forelimb Motor Cortex 
 
 
Figure 5.16. Basilar dendritic tree morphology. Basilar tree morphology was 
quantified for number of branch points by branch order and branch length by branch 
order. (A) Treatment with anti-Nogo-A immunotherapy had no effect on the number of 
dendritic branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment 
with anti-Nogo-A immunotherapy had no effect on the total number of branches in the 
basilar dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A 
immunotherapy had no effect on the basilar branch length across branch orders (p > 0.05, 
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on 
the total basilar dendritic length (p > 0.05, one-way ANOVA). 
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 Apical Dendritic Complexity of Layer II/III Pyramidal Neurons Located in the 
Contralesional Caudal Forelimb Motor Cortex 
 
 
Figure 5.17. Apical dendritic tree morphology. Apical tree morphology was quantified 
for number of branch points by branch order and branch length by branch order. (A) 
Treatment with anti-Nogo-A immunotherapy had no effect on the number of dendritic 
branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment with 
anti-Nogo-A immunotherapy had no effect on the total number of branches in the apical 
dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A 
immunotherapy had no effect on the apical branch length across branch orders (p > 0.05, 
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on 
the total apical dendritic length (p > 0.05, one-way ANOVA). 
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Basilar Dendritic Complexity of Layer II/III Pyramidal Neurons Located in the 
Contralesional Caudal Forelimb Motor Cortex 
 
 
Figure 5.18. Basilar dendritic tree morphology. Basilar tree morphology was 
quantified for number of branch points by branch order and branch length by branch 
order. (A) Treatment with anti-Nogo-A immunotherapy had no effect on the number of 
dendritic branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment 
with anti-Nogo-A immunotherapy had no effect on the total number of branches in the 
basilar dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A 
immunotherapy had no effect on the basilar branch length across branch orders (p > 0.05, 
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on 
the total basilar dendritic length (p > 0.05, one-way ANOVA).  
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Apical Dendritic Complexity of Layer V Pyramidal Neurons Located in the 
Contralesional Caudal Forelimb Motor Cortex 
 
 
Figure 5.19. Apical dendritic tree morphology. Apical tree morphology was quantified 
for number of branch points by branch order and branch length by branch order. (A) 
Treatment with anti-Nogo-A immunotherapy had no effect on the number of dendritic 
branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment with 
anti-Nogo-A immunotherapy had no effect on the total number of branches in the apical 
dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A 
immunotherapy had no effect on the apical branch length across branch orders (p > 0.05, 
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on 
the total apical dendritic length (p > 0.05, one-way ANOVA). 
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Basilar Dendritic Complexity of Layer V Pyramidal Neurons Located in the 
Contralesional Caudal Forelimb Motor Cortex 
 
 
Figure 5.20. Basilar dendritic tree morphology. Basilar tree morphology was 
quantified for number of branch points by branch order and branch length by branch 
order. (A) Treatment with anti-Nogo-A immunotherapy had no effect on the number of 
dendritic branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment 
with anti-Nogo-A immunotherapy had no effect on the total number of branches in the 
basilar dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A 
immunotherapy had no effect on the basilar branch length across branch orders (p > 0.05, 
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on 
the total basilar dendritic length (p > 0.05, one-way ANOVA). 
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Comparison of anti-Nogo-A immunotherapy efficacy across different treatment 
initiation time points and ages of animals 
 
 
Table 5.5. Comparison of anti-Nogo-A immunotherapy efficacy across different 
treatment initiation time points and ages of animals. 
  
Treatment 
Initiation 
Age   Data 
Type 
Stroke 
Lesion 
Volume 
(SEM) 
% Improv.
at 8 
Weeks 
Post‐
Treatment 
% Improv.
at 12 
Weeks 
Post‐
Treatment 
% Improv. 
at 14 
Weeks 
Post‐
Treatment 
Author
Immediate. 
after stroke  
Adult  ?  8%	  30% ‐‐ ‐‐ Papadopoulos
1 week post‐
stroke 
Adult  ?  10% 35% ‐‐ ‐‐ Seymour
1 week post‐
stroke 
Aged  ?  ? 20% 20% 45%  Markus
9 weeks 
post‐stroke 
Adult  PP   
16% 
30% ‐‐ ‐‐ Tsai 
9 weeks 
post‐stroke 
Adult  ITT  27% 10.5% 13% ‐‐ Podraza
9 weeks 
post‐stroke 
Adult  PP  27%  20% Nearing 
35% 
‐‐ Podraza
25 weeks 
post‐stroke 
Adult  PP  20% 35% ‐‐ ‐‐ Podraza
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DISCUSSION 
This present study demonstrates that there exists an extended treatment window 
for the use of anti-Nogo-A immunotherapy to improve sensorimotor function in adult rats 
with chronic moderate to very severe stroke deficits. Adult rats that were treated with 
anti-Nogo-A antibodies at either 9 (~ 2 months) or 25 (~ 6 months) weeks post-stroke 
displayed an improvement in skilled forelimb reaching performance but exhibited no 
change in skilled walking or sensory function. Furthermore, the improvement in skilled 
forelimb reaching performance was not associated with changes in dendritic tree 
complexity in layer V pyramidal neurons located in the perilesional caudal forelimb 
motor cortex or in layers II/III and V pyramidal neurons located in the contralesional 
caudal forelimb motor cortex.  
 In order to determine an unbiased efficacy rate for anti-Nogo-A immunotherapy 
in animals with moderate to very severe stroke deficits treated at 9 weeks post-stroke, the 
data was first evaluated using an intention-to-treat analysis and then using a per-protocol 
analysis. An intention-to-treat (ITT) procedure was used whereby all randomized 
animals, regardless of experimental protocol deviations, were used in the final analysis. 
Although, this approach may lead to conservative estimates of efficacy, it provides the 
most valid assessment of meaningful differences across groups and is considered the gold 
standard approach to data analysis in human clinical trials (Day et al., 2008; FDA, 1988). 
The ITT dataset included all animals that scored 10 out of 20 pellets or less on the skilled 
forelimb reaching task, and could be stratified by deficit severity. Our ITT population 
included a range of animals with moderate stroke deficits (36%), severe deficits (42%), 
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and very severe deficits (22%). We found that this population when treated with anti-
Nogo-A immunotherapy at 9 weeks post-stroke had a statistically significant 
improvement in the final recovery asymptote (probability of success out of 20 trials) as 
compared to both of the control groups. Animals treated with anti-Nogo-A antibody had a 
final recovery asymptote of 33.31%  2.0, compared to animals treated with control 
antibody (20.64%  1.0), and stroke only animals (21.09%  1.0). When adjusting the 
recovery percent by initial deficit pre-treatment (post-stroke week 8), anti-Nogo-A 
antibody treated animals displayed an improvement in skilled forelimb reaching 
performance by 21.89%, while animals treated with control antibody improved by only 
6.94% and stroke only animals improved by only 12.11%. However, of note, only 
animals with moderate to severe deficits improved after anti-Nogo-A immunotherapy. 
Animals in the very severe category, i.e. those that never grasped a pellet in the 
timeframe between their stroke and prior to treatment, showed no improvement on the 
skilled reaching task after treatment. Therefore, these results show the effectiveness of 
anti-Nogo-A immunotherapy in the early chronic stage after stroke (9 weeks post-stroke) 
in adult rats with moderate to very severe stroke deficits, but also highlight the inability 
of anti-Nogo-A immunotherapy to result in recovery of skilled forelimb reaching when 
there is no residual ability to move the forelimb prior to treatment. To our knowledge, the 
present study is the first report of using anti-Nogo-A immunotherapy to improve 
sensorimotor function after stroke at a clinically relevant chronic time point and in a 
population that includes rats with severe and very severe stroke deficits and 
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corresponding large stroke sizes. The positive results from the present study support the 
perspective that the brain can respond to treatment interventions in the chronic phase 
after stroke and also in the context of severe stroke damage.  
However, given the fact that the ITT treatment efficacy estimates were based on a 
dataset that included animals that deviated from the experimental protocol, we set out to 
see how the efficacy of anti-Nogo-A immunotherapy is affected by post-randomization 
exclusions. Animals were excluded for various reasons. Firstly, animals were excluded if 
the antibody intracerebroventricular pump was found to be disconnected upon removal, 
thereby potentially supplying a suboptimal therapeutic dose of antibody to the animal. 
Secondly, animals were excluded when displaying very severe reliance on using the 
unimpaired forelimb during the skilled reaching task. These animals primarily used their 
“good” forelimb for reaching for pellets leading to very inaccurate success score 
estimations for the impaired forelimb. Thirdly, animals were excluded if they displayed 
an “absolute deficit” phenotype where post-stroke, no pellets were ever successfully 
grasped and brought to the mouth. Fourthly, rats were excluded with very severe 
subcortical damage (complete damage of dorso-lateral striatum). Our PP results showed 
that once these animals were excluded from the study, the efficacy rate of anti-Nogo-A 
immunotherapy in animals treated at 9 weeks post-stroke improved. Although the mean 
total stroke size per treatment group did not change between the ITT and PP datasets, the 
distribution of stroke deficit severity at time of treatment in the population was affected. 
Our PP population on average included animals with moderate stroke deficits (43.5%), 
and severe deficits (56.5%), with no animals displaying very severe deficits (0%). 
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Animals treated with anti-Nogo-A antibody had a final recovery asymptote of 55.75%  
3.0, compared to animals treated with control antibody (24.45%  1.0), and stroke only 
animals (26.10%  1.0). When adjusting the recovery percent by initial deficit pre-
treatment, anti-Nogo-A antibody treated animals displayed an improvement in skilled 
forelimb reaching performance by 47.03%, while animals treated with control antibody 
improved by only 8.51% and stroke only animals improved by only 14.75%. Therefore, 
the results from the PP analysis show that when animals with chronic moderate to severe 
stroke deficits are treated at 9 weeks post-stroke with anti-Nogo-A immunotherapy, 
recovery from initial impairment will be 35% greater than that of controls. These PP 
results suggest that in a population of rats that received the entire dose of anti-Nogo-A 
antibody, had no behavioral abnormalities during testing procedures, did not have very 
severe deficits or severe subcortical damage, we can expect a greater improvement of 
sensorimotor function after treatment with anti-Nogo-A immunotherapy at 9 weeks after 
stroke than suggested by the ITT efficacy rates.  
 As mentioned above, comparison of the ITT and PP datasets shows that among 
moderate to very severe stroke deficits, and correspondingly moderate to very large 
stroke sizes, not all animals will recover and not all will recover the same amount with 
anti-Nogo-A antibody treatment. Based on the ITT and PP results, the mean efficacy rate 
for anti-Nogo-A immunotherapy above controls when administered at 9 weeks post-
stroke may vary anywhere from 12% to 35%. The efficacy rates of anti-Nogo-A 
immunotherapy in this present study may be related to an animal’s individual total stroke 
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size, total damage to particular areas important for skilled reaching (rostral forelimb area, 
caudal forelimb area, striatum), specified and unspecified behavioral characteristics, 
experimental error, and unknown factors. Therefore we evaluated the correlation between 
total stroke size and recovery in both the ITT and PP datasets. Although we found a 
significant correlation between the total stroke lesion size and final reaching success 
score (out of 20), we found no correlation between the total stroke size and the final 
absolute increase in pellets obtained in the skilled reaching task. Hence the relationship 
between the total stroke lesion size and treatment induced improvement is complex. This 
complex relationship has been seen in human stroke studies as well. Studies have shown 
conflicting results, with some showing significant correlations between total stroke lesion 
size and upper extremity recovery (Beloosesky et al. 1995; Van Everdingen et al., 1998), 
while others have shown little to no correlation between total stroke lesion size and upper 
extremity recovery (Pantano et al., 1996; Miyai et al., 1997). Interestingly, using both 
total stroke lesion size and lesion size based on location seems to be more strongly 
correlated with recovery potential (Chen et al., 2000). Therefore we decided to perform a 
preliminary location specific stroke lesion analysis to gain a greater understanding 
between anti-Nogo-A immunotherapy induced improvements and lesion size and 
location. We evaluated, in a small subset of the animals (n=4), the correlation between 
the final absolute increase in pellets obtained after treatment and the % damage in the 
rostral forelimb motor cortex, caudal forelimb motor cortex, and striatum. Although not 
statistically significant, we found a strong inverse correlation between the damage in the 
rostral forelimb motor cortex and the final improvement in the number of pellets obtained 
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at the end of the study in animals treated with anti-Nogo-A immunotherapy at 9 weeks 
post-stroke. Based on these preliminary results, this might suggest that the residual 
ipsilesional rostral forelimb motor cortex may also play a role in the recovery seen after 
anti-Nogo-A immunotherapy and underscore the importance of detailed lesion location 
analysis. Future analyses will complete detailed lesion based analysis on all animals in 
the ITT and PP datasets.  
 In addition to evaluating skilled reaching recovery after anti-Nogo-A 
immunotherapy at 9 weeks post-stroke, we evaluated recovery in sensory function and 
skilled walking. Results from these two tasks showed that the improved skilled forelimb 
reaching recovery did not translate to improvements seen in sensory function and skilled 
walking. Sensory function, tested by the use of the bilateral adhesive removal task, has 
been tested after anti-Nogo-A immunotherapy after a corticospinal tract (CST) lesion and 
after a traumatic brain injury. In the first study, adult rats were given unilateral CST 
lesions at the medulla oblongata and sensory function was tested using the bilateral 
adhesive removal task. Animals treated with anti-Nogo-A antibodies (IN-1) showed a 
profound recovery of sensory function (Thalmair et al., 1998). In contrast, another study 
showed no improvement in sensory function, as measured by the bilateral adhesive 
removal task, in animals treated with anti-Nogo-A antibodies (11C7) after traumatic brain 
injury (Lenzlinger et al., 2005). Therefore, sensory recovery after anti-Nogo-A 
immunotherapy may be related to lesion type and location. Additionally, the task used to 
test sensory function, the bilateral adhesive removal task, has been shown to be highly 
variable and requires a large number of subjects to show significant differences 
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(Whishaw & Kolb., 2005). The task sensitivity can also be affected by the type of stickers 
used since different levels of adhesiveness can affect the difficulty of the task. It is 
possible the sensitivity of our task was low and our sample size was too small to pick up 
any meaningful differences across groups. Regarding skilled walking, at the chronic time 
points assessed, there were very mild deficits seen after stroke on this task at pre-
treatment and therefore there was little room for improvement after treatment. The lack of 
large deficits on this task may be related to the spinal cord’s ability to mediate 
locomotion with little input from the sensorimotor cortex (Dietz et al., 2003; Forssberg et 
al., 1975). The discrepancy between improved recovery seen in the skilled forelimb 
reaching task and the little improvement seen in both the bilateral adhesive removal task 
and the skilled horizontal ladder walking task also underscore the complex relationship 
mediating the transfer of task related improved skills. The topic of whether trained skills 
can be translated to an untrained task is controversial, with both supporting evidence 
(Multon et al., 2003; Engessser-Cesar et al., 2007) and conflicting evidence (Edgerton et 
al., 1997; De Leon et al., 1998; Grasso et al., 2004). In the case of this study, rats were 
trained on the skilled forelimb reaching task prior to stroke injury and then during the 
treatment phase, were tested on the task almost daily. In contrast, the bilateral adhesive 
removal task and the skilled ladder horizontal ladder walking task do not require training, 
and simply require habituation to the testing environment. Furthermore, the rats in this 
present study were tested on these two tasks only four times during the study (baseline, 
pre-treatment, post-treatment time 1, post-treatment time 2), therefore negating any 
training effects that could have helped stimulate recovery. Finally, since the neural 
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strategy used for the movements in our three tasks differ, it might be less likely for the 
recovery of function on one task to be converted to the recovery of function in another 
task (Singh et al., 2010). 
 Next we evaluated skilled reaching recovery after treatment with anti-Nogo-A 
immunotherapy at 25 weeks post-stroke. These results are based on a small dataset (n = 
7). All animals in this dataset were analyzed as randomized, however since the animals 
selected for this time point did not have any protocol deviations as seen in the 9 week 
treated group, the results could be considered as a PP analysis, in order to compare the 
results to the 9 week time point. Nonlinear modeling was not possible with this dataset 
due to the small number of animals. Repeated measures ANOVA showed anti-Nogo-A 
antibody treated animals had a significant interaction between time and treatment as 
compared to the control treated animals. However, the study was not properly powered 
for post-hoc tesing to show a significant difference between control treated and anti-
Nogo-A antibody treated animals at any given time point. However, we did find that the 
linear mean rate of improvement was significantly greater in the animals treated with 
anti-Nogo-A antibodies. Additionally, rats treated with anti-Nogo-A immunotherapy at 
25 weeks post-stroke showed a similar final magnitude of improvement as the animals 
treated with anti-Nogo-A immunotherapy at 9 weeks (PP analysis). Although the final 
magnitude of recovery was similar, the animals treated at 25 weeks had a faster rate of 
recovery than the animals treated at 9 weeks post-stroke. This difference in recovery rates 
may be due to the smaller lesion size in the animals treated with anti-Nogo-A 
immunotherapy at 25 weeks versus the lesion size in animals treated at 9 weeks.  
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 Numerous reports from our laboratory have investigated whether treatment with 
anti-Nogo-A immunotherapy at various time points post-stroke is efficacious for 
improving sensorimotor recovery in skilled reaching function (for a summary refer to 
Table 5.5). Treatment with anti-Nogo-A immunotherapy immediately and up to 1 week 
post-stroke in adult rats with mild to moderate stroke deficits (~10% stroke size) has been 
found to improve recovery beyond control therapy by 30-35% within 8 weeks of 
treatment initiation (Papadopolous et al., 2002; Seymour et al., 2005). A similar final 
recovery magnitude was also found in aged animals treated with anti-Nogo-A 
immunotherapy however, it took longer for the animals to reach this final recovery, up to 
post-stroke week 14 (Markus et al., 2005). A recent study by Tsai et al. (2010) treated 
adult rats with mild to moderate stroke deficits (~16% stroke size) at 9 weeks post-stroke 
and also found a similar rate and final magnitude of recovery as adult rats treated one 
week post-stroke, implying that recovery from anti-Nogo-A immunotherapy is 
independent from the differences between the post-ischemic brain at one week versus 9 
weeks post-stroke. Our study set out to further analyze the efficacy of anti-Nogo-A 
immunotherapy in the chronic phases after stroke. As discussed previously, the animals 
treated at 9 weeks and 25 weeks post-stroke used in our study were considered to have 
moderate to very severe chronic stroke deficits and had an average stroke size of 27% 
and 19% respectively. In the animals treated with anti-Nogo-A immunotherapy at 9 
weeks post-stroke, the final improvement in the recovery asymptote according to the non-
linear modeling in the PP analysis, was determined to be ~ 35%, similar to the Tsai study. 
However, it is important to note that the animals did not near this final recovery 
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magnitude until 12 weeks post-stroke. Given that the experimental parameters of the 
study were identical to the Tsai et al. (2010) study, it is likely that the stroke lesion size 
and/or location played a role in the delayed recovery rate seen in this study. The recovery 
results from the animals treated at 25 weeks post-stroke support the relationship between 
stroke lesion size/location and recovery since these animals had a nearly identical 
magnitude and rate of improvement as the animals treated at 9 weeks post-stroke in Dr. 
Tsai’s study. Not surprisingly, the stroke lesion size in the animals treated at 25 weeks 
post-stroke was smaller (~ 19% ) than the lesion size of animals treated at 9 weeks post-
stroke in this study (~27%). Since overall we do not see a decrease in potency of anti-
Nogo-A immunotherapy chronically after stroke, it is likely that other factors such as 
lesion size and location are playing some role in the different recovery rates seen after 
treatment.  
Following cortical lesions, various areas directly and remotely connected to the 
damaged cortex are thought to undergo spontaneous neuroanatomical structural plasticity 
(Murphy et al., 2009). Additional supporting evidence for this idea comes from previous 
work in our laboratory showing an increase in dendritic complexity in layer V pyramidal 
neurons in the contralesional sensorimotor cortex following treatment with anti-Nogo-A 
immunotherapy one week post-stroke (Papadopoulos et al., 2006). Therefore, we decided 
to investigate whether the improved skilled reaching recovery seen after administration of 
anti-Nogo-A immunotherapy at 9 weeks post-stroke in the adult rat was correlated with 
structural changes in neurons located within the contralesional caudal forelimb motor 
cortex.  
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We found no evidence of increased dendritic complexity in either layer II/III or 
layer V pyramidal neurons in the contralesional caudal forelimb motor cortex. This lack 
of apparent dendritic structural plasticity following anti-Nogo-A immunotherapy may be 
due to several reasons. Following large-scale damage to the motor cortex, rats often 
display a change in preferred forelimb use in the skilled reaching task (Castro-Alamancos 
et al., 2003). Given this change in preference, rats will try to use the unimpaired forelimb 
to obtain sugar pellets during skilled reaching. Without directly inhibiting the use of the 
unimpaired forelimb through the application of some sort of constraint, it is likely that the 
rat will over time acquire improved skill training in this forelimb, even with the best 
attempts at disallowing reaching attempts with this forelimb. Therefore, it is likely that 
this inadvertent skilled reach training may lead to increased dendritic complexity in the 
contralateral sensorimotor cortex innervating this forelimb, as has been shown with 
skilled reaching training (Kolb et al., 2008). However, since this is the same sensorimotor 
cortex being evaluated for treatment-induced changes in plasticity, any treatment effects 
may be obscured. In the previous study by Papadopoulos et al. (2006) that found 
increased dendritic plasticity in the contralesional sensorimotor cortex, the adult rats were 
not trained on the skilled reaching task and therefore forelimb switching was not a 
confounding factor in that study. It is possible that in our study, one reason for the lack of 
apparent changes in dendritic complexity in the contralesional caudal forelimb motor 
cortex may be due to the potential increase in basal level plasticity seen in this area due to 
the widespread use of the unimpaired forelimb among most rats post-stroke. Furthermore, 
the total number of apical and basilar branches and the total apical and basilar dendritic 
157 
 
 
 
length in layer V pyramidal neurons in the contralesional sensorimotor cortex in stroke 
only animals in this present study are much higher than the averages seen in stroke only 
animals seen in the study by Papadopoulos (Papadopoulos et al., 2006). The 
neuroanatomical data also supports the possibility that skilled use of the unimpaired 
forelimb in the animals in our study increased the basal complexity of layer V pyramidal 
neurons in the contralesional sensorimotor cortex. Additionally, the larger stroke size 
seen in our study as compared to the Papadopoulos study could have also increased the 
basal level of dendritic complexity as there is a direct relationship between increasing 
stroke size and increased dendritic complexity in the contralesional caudal forelimb 
motor cortex (Biernkaske et al., 2004). Furthermore, the treatment antibody used in the 
two studies was different. In the present study, the monoclonal antibody used was 11C7, 
a specific antibody raised against an 18-amino Nogo-A peptide to the rat sequence of 
amino acids 623-640. However in the Papadopolous study, hybridoma cells secreting IN-
1 antibody were used. The use of hybridoma cells could have had the additional effect of 
secreting growth factors that may have enhanced the plasticity response in the animals 
treated with IN-1 in the Papadopoulous study. Another difference between the two 
studies is that the animals were treated at different times post-stroke, either one week 
post-stroke or 9 weeks post-stroke.  Finally, dendrites were also evaluated much later 
post-treatment in this present study than in the Papadopolous study. The dendrites were 
evaluated for plasticity more than 12 weeks post-treatment initiation in our study while in 
the Papadopolous study, dendrites were evaluated 6 weeks post-treatment. It is possible 
that an increase in dendritic plasticity early after treatment could have undergone 
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pruning, such as seen in mammalian neurological development (Rakic & Bourgeouis, 
1986) so that by 12 weeks post-treatment, dendritic changes may not have been 
detectible. In summary, a plasticity response in the neurons within the contralesional 
caudal forelimb motor cortex may have been masked due to a potential higher level of 
dendritic complexity due to forelimb switching, coupled with the a pruning response and 
therefore not detectible by our evaluation. Conversely, it is possible that anti-Nogo-A 
immunotherapy at 9 weeks post-stroke does not enhance plasticity in pyramidal neurons 
found within layers II/III and V of the contralesional caudal forelimb motor cortex and 
dendritic changes in other brain areas related to sensorimotor function, such as the 
contralesional rostral forelimb motor cortex or contralesional striatum, may account for 
the improved sensorimotor function seen in our study.  
There have been conflicting reports of increased plasticity in the perilesional area 
after stroke. Brown and colleagues found an increased number of spines on layer V 
pyramidal neurons that were located within 200 microns of the infarct border in adult rats 
after photothrombotic stroke (Brown et al., 2008). In direct conflict with this study are 
the results from Mostany and colleagues that used in vivo two-photon imaging in adult 
mice and found no large scale dendritic plasticity of layer V pyramidal neurons located in 
the peri-infarct cortex (Mostany et al., 2011). However, functional imaging studies in 
humans have also supported the role of the perilesional cortex in stroke recovery (Dong 
et al., 2007). Therefore, we decided to investigate the effect of anti-Nogo-A 
immunotherapy administered at 9 weeks post-stroke on dendritic plasticity in the 
perilesional caudal forelimb motor cortex. We found no change in dendritic complexity 
159 
 
 
 
in layer V pyramidal neurons located within the perilesional caudal forelimb motor 
cortex. The lack of dendritic plasticity in the perilesional area may to due to various 
reasons. Since we did not analyze dendritic spine number and morphology it is possible 
that spine dynamics could have played a role in the improved sensorimotor function seen 
after anti-Nogo-A immunotherapy in our experiments. Additionally, dendritic 
rearrangements may be related to the distance of the neuron from the ischemic border 
(Brown et al., 2008). Since in our study we included neurons within 2 millimeters from 
the ischemic border, it is possible that only neurons close to the ischemic border (200 
microns) could have undergone reorganization. Additionally, dendritic pruning could 
have also played a role in the perilesional cortex and hence our evaluation time point 
could have missed the dendritic rearrangements. Finally, dendritic changes could have 
occurred in other brain areas such as the ipsilesional rostral forelimb area and the 
ipsilesional striatum.  
 Due to the lack of dendritic plasticity in either perilesional or contralesional areas 
of the caudal forelimb motor cortex in animals treated with anti-Nogo-A immunotherapy 
at 9 weeks post-stroke, it is possible that behavioral improvement is occurring due to 
other mechanisms that do not involve the dendritic arbors. In the study by Tsai and 
colleagues (2010), animals with mild to moderate stroke deficits treated with anti-Nogo-
A immunotherapy at 9 weeks post-stroke displayed skilled reaching recovery that was 
correlated with enhanced corticorubral axonal sprouting from the contralesional forelimb 
motor cortex to the deafferented red nucleus. Therefore, it is likely that axonal sprouting 
from the undamaged corticospinal tract is also the source of the improvements seen in our 
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study. Other areas that may be undergoing axonal sprouting and may be playing a role in 
the improvements seen in our study include axonal sprouting from callosal fibers of the 
undamaged hemisphere to the rostral forelimb motor cortex, callosal fibers in the 
undamaged hemisphere to the ipsilesional dorso-lateral striatum, undamaged 
corticospinal tract axonal sprouting to the basilar pontine nuclei, and undamaged 
corticospinal tract axonal sprouting in the spinal cord. Additionally, it is possible that 
anti-Nogo-A immunotherapy could have enhanced the electrophysiological 
characteristics or biochemical functioning of neurons in neural circuits important for 
sensorimotor function.  
 In conclusion, in this study we have found that anti-Nogo-A immunotherapy 
is efficacious up to 25 weeks post-stroke for improving sensorimotor recovery on the 
skilled forelimb reaching task and is a promising therapeutic strategy for improving 
disability after stroke, even long after the ischemic injury has taken place, although the  
exact mechanism by which this improvement occurs is still not known.  
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CHAPTER SIX 
GENERAL DISCUSSION 
 
Summation of Results 
In animals with spinal cord injury, anti-Nogo-A immunotherapy has been found 
to be efficacious when administered up until one-week post-lesion, with treatment 
potency dropping if administered after two weeks post-lesion (Gozenbach et al., 2011). 
Given this short treatment window for the use of anti-Nogo-A immunotherapy in spinal 
cord injury, a previous study from our laboratory set out to determine whether anti-Nogo-
A immunotherapy was efficacious over a similar or longer time frame when applied in 
the chronic phase after ischemic stroke. We found that in animals with mild to moderate 
stroke deficits (15% stroke size), treatment with anti-Nogo-A immunotherapy up to 9 
weeks post-stroke was able to induce functional sensorimotor functional recovery in adult 
rats after stroke (Tsai et al., 2010). Interestingly, the effect size and time course of 
treatment-induced recovery was similar to that of animals treated immediately or up to 1 
week post-stroke, implying no loss in treatment effect potency. We therefore set out to 
further examine the critical time window for the application of anti-Nogo-A 
immunotherapy in the chronic phases after stroke. In addition to the critical time window 
for applying such a neuro-restorative therapy, we were also interested in studying 
whether the initial severity of stroke deficit mitigates the efficacy of anti-Nogo-A 
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immunotherapy. Therefore, we investigated the efficacy of anti-Nogo-A immunotherapy 
for improving moderate to very severe stroke deficits when applied either at 9 weeks (~ 2 
months) and 25 weeks (~ 6 months) post-stroke in adult rats. 
 Previous studies have shown that a limited amount of spontaneous recovery 
occurs in rats as well as humans post-stroke. Therefore, we evaluated the time-course of 
spontaneous recovery of skilled forelimb performance after stroke for the first 8 and 24 
weeks prior to the application of anti-Nogo-A immunotherapy. Interestingly we found 
two important parallels in motor recovery post-stroke in adult rats that correspond very 
well to human post-stroke recovery. Firstly, limited but statistically significant post-
stroke recovery in skilled reaching performance was seen overall in animals during the 
first month post-stroke. Statistically significant recovery post stroke was seen until post-
stroke week 2, however minimal improvement was seen up to 4 weeks post-stroke with a 
stable plateau in recovery seen thereafter. The timeframe in recovery seen in adult rats 
post-stroke is similar to the timeframe seen in humans. Typically, the majority of 
spontaneous recovery seen in humans post-stroke is seen within three months post-stroke.  
However, some estimates show that the majority (80%) of significant motor recovery 
takes place within 4.5 week post-stroke (Jorgensen et al., 1995a; Jorgensen et al., 1995b) 
and corresponds well to the time-frame of spontaneous recovery we see in adult rats post-
stroke in this study. Secondly, we found that initial deficit severity after stroke modulates 
the rate and magnitude of spontaneous recovery seen after stroke in adult rats. This 
relationship between initial deficit severity after stroke and recovery potential has also 
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been well demonstrated in human stroke recovery (Jorgensen et al., 1995a; 1995b; 1995c) 
and underscores the similarity between rat and human post-stroke recovery profiles. 
Animals with initial mild to moderate deficits at 1 week post-stroke generally showed 
both little deficit and little improvement over time.  Effectively, animals in these two 
deficit categories show very mild deficits and the need for treatment or rehabilitation is 
low. Conversely, animals with severe deficits at 1 week post-stroke, show statistically 
significant recovery over time up to post-stroke week 3, however the magnitude of 
recovery is quite low. This population of animals has the greatest need for a neuro-
restorative therapy and most likely will show the greatest benefit. Animals with very 
severe deficits at post-stroke week 1 show no improvement over time and may be very 
difficult to rehabilitate with any form of treatment.  
 Based on the spontaneous recovery profiles seen after stroke in adult rats, we 
decided to treat animals with anti-Nogo-A immunotherapy at two delayed chronic time 
points, 9 (subchronic) and 25 (chronic) weeks post-stroke. The stroke deficits seen at 
post-stroke week 9 and 25 are thought to be stable and the potential for spontaneous 
recovery of function minimal. The cohort of animals treated with anti-Nogo-A 
immunotherapy at 9 or 25 weeks post-stroke included animals with moderate, severe, and 
very severe deficits. Two separate approaches to analyze the recovery data were used for 
these results. An intention-to-treat analysis was performed that included all deficit 
severity animals (moderate, severe, very severe) as well as any protocol deviations. A 
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per-protocol analysis was performed including only animals with moderate and severe 
deficits as well as no protocol deviations.       
The experimental data from these experiments supports the existence of an 
extended therapeutic time window for the use of anti-Nogo-A immunotherapy to improve 
sensorimotor functional recovery after stroke in the chronic phase. We demonstrate the 
effectiveness of anti-Nogo-A immunotherapy when initiated 9 and 25 weeks post-stroke 
in the adult rat to significantly improve sensorimotor performance on the skilled reaching 
task using both an intention-to-treat and per-protocol paradigm. Based on these results, it 
is likely that anti-Nogo-A immunotherapy is effective chronically after stroke and long 
after the lesion-induced neuroplasticity-promoting environment in the brain has 
diminished (Biernaske et al., 2004). However, given the fact that animals with very 
severe deficits prior to treatment do not improve with anti-Nogo-A immunotherapy and 
that the recovery rates and recovery plateau (based on PP analysis) are slower and lower 
than that seen in previous studies at similar time points, it is likely that anti-Nogo-A 
immunotherapy may have differential efficacy rates based on initial stroke deficit 
severity prior to treatment.  
Multiple research studies show that inhibiting protein Nogo-A leads to axonal and 
dendritic reorganization that is associated with functional recovery (Seymour et al., 2005; 
Papadopoulos et al., 2006; Tsai et al., 2011). Therefore, we evaluated dendritic plasticity 
in the perilesional and contralesional forelimb motor cortex. We did not find any changes 
in complexity across layer V pyramidal neurons in either the perilesional or 
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contralesional caudal forelimb motor cortex or layer II/III neurons in the contralesional 
caudal forelimb motor cortex. These results underscore the difficulty relating 
neuroanatomical structural plasticity with recovery in function and potentially imply 
other mechanisms or brain areas are responsible for the functional recovery seen in these 
experiments.  
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Translation of Anti-Nogo-A Immunotherapy to the Clinic 
Over the last two decades, there has been a paradigm shift regarding the ability of 
the adult CNS to undergo spontaneous cortical reorganization as well as the ability to 
induce substantial neuronal plasticity through neuro-restorative therapies. With the 
discovery and cloning of the neurite outgrowth inhibitory myelin associated protein, 
Nogo-A (Chen et al., 2000; GrandPre et al., 2000; Prinjha et al., 2000), a new era of 
investigation geared towards improving function following various CNS lesions has 
taken place. Since then, the inhibition of Nogo-A has been shown to promote functional 
recovery following various brain injuries such as stroke, spinal cord injury and traumatic 
brain injury in animal studies. 
 Proof of concept experiments using anti-Nogo-A immunotherapy to improve 
functional recovery after stroke has been extensively studied in pre-clinical studies and 
been shown to be effective. Studies primarily from the Kartje laboratory have shown that 
inhibiting protein Nogo-A using function inhibiting monoclonal antibodies after ischemic 
middle cerebral artery occlusion leads to substantial sensorimotor functional recovery 
when applied immediately (Papadopoulos et al., 2002), 24 hours (Weissner et al., 2003), 
1 week (Seymoure et al., 2005), 9 weeks (Tsai et al., 2011; this dissertation), and 25 
weeks post-stroke (this dissertation). Furthermore, significant improvement using this 
therapy was seen in the Weissner study that used a rat model that is spontaneously 
hypertensive, showing the efficiacy of this thereapy in a model with hypertension as a 
comorbid factor. Additionally, we have shown that this therapy is efficacious in the aged 
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rat, showing only a slowing of recovery, but ultimately the same magnitude of recovery 
(Markus et al., 2005). Finally, other methods of inhibiting the protein Nogo-A signaling 
pathway have also been shown to be significant at inducing sensorimotor recovery after 
stroke, i.e. targeting the Nogo-A related receptor, NgR (Lee et al., 2004) as well as using 
NEP1-40 to competitively antagonize the NgR receptor (Fang et al., 2010). All these 
findings support the use of blocking protein Nogo-A in order to improve functional 
recovery after stroke.  
General limitations to the translation of this therapy to the clinic is the necessity 
of either intrathecal or intracerebroventircular infusion of the antibody. Although an 
intravenous route of application would improve the feasibility of this therapy, intrathecal 
and intracerebroventricuar drug application routes are already in possible in clinical 
practice and therefore can be used. Examples of drugs delivered intracerebroventircularly 
include the anti-spasmodic drug baclofen used for dystonia (Rocque et al., 2012), 
chemotherapeutic agents such as methotrexate for brain neoplasms (Gabay et al., 2012), 
and anti-fungals such as amphotericin B for fungal brain infections (Tsung et al., 2010). 
However, development of a less invasive route of delivery would be of great clinical 
importance, especially if clinical trials for the use of this therapy show positive results for 
spinal cord injury and pave the way for this therapy to be tested in clinical trials for other 
central nervous system injures and disorders.        
 Currently, anti-Nogo-A immunotherapy is being evaluated in a phase I human 
clinical trial in patients with spinal cord injury and a phase II trial is currently being 
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planned (Abel al., 2011). A phase I clinical trial is meant to evaluate the safety of a new 
treatment and identify side effects. In the case of anti-Nogo-A immunotherapy, since 
Nogo-a plays a role in stabilizing mature neuronal circuits in the human adult brain, it is 
possible that increasing neuroplasticity in the brain could have other effects than to 
restore impaired functions. There is a potential risk of destabilizing important circuits 
involved in long term memory and a potential risk of psychiatric symptoms (Mirnova et 
al., 2013). Although, no side effects of the treatment have been reported in animal or the 
phase I clinical trial (Abel et al., 2011), it will be important to monitor cognitive function 
during anti-Nogo-A immunotherapy in humans. Other potential side effects of too much 
neuroplasticity in the brain could include the development of seizures and pain 
syndromes.  
 The results from our laboratory over the years and specifically this project can be 
used to better design a human clinical trial for the evaluation of anti-Nogo-A 
immunotherapy in human stroke. Firstly, our studies have shown that anti-Nogo-A 
immunotherapy can be used in chronic stroke, and therefore many more stroke survivors 
could be enrolled in a clinical trial. Secondly, we have shown that anti-Nogo-A 
immunotherapy is effective in chronic stroke in adult rats with moderate and severe 
deficits after stroke. Therefore, it is possible that this therapy could be efficacious in 
moderate and severe human stroke, thereby also providing a larger group of patients 
eligible for testing. Finally, an important caveat regarding patient enrollment in an anti-
Nogo-A immunotherapy study is the fact that patients will need to have some residual 
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function in their upper extremity since we have shown that adult rats with very severe 
deficits where no forelimb grasping is possible do not improve after anti-Nogo-A 
immunotherapy.  
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Future Directions  
 It is of interest to further characterize the efficacy of anti-Nogo-A immunotherapy 
across acute and chronic time points of administration and how treatment effects are 
modulated by initial deficit severity, stroke size, and stroke location. Results from this 
type of analysis would have the ability to further inform clinical trial design for testing 
anti-Nogo-A immunotherapy in humans after ischemic stroke. Therefore, future analyses 
will incorporate data from all experiments from the Kartje laboratory utilizing anti-Nogo-
A immunotherapy, including those from this dissertation, in a non-linear regression 
model using stroke lesion size and location as co-variate parameters. This way, 
differences in recovery rate and magnitude can be evaluated directly to see what factors 
modulate anti-Nogo-A immunotherapy efficacy (age, lesion size, lesion location, initial 
deficit severity, treatment delay time).  
 Furthermore, additional experiments can be conducted to evaluate which other 
neural correlates of recovery may be playing a role in the improved recovery seen in the 
experiments in this dissertation. Additional brain areas associated with spontaneous 
recovery after stroke in humans and non-human primates involve the premotor and 
supplementary areas (Benowitz et al., 2010). An area in the rat brain that is important for 
forelimb reaching and corresponds to either a premotor or supplementary motor function 
is called the rostral forelimb area (also known as the forelimb area of Neafsey; Neafsey et 
al. 1986). Therefore, dendritic plasticity could be evaluated in the 
ipsilesional/contralesional rostral forelimb area.  Furthermore, other brain areas involved 
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in motor function could be evaluated such as the ipsilesional/contralesional dorsolateral 
striatum and ipsilesional/contralesional cerebellum. Additionally, axonal sprouting into 
the denervated red nucleus was already shown to be correlated with sensorimotor 
recovery displayed by rats with mild to moderate stroke deficits treated at 9 weeks post-
stroke with anti-Nogo-A immunotherapy (Tsai et al., 2010). It is possible that axonal 
plasticity is playing a larger role than dendritic plasticity in recovery after anti-Nogo-A 
immunotherapy and axonal sprouting from the undamaged corticospinal tract could be 
evaluated at the level of the red nucleus, basal pontine nuclei and spinal cord. 
Additionally, axonal sprouting within the ipsilesional dorsolateral striatum, or callosal 
sprouting in the perilesional cortex or ipsilesional rostral forelimb motor cortex could be 
evaluated.  
 Further experiments could look to see how to rehabilitate the animals that did not 
respond to therapy, the very severe deficit animals. It is possible that additional methods 
to improve functional recovery need to be used in addition to anti-Nogo-A 
immunotherapy. Methods such as intensive skilled reaching rehabilitation or 
environmental enrichment have been shown to improve functional recovery after stroke 
in adult rats. Therefore, a combinatorial approach could be taken with these very severe 
animals to see if a regimen of anti-Nogo-A immunotherapy, intensive skilled reach 
training, and environmental enrichment could lead to improved skilled forelimb reaching 
performance. Additionally, increased dosage and length of treatment using anti-Nogo-A 
antibodies could also be effective.
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